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1. Introduction 
 
1.1 Cancer incidence 
   Today, cancer is the second major reason for global death: 9,6 million people have 
died of cancer in 2018, while 18,1 million new cases have been registered (Figure 1) 
(as of 12th of September 2018 at (www.who.int/cancer/PRGlobocanFinal.pdf?ua=1)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Cancer incidence in 2018. Number of new cases (upper panel) and cancer related 
deaths (lower panel) in 2018. Colorectal cancer is highlighted. Taken from: 
http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf. As of 12th 
of September 2018. 
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   Colorectal cancers (CRCs) constitute about 1.8 million new cases and 10.2% of all 
new cancer cases in 2018 worldwide, while CRC related deaths include 881.000 cases 
and 9,2% of all cancer related deaths. CRC is the third most frequent cause of new 
cancer cases and the second most frequent cause of cancer related deaths worldwide 
(Figure 1). 
 
1.2 The hallmarks of cancer 
   Cancer develops after an accumulation of mutations in genes leading to constant 
activation of cancer promoting oncogenes or inactivation of tumor suppressor genes.  
While tumor promoting oncogenes only require a single mutation for activation, tumor 
suppressor genes require two mutations for inactivation - one mutation in both alleles. 
These mutations are responsible for the six so-called hallmarks of cancer that leads to 
survival and proliferation of cancer cells followed by metastasis to other tissues and 
organs in the body: sustaining proliferation, evading growth suppressors, resisting 
apoptosis, inducing angiogenesis, enabling replicative immortality and activation of 
invasion and metastasis (Figure 2) (Hanahan and Weinberg, 2000, 2011).   
 
 
 
Figure 2 The Hallmarks of Cancer. Schematic representation of the six hallmarks of cancer. 
Taken from (Hanahan and Weinberg, 2011). 
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1.3 The genetics of colorectal cancer 
   Around 85% of all human colorectal cancers have mutations in the APC 
(Adenomatous polyposis coli) gene (Kinzler and Vogelstein, 1996), which is true for 
both sporadic CRC (Payne, 1990) and inherited CRC (Powell et al., 1993). An 
activation of the WNT (Wingless/Int-1)-signaling pathway by mutations in APC or 
CTNNB1 (Catenin Beta 1, gene encoding β-CATENIN) is the initiating event in CRC 
(Figure 3). The β-CATENIN/TCF4 (T-cell factor 4) complex induces the expression of 
a large number of genes, which maintain intestinal stem cells (ISCs) in an 
undifferentiated state. Uncontrolled proliferation of these cells results in benign 
adenomas, which progress to malignant intestinal cancer with almost 100% probability 
(Clevers and Nusse, 2012). During progression, additional mutations occur, as for 
example the oncogenic activation of K-RAS and the inactivation of the tumor-
suppressor gene p53 (Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 1996; 
Sancho et al., 2004). 
 
 
Figure 3 Genetic mutations correlated with colorectal tumorigenesis. Mutation in the APC 
gene initiate the process of colorectal tumorigenesis. Mutations in additional, indicated genes 
result in further progression. Taken from (Kinzler and Vogelstein, 1996). 
 
   The ApcMin (Multiple intestinal neoplasia) mouse model is commonly used for the study of 
genes involved in colorectal cancer. These mice harbor a mutation in codon 850 in the 
Apc gene leading to a premature stop in translation resulting in an incomplete Apc 
protein, which is no longer able to inactivate Wnt signaling. The consequence is the 
development of about 100 adenomas in the small intestine and few adenomas in the 
colon which represent the early stage of colorectal cancer (Moser et al., 1990; Su et 
al., 1992). The human and mouse Apc genes display sequence similarity of around 
90% (Su et al., 1992). The ApcMin mouse model and the human inherited human 
familial adenomatous polyposis (FAP) syndrome show high genetic and phenotypic 
similarities. In humans the FAP syndrome leads to 100-1000 benign tumors in the 
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colon which ultimately develop into malignant colorectal cancer in all cases. Since the 
APC gene is mutated in almost all human colorectal cancers, ApcMin mice represent a 
relevant mouse model of colorectal cancer (Su et al., 1992). Due to high tumor burden 
and a consequently short lifespan of mice with a C57BL/6 background, tumor cells in 
the adenomas do not accumulate further mutations necessary for progression into 
adenocarcinomas and metastasis (Halberg et al., 2009). Only in a mixed background 
causing lower tumor burden and subsequent longer survival time, the adenomas 
progress into malignant cancer (Halberg et al., 2009). Early detection of CRC is critical 
for curing cancer and the understanding of the earliest mechanisms in the development 
of CRC is necessary. The mutation of Apc is modelling the initiation of human CRC, 
which makes it possible to study the early steps of cancer progression.  
 
1.4 Canonical Wnt-signaling in colorectal cancer 
   The canonical Wnt signaling pathway is highly conserved between species. In the 
absence of Wnt ligands, β-catenin is phosphorylated by the destruction complex. The 
destruction complex consists of Axin (axis inhibition protein), which functions as a 
scaffold protein, the tumor suppressor protein Apc (adenomatous polyposis coli) as 
well as the protein kinases Ck1 (Casein kinase 1) and Gsk3 (Glycogen synthase kinase 
3), which phosphorylate β-catenin. The phosphorylation of β-catenin leads to its 
degradation by the β-transducin-repeat-containing protein (βTrCP). In the absence of 
β-catenin, Tcf transcription factors bind to Groucho corepressors resulting in 
repression of transcription of Wnt target genes (Figure 4, left panel). When the Wnt 
ligand binds to the complex of the receptor Frizzled (Fz) and its coreceptor Lrp 
(lipoprotein receptor-related protein), Axin as well as Ck1 and Gsk3 are recruited to 
the Lrp receptor and no destruction complex is formed. β-catenin enters the nucleus, 
where it displaces the Groucho repressors by binding to Tcf-transcription factor 
proteins to promote the transcription of Wnt target genes (Figure 4, right panel).  
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               Figure 4 Canonical Wnt signaling. Molecular processes in the Wnt  
               signaling pathway are illustrated. See main text for further explanation. 
               Taken from (Clevers, 2006). 
 
1.5 The Notch signaling in colorectal cancer 
   The Notch signaling pathway consists of four different Notch receptors (Notch1-4) 
and five Notch ligands from the Dsl (Delta/Serrate/Lag-2) transmembrane protein 
family, three are delta like (ligand) proteins (Dll1, Dll3 and Dll4) and two are the Jagged 
proteins (Jag1 and Jag2). Three cleavages (S1-S3) of the native Notch protein occur 
during maturation and signaling activation (Figure 5). For maturation, the immature 
Notch receptor is glycosylated by the proteins Pofut1 (protein O-fucosyltransferase 1) 
and Fringe in the endoplasmic reticulum (ER) which leads to cleavage by a furin-like 
convertase (S1). After binding of the DSL ligand presented by the signal-sending cell 
to the Notch receptor at the membrane of the signal-receiving cell, Adam (a disintegrin 
and metalloprotease pepdidase) cleaves the Notch receptor (S2), after which the 
Notch extracellular domain is endocytosed by the signal-sending cell. The gamma (γ)-
secretase cleaves the intracellular domain of the Notch receptor (S3), which releases 
the Notch intracellular domain (Nicd) into the cytoplasm. In the nucleus, Nicd forms a 
transcriptional complex with the DNA binding protein Rbp-Jκ (recombination signal 
binding protein for immunoglobulin kappa J region), also known as Csl 
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(Cbf1/suppressor of hairless/Lag-1), as well as other transcriptional coactivators such 
as Maml1 (mastermind like transcriptional coactivator 1). This complex mediates target 
gene regulation (Noah and Shroyer, 2013). A known Notch target gene is Hes1 (hairy 
and enhancer of split-1), whose gene transcription is activated in response to an active 
Notch signaling (Fre et al., 2005; Jarriault et al., 1995; Jarriault et al., 1998). For 
inactivation, Nicd is ubiquitinated by Fbw7 (F-box and WD repeat domain-containing 
7). The ubiquitination targets Nicd for degradation  (Noah and Shroyer, 2013). Another 
function of the DSL on the signal-sending cell is to inhibit their own Notch receptor. 
Furthermore, the DSL ligand undergoes proteolytic cleavage by Adam and γ-
secretase, whereafter it binds to Rbp-Jκ (Csl) in combination with corepressors (CoR) 
to inhibit Notch target gene expression. The lack of Hes1 expression leads to 
expression of Atoh1 (protein atonal homolog 1), which induces transcription of new 
DSL ligands (Noah and Shroyer, 2013). 
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Figure 5 The Notch signaling pathway. a Schematic representation of the Notch receptors 
and ligands (Delta/Serrate/Lag-2: DSL). NRR: negative regulatory region, EGF-like repeat: 
epidermal growth factor-like repeat, LNR module: Lin12-Notch repeat module, RAM domain: 
RBP-Jkappa-associated module domain, PEST sequence: a peptide sequence rich in proline 
(P), glutamic acid (E), serine (S) and threonine (T), DOS domain: Dll4 delta and Osm‐11 
domain, PDZ ligand motif: domain present in Psd-95, Dlg, and Zo-1/2. b Molecular processes 
in the Notch signaling pathway. See main text for further explanation. ER: endoplasmic 
reticulum. Taken from (Noah and Shroyer, 2013). 
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   NOTCH signaling is deregulated in human CRCs and is active during the whole 
process of tumor formation (Wu et al., 2013). In tumor development, NOTCH1-4 seems 
to have different functions. Upregulation of NOTCH1 (Chu et al., 2011) and NOTCH3 
(Serafin et al., 2011) positively correlates with poor survival in patients with CRC. In 
addition, ectopic expression of NOTCH1 (Wu et al., 2013; Zhang et al., 2010) or 
NOTCH3 (Serafin et al., 2011) promotes tumor progression and metastasis. However, 
NOTCH1 and NOTCH2 negatively correlate with each other and NOTCH2 expression 
negatively correlates with poor survival in contrast to NOTCH1 (Chu et al., 2011). 
Ectopic NOTCH4 expression in human CRC cell lines leads to a decreased 
proliferation rate as well as decreased migration and invasion (Zhang et al., 2018). 
This means, while NOTCH1 and NOTCH3 support tumorigenesis and metastasis in 
human CRC, NOTCH2 and NOTCH4 inhibit the same event. However, high 
expression of both NOTCH1 and NOTCH2 is associated with the poorest survival (Chu 
et al., 2011). Therefore, an interplay of different NOTCH receptors results in other 
effects than elevated expression of a single receptor. 
   Like in humans, Notch signaling plays a role in tumorigenesis in mice, since activated 
Notch in intestinal epithelial cells of ApcMin mice leads to an increase in intestinal 
adenomas and a shortened lifespan (van Es et al., 2005b). Furthermore, there is a link 
between the cancer initiating Wnt/β-catenin pathway activation and Notch signaling, 
since a high level of β-catenin activates the transcription of the Notch ligand Jag1 in 
ApcMin mice (Rodilla et al., 2009), which could be, at least in part, the cause for 
activation of both pathways in intestinal tumorigenesis. 
 
1.6 The transcription factor AP4 
   The TFAP4/AP4 (transcription factor activating enhancer binding protein 4) protein 
belongs to the class of basic-helix-loop-helix leucine zipper (bHLH-LZ) transcription 
factors. AP4 exclusively forms homodimers via interaction of the three protein 
dimerization sites HLH, LZ1 and LZ2. The AP4 homodimers use the N-terminal basic 
region to bind to the E-box motif CA(G/C)CTG in the promoter, thereby activating the 
expression of target genes. For repression of target genes the AP4 homodimer binds 
to a geminin-SMRT complex to recruit HDAC3 (Histone deacetylase 3) or it binds 
directly to HDAC1. The AP4 protein contains a highly conserved TIV motif consisting 
of the amino acids Threonine (T), Isoleucine (I) and Valine (V), but its function is 
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unknown (Figure 6) (reviewed in (Jung and Hermeking, 2009)). The gene encoding 
AP4 was previously identified as a direct transcriptional target of c-MYC (Jung et al., 
2008). c-MYC also belongs to the bHLH-LZ transcription factors, but binds to the E-
box motif CA(C/T)GTG as a heterodimer with MAX (reviewed in (Jung and Hermeking, 
2009)). 
                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Scheme of the structure of the AP4 protein and its molecular interactions.  
B: basic region, HLH: helix-loop-helix, LZ: leucine zipper, HDAC: histone deacetylase, AA: 
amino acid position. Taken from (Jung and Hermeking, 2009). 
 
   In human CRC cells AP4 directly repress the gene encoding the CDK-inhibitor p21 
(encoded by the gene CDKN1A) to block differentiation and to induce proliferation and 
apoptosis. This result points to an important role of AP4 in mediating the repressing 
effect of c-MYC on p21 expression. In addition, AP4 is expressed in 
progenitor/transient amplifying cells in human colonic crypts as well as in colorectal 
cancer in a pattern similar to c-MYC and in a converse pattern to p21, indicating an 
identical or at least similar function of AP4 in human tissue as in human cell lines (Jung 
et al., 2008).   
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1.7 The role of AP4 in colorectal cancer 
   The prototypic oncogene c-MYC is a direct target of the APC/WNT pathway (He et 
al., 1998) and an essential mediator of tumor formation induced by inactivation of Apc 
in the intestine of mice (Sansom et al., 2007; Sur et al., 2012). Deletion of one c-Myc 
allele decreases the tumor load in ApcMin mice (Sur et al., 2012), while a complete loss 
of c-Myc prevents adenoma formation caused by homozygous Apc deletion in mice 
(Sansom et al., 2007). In addition, both human and murine c-MYC are direct targets of 
the Notch pathway (Palomero et al., 2006; Weng et al., 2006).  Therefore, c-MYC may 
be an important effector of APC/WNT-induced and/or NOTCH-induced tumor 
formation in the intestine and direct target genes of c-MYC could have an important 
influence in the development and progression of cancer. High expression of the c-MYC 
target gene AP4 positively correlated with survival and formation of distant metastases 
in the liver in two different colorectal cancer patient cohorts (Jackstadt et al., 2013c). 
Additionally, high expression of AP4 also correlated with poor survival in other tumor 
entities, such as gastric cancer, non-small cell lung carcinomas and hepatocellular 
tumors (Gong et al., 2014; Hu et al., 2013; Xinghua et al., 2012). Moreover, a genome-
wide analysis of AP4-regulated genes and AP4 DNA binding has been performed in a 
human colon cancer (CRC) cell line (Jackstadt et al., 2013c). Interestingly, AP4 could 
be identified as an epithelial-mesenchymal transition inducing transcription factor 
(EMT-TF), which regulates a large number of genes controlling EMT, stemness and 
proliferation. AP4 was required for metastases formation by CRC lines in a xenograft 
mouse model (Jackstadt et al., 2013c). Furthermore, a double negative feedback-loop 
between AP4 and the tumor-suppressor microRNA-15a/16-1 controls the balance of 
EMT and MET (mesenchymal-epithelial transition) during metastases formation of 
human CRCs (Shi et al., 2014). In addition, microRNA-302c directly targets AP4 and 
represses the transcription of AP4, thereby repressing EMT and metastasis formation 
of CRC cell lines (Ma et al., 2018). On the other hand, the ubiquitin specific peptidase 
22 (USP22) binds to the promoter of AP4 to activate its transcription to enhance EMT 
and metastasis formation of CRC cell lines (Li et al., 2017). 
   In mouse embryonic fibroblasts (MEFs) loss of Ap4 leads to premature senescence 
through induction of the known target p21 as well as the additional CDK (Cyclin 
dependent kinase)-inhibitor p16. c-Myc activation is not able to repress p21 and p16 in 
the absence of Ap4, indicating that Ap4 is necessary for the regulation of proliferation 
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by c-Myc (Jackstadt et al., 2013a). Ectopic expression of both Ap4 and Ras (Rat 
sarcoma protein) combined with loss of p53 leads to cellular transformation of MEFs 
(Jackstadt et al., 2013a). In addition, AP4 is regulated on posttranscriptional level, 
since it is a target for proteasome-dependent degradation by the βTrCP ubiquitin ligase 
(D'Annibale et al., 2014). This degradation takes place in the G2 phase of the cell cycle 
and is mediated by phosphorylation of a conserved degron. Furthermore, the ectopic 
expression of a non-degradable stabilized AP4 mutant revealed that βTrCP-dependent 
degradation of AP4 is required for the fidelity of mitotic division, as it increase 
chromosomal instability leading to cancer initiating mutations.  
   These results indicate an important role of AP4 in cancer development and 
progression. However, the organismal function of AP4 in the intestinal epithelium and 
its relevance for intestinal tumor formation has so far not been analysed using a genetic 
approach. 
 
1.8 The homeostasis of the intestinal epithelium 
   The intestinal epithelium is one of the fastest dividing tissues in the body. The small 
intestine contains crypts and villi, where each villus is surrounded by at least 6 crypts 
(Figure 7). In contrast to the small intestine the colon does not contain villi. In the small 
intestine the crypt base harbors 4-6 intestinal stem cells (ISCs) surrounded by 
supporting Paneth cells (Barker et al., 2007). Paneth cells are differentiated cells, 
which are exclusively located in the base of the crypt (Clevers and Bevins, 2013). Lgr5 
(Leu-rich repeat-containing G protein-coupled receptor 5)-positive ISCs generate all 
differentiated cells in the intestine (Barker et al., 2007). The Lgr5+ ISCs divide 
asymmetrically to self-renew and to generate highly proliferative, Lgr5-negative transit 
amplifying (TA) cells, which differentiate into absorptive enterocytes or secretory cells, 
such as goblet, Tuft and entero-endocrine cells (Barker, 2014; Barker et al., 2007; 
Beumer and Clevers, 2016; Sancho et al., 2004). Goblet cells are located in both the 
crypt and the villus, and function as mucus producing cells. Paneth cells are derived 
from Lgr5+ precursors generated by asymmetric division of ISCs, which proliferate 
slowly and therefore represent label-retaining cells (LRCs) (Buczacki et al., 2013). 
Paneth cells control the maintenance of the ISCs by secretion of Wnt and Notch 
ligands, which suppress differentiation into the secretory lineage, and protect ISCs 
from bacteria and fungi through secretion of Lysozyme and Cryptdin (Clevers and 
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Bevins, 2013; Sato et al., 2011b). However, the presence of Paneth cells in the colon 
is currently unknown. So-called deep crypt secretory (DCS) cells were identified in 
colonic crypts, which may have Paneth cell like functions (Sasaki et al., 2016). DCS 
cells are positive for Reg4 (Regenerating Family Member 4) and intermingled with 
ISCs.  
 
 
Figure 7 The structural organization and homeostasis of the intestinal epithelium. Left 
panels: structural organization of the small intestine (a) and colon (b) shown by electron 
microscopy. Middle panels: Schematic representation of the cellular organization in the small 
intestine (a) or colon (b). Right panels: Schematic representation of cellular differentiation in 
the small intestine (a) and colon (b). Taken from (Barker, 2014). 
LGR5+ stem cell: Leu-rich repeat-containing G protein-coupled receptor 5-expressing stem 
cell, CBC stem cells: crypt base columnar stem cells, TA cell: transit-amplifying cell.  
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   The homeostasis of the intestinal epithelium is regulated mainly by the Wnt/β-catenin  
and Notch pathways, which control ISC maintenance and differentiation (Beumer and 
Clevers, 2016; Sancho et al., 2004). During the upward migration of cells these signals 
become weaker and cells differentiate to replace the epithelial cells lost by anoikis 
(Figure 7) (Clevers and Bevins, 2013). The turnover of epithelial cells occurs every 3-
5 days in the small intestine and every 5-7 days in the colon, while Paneth cells are 
long-lived cells surviving 3-6 weeks (Barker, 2014). In addition to the fast cycling ISCs 
quiescient Bmi1+ (B lymphoma Mo-MLV insertion region 1 homolog) ISCs reside at 
position +4 above the crypt base (Sangiorgi and Capecchi, 2008). These cells start to 
proliferate to rebuild the Lgr5+ ISC pool after tissue injury (Tian et al., 2011).  
 
1.9 The role of the Wnt and Notch pathway in intestinal homeostasis 
   The maintenance of intestinal stem cells is positively controlled by the Wnt, Notch 
and Egf (epidermal growth factor) pathway as well as negatively controlled by the Bmp 
(bone morphogenetic protein) pathway (Figure 8) (Sato and Clevers, 2013). Wnt/β-
catenin signaling activity is strongest in the intestinal crypt base and decreases as a 
gradient in the direction towards the villi (Batlle et al., 2002; Munoz et al., 2012; Van 
der Flier et al., 2007), suggesting an important role at the crypt base. Paneth cells are 
the main source of Wnt ligands to activate Wnt signaling in ISCs, which is important 
for the stem cell maintenance and self-renewal capability (Figure 8) (Clevers et al., 
2014; Gregorieff and Clevers, 2005; Sato and Clevers, 2013; Sato et al., 2011b). 
However, also stroma cells provide Wnt signals to the ISCs (Clevers et al., 2014).  
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Figure 8 Interaction of intestinal stem cells with their niche. A Schematic representation 
of the localization of small intestinal crypts. Gradients of expression of Wnt, Bmp, and Egf 
signals are acting along the crypt axis. B Scheme of the stem cell niche. C Egf, Notch and Wnt 
signals positively control stem cell characteristics/stemness, whereas Bmp signals negatively 
control stem cell characteristics of intestinal epithelial cells. Taken from (Sato and Clevers, 
2013). 
 
   A complete abrogation of Wnt signaling by deletion of Tcf4 results in a complete loss 
of Lgr5+ ISCs (Korinek et al., 1998; van Es et al., 2012), while inactivation of Ctnnb1/β-
catenin results in loss of ISCs due to increased differentiation and as a consequence 
loss of all intestinal crypts (Fevr et al., 2007). However, partial inhibition of Wnt 
signaling results only in a reduction of ISCs (Huels et al., 2018). Furthermore, 
overexpression of the Wnt inhibitor Dkk1 (Dickkopf-related protein 1) results in 
decreased proliferation and loss of intestinal crypts (Kuhnert et al., 2004; Pinto et al., 
2003). However, a constitutively active Wnt signaling in intestinal stem cells, but not in 
progenitors or differentiated cells of mice can effectively initiate colorectal cancer 
(Barker et al., 2009; Zhu et al., 2009). These results confirm the importance of a well-
balanced Wnt/β-catenin signaling in the homeostasis and tumorigenesis in the 
intestine. 
   Both the Notch receptor and the Notch target gene Hes1 are expressed in ISCs at 
the base of intestinal crypts as well as in some cells of the TA unit, suggesting a critical 
role of active Notch signaling in ISCs and their progenitors (Fre et al., 2005; Jensen et 
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al., 2000; Kayahara et al., 2003; Riccio et al., 2008). In the intestinal crypt base Paneth 
cells present the Notch ligands to the Notch receptors present on ISCs, thereby 
activating Notch signaling and maintaining the stemness character (Figure 8) (Sato 
and Clevers, 2013; Sato et al., 2011b). The main ligands mediating the activation of 
Notch signaling important for the homeostasis of ISCs in the intestine probably are the 
Dll1 and Dll4 ligands. Mutation of these two ligands reduced proliferation of ISCs and 
forced them to differentiate, while mutation of the ligand Jag1 had no effect on 
proliferation and differentiation (Pellegrinet et al., 2011).  
   Since the Notch1 and Notch2 receptor are expressed in the crypt base of the 
intestine, while the Notch3 and Notch4 receptor are mostly expressed in the villus, only 
Notch1 and Notch2 seems to play a role in the maintenance of ISCs (Riccio et al., 
2008). Partial Notch inhibition by the γ-secretase inhibitor Dibenzazepine (DBZ) or by 
deleting Notch1 (but not Notch2) leads to a decrease of ISCs, an increase in secretory 
cells such as goblet and Paneth cells, a decrease in the expression of the Notch target 
gene Olfm4 (Olfactomedin 4) as well as reduced stem cell proliferation (Carulli et al., 
2015; VanDussen et al., 2012). Notch1 may be the main factor regulating intestinal 
homeostasis, since conditional deletion of Notch1 leads to the known phenotype of 
Notch inhibition as well as a decreased expression of the Notch target genes Hes1, 
Olfm4 and c-Myc, while no differences can be seen after conditional deletion of Notch2 
alone (Carulli et al., 2015). However, a complete loss of Notch signaling, e.g. by 
simultaneous Notch1 and Notch2 receptor deletion or by Rbp-Jκ (Csl) deletion results 
in a complete loss of ISCs (Riccio et al., 2008; van Es et al., 2010; van Es et al., 2005b; 
VanDussen et al., 2012). In addition, complete loss of Notch signaling results in more 
hyperplasia in goblet and Paneth cells as seen after deletion of Notch1 alone (Carulli 
et al., 2015), indicating a role of Notch2 in stem cell maintenance and secretory cell 
differentiation in combination with Notch1. Taken together, these results show that 
intestinal homeostasis is dependent on a functional Notch signaling pathway. 
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2. Aims of the study 
The present study had the following aims: 
• Genetic analysis of Ap4 in an ApcMin mouse model 
• Characterization of pathways and mechanisms by which Ap4 influences 
tumorigenesis and intestinal homeostasis 
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3. Materials 
 
3.1 Chemicals and reagents 
Application Chemical compound Supplier 
IHC, IF, 
Histology 
30% H2O2 Carl Roth 
Rabbit serum PAA Laboratories 
Roti®-Histokitt II Carl Roth 
Antibody diluent, background-reducing Dako 
Pro taqs IX pH10 BioCyc 
Target retrieval solution, citrate pH 6 Dako 
TRS (Target retrival solution) pH 6 Dako 
DAPI Carl Roth 
ProLong gold antifade reagent Life Technologies 
Hematoxylin Vector Laboratories 
Hematoxylin Waldeck 
Eosin Sigma-Aldrich 
Alcian blue BioOptica 
Periodic acid Merck Millipore 
Schiff`s reagent Sigma-Aldrich 
WB 
Rotiphorese gel 30 (37,5:1) Carl Roth 
Ammonium peroxodisulfate (APS) Carl Roth 
Tetramethylethylenediamine (TEMED) Carl Roth 
Sodium dodecyl sulfate (SDS) Carl Roth 
β-mercaptoethanol Sigma-Aldrich 
Complete mini protease inhibitor cocktail Roche Diagnostics 
Bradford reagent Bio-Rad 
PageRuler™ plus prestained protein ladder Thermo Fisher Scientific 
Immobilon-P PVDF,0.45µm membrane Merck Millipore 
Skim milk powder Sigma-Aldrich 
Methanol Carl Roth 
Tween-20 Sigma-Aldrich 
Nonidet®P40 substitute Sigma-Aldrich 
ECL/HRP substrate Merck Millipore 
Western lightning plus ECL Perkin Elmer 
Organoids 
Growth factor reduced, phenol red-free matrigel Corning 
Advanced DMEM/F12 Gibco/Life Technologies 
Penicillin-streptomycin Gibco/Life Technologies 
Glutamax Gibco/Life Technologies 
Hepes Gibco/Life Technologies 
Noggin Preprotech 
N2 Gibco/Life Technologies 
B27 Gibco/Life Technologies 
EGF Preprotech 
RSPO1 Sinobiological 
Y-27632 MedBiochem Express 
Wnt-3a Abcam 
4-hydroxytamoxifen (4-OHT) Sigma-Aldrich 
Hank's Balanced Salt Solution (HBSS) Gibco/Life Technologies 
 Materials 
18 
 
Application Chemical compound Supplier 
ISH 
Kaiser glycerine gelantin Merck Millipore 
Formamide Sigma-Aldrich 
Paraformaldeyd Merck Millipore 
3-[(3-cholamidopropyl)dimethyl-ammonio]-1-
propane sulfonate (CHAPS) Sigma-Aldrich 
Diethyl pyrocarbonate (DEPC) Sigma-Aldrich 
Blocking solution Roche Diagnostics 
NBT/BCIP solution, ready to use Sigma-Aldrich 
RNA from Yeast Sigma-Aldrich 
Heparin sodium Sigma-Aldrich 
qChiP 
Protein G agarose/salmon sperm DNA Merck Millipore 
Fatty acid-free BSA Sigma-Aldrich 
37% formaldehyde  Merck Millipore 
Cell culture 
FBS (Fetal Bovine Serum) Invitrogen 
Penicillin-streptomycin Gibco/Life Technologies 
DMEM–Dulbecco's Modified Eagle Media Gibco/Life Technologies 
McCoy's 5A (Modified) media Gibco/Life Technologies 
RPMI 1640 media without L-glutamine Gibco/Life Technologies 
Hank's Balanced Salt Solution (HBSS) Gibco/Life Technologies 
DMSO (Dimethyl Sulfoxide) Carl Roth 
FuGENE® HD transfection reagent Promega Corporation 
HiPerFect transfectin reagent QIAGEN 
Lipofectamine® 2000 transfection reagent Invitrogen 
Opti-MEMTM reduced serum media Gibco/Life Technologies 
Doxycycline (DOX) Sigma-Aldrich 
Puromycin dihydrochloride Sigma-Aldrich 
Cloning /  
generation 
of vectors 
Ampicillin Carl Roth 
LB agar (Lennox) Carl Roth 
LB medium (Luria/Miller) Carl Roth 
Universal agarose PeqGold PeqLab 
Ethidium bromide Carl Roth 
Gene ruler 1kb DNA ladder Thermo Fisher Scientific 
PCR, Gel 
electro-
phoresis,  
q-PCR 
Deoxynucleotides (dNTPs) Thermo Fisher Scientific 
Gene ruler low range DNA laddder Thermo Fisher Scientific 
Gene ruler 100bp plus DNA laddder Thermo Fisher Scientific 
Gene ruler 1kb DNA ladder Thermo Fisher Scientific 
Universal agarose PeqGold PeqLab 
Ethidium bromide Carl Roth 
Fast SYBR® green master mix Applied Biosystems 
Trizol Invitrogen 
Luciferase 
reporter 
assays 
 
Ampicillin Sigma-Aldrich 
LB-Agar (Lennox) Carl Roth 
LB-Medium (Luria/Miller) Carl Roth 
Hi-Di™ Formamide Applied Biosystems 
Universal agarose PeqGold PeqLab 
Gene Ruler 1kb DNA ladder Thermo Fisher Scientific 
Ethidium bromide Carl Roth 
FuGENE® HD transfection reagent Promega Corporation 
Opti-MEM® Reduced Serum Medium Gibco/Life Technologies 
Electron 
microscopy 
Osmium tetroxide Serva Electrophoresis 
EPON 812 glycid ether 100 Serva Electrophoresis 
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Application Chemical compound Supplier 
DBZ-
treatment 
Tween-80 Sigma-Aldrich 
Methocel® MC low viscosity Sigma-Aldrich 
Dibenzazepine (DBZ) Axon Medchem 
 
3.2 Enzymes 
Application Enzyme Supplier 
Organoids Collagenase Type IV Merck Millipore Dispase Type II Sigma-Aldrich 
ISH Proteinase K Sigma-Aldrich 
Cell culture Trypsin-EDTA (0.5%, 10x, phenol-red free) Gibco/Life Technologies 
Generation 
of vectors 
restriction endonucleases New England Biolabs 
T4 DNA ligase Thermo Fisher Scientific 
qPCR DNase I (RNase-free) Sigma-Aldrich 
PCR FIREPol® DNA Polymerase Solis BioDyne Hot FIREPol® DNA Polymerase Solis BioDyne 
 
3.3 Kits 
Application Kit Supplier 
IHC 
DAB Substrate Chromogen System Vector laboratories 
DAB+ Substrate Chromogen System  Dako 
Vectastain Elite ABC HRP detection Kit Vector laboratories 
AEC Substrate Chromogen System Thermo Fisher Scientific  
Immpress HRP Anti Goat Ig Vector laboratories 
Immpress HRP Anti Rabbit Ig Vector laboratories 
Impress Excel Staining Kit, Anto Rabbit-Ig Vector laboratories 
Immpress HRP Anti Mouse Ig Vector laboratories 
M.O.M. (mouse on mouse) Kit Vector laboratories 
WB BCA Protein Assay Kit  Thermo Fisher Scientific 
 
ISH 
DIG Northern Starter Kit Roche Diagnostics 
BCIP/NBT substrate system Sigma Aldrich 
 
Cloning / 
generation 
of vectors 
 
QIAquick Gel Extraction Kit QIAGEN 
Pure Yield™ Plasmid Midiprep System Promega Corporation 
QIAprep Spin Miniprep Kit QIAGEN 
BigDye Terminator v1.1 cycle sequencing Kit Applied Biosystems 
Dye Ex 2.0 Spin Kit QIAGEN  
qPCR 
High Pure RNA Isolation Kit Roche Diagnostics 
RNeasy Kit QIAGEN  
Verso cDNA Synthesis Kit Thermo Fisher Scientific 
Luciferase 
reporter 
assays 
Dual-Luciferase® Reporter Assay System Promega Corporation 
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3.4 Antibodies 
3.4.1 Primary antibodies 
epitope source company catalog 
no. 
use 
dilution 
mouse 
dilution 
human 
α-Tubulin mouse Sigma-Aldrich #T9026 WB 1:1000 1:1000 
β-catenin mouse BD Pharmingen 610154 IHC 1:300  
BrdU rat AbD Serotec MCA2060 IHC 1:400  
Cleaved 
caspase-3 rabbit Cell signaling #9661 IHC 1:100  
c-myc rabbit Merck Millipore #06-340 IHC 1:300  
GFP rabbit Santa Cruz SC-8334 IHC; IF 1:700; 1:700  
Hes1 rabbit Cell signaling #11988 IHC; WB 1:50; 1:1000 1:50; 1:1000 
Ki67 rat Dako E0468 IHC 1:500  
Lysozyme rabbit 
Biozol, 
Lifespan 
Biosciences 
LS-
C138144-
100 
IHC; IF 1:4000; 1:4000  
NICD1 rabbit Cell Signaling #4147 IHC; WB 1:50; 1:1000 1:100; 1:1000 
TFAP4 mouse AbD Serotec MCA4993Z IHC; IF; WB; ChiP 
1:100; 1:100; 
1:1000; 3µg 
1:400; 
1:1000 
VSV rabbit Sigma-Aldrich #4888 WB  1:7500 
Rabbit IgG  Biozol Diagnostica BZL04060 IHC; IF   
Rabbit (DA1E) 
mAB IgG  Cell Signaling 3900 IHC   
Mouse IgG2a  Biozol Diagnostica 
SER-
MCA929-
100 
IHC; IF   
Mouse IgG1  Southern Biotech 
SBA-0102-
01 IHC   
Rat IgG2a  Biozol Diagnostica BZL01284 IHC   
Mouse IgG  Sigma-Aldrich M7023 ChiP   
ChiP: Chromatin Immunoprecipitation; IF: Immunoflourescence; IHC: Immunohistochemistry;           
WB: Western Blotting;                                        
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3.4.2 Secondary antibodies 
name source company catalog no. use dilution Used for pAB 
Anti-mouse-
HRP goat 
Promega 
Corporation #4021 WB 1:10000 
α-Tubulin, 
TFAP4 
Anti-Rabbit-
HRP goat Sigma-Aldrich #A0545 WB 1:10000 
c-Myc, 
NICD1, 
Hes1 
Anti-mouse-
Alexa 555 goat Invitrogen A-21422 IF 1:500 TFAP4 
Anti-Rabbit-
FITC donkey 
Jackson 
Immuno 
Research 
711-095-152 IF 1:500 GFP, Lysozyme 
Anti-Rat-
biotinylated rabbit Dako E0468 IHC 1:500 Ki67 
ChiP: Chromatin Immunoprecipitation; IF: Immunoflourescence; IHC: Immunohistochemistry;           
WB: Western Blotting;                                        
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3.5 Buffers and solutions 
 
 
Immunohistochemistry: 
 
10x PBS (1l):  
80g NaCl; 1 g KCl; 14.42 g Na2HPO4*2H2O; 2 g KH2PO4; ad 1 l ddH2O 
 
Tris-Buffer: 
43.90 g NaCl; 34.25 g Tris-HCL; 4.50 g Tris-Base; add ddH2O to 5 l  
 
 
Western Blotting: 
 
2x Laemmli buffer:  
125 mM Tris/HCl (pH 6.8); 4% SDS; 20% glycerol; 0.05% bromophenol blue (in H2O); 10% β-
mercaptoethanol (added right before use) 
 
RIPA lysis buffer (for protein lysates):  
1% NP40 (Nonidet P-40); 0.5% sodium deoxycholate; 0.1% SDS; 150 mM NaCl; 50 mM 
Tris/HCl (pH 8.0), add 1 tablet of protease (Roche Diagnostics) to 10 ml of RIPA buffer   
 
10x Tris-glycine-SDS running buffer (5l, for SDS-PAGE):  
720 g Glycin; 150 g Tris; 50 g SDS; pH 8.3-8.7; ad 5 l ddH2O 
 
Towbin buffer (for Western blotting):  
200 mM glycine; 20% methanol; 25 mM Tris (pH 8.6) 
 
10x TBS-T (5l):  
500 ml 1M Tris (pH 8.0); 438.3 g NaCl; 50 ml Tween20; ad 5 l ddH2O 
 
 
Genotyping of mice: 
 
10x Gitschier`s Buffer (10x GB): 
1675 µl of 2M Tris (pH 8.8); 830 µl of 1M (NH4)2SO4; 670 µl of 0.5M MgCl2; 1825 µl ddH2O 
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Soriano Buffer:  
5040 µl of ddH2O; 600 µl of 10x GB; 300 µl of 10% Triton X-100; 60 µl 2-Mercaptoethanol 
 
10x Vogelstein PCR buffer:  
166 mM (NH4)2SO4; 670 mM Tris/HCL (pH 8.8); 67 mM MgCl2; 100 mM β-mercaptoethanol  
 
 
In situ Hybridization 
 
Acetic anhydride solution: 
0.2 % acetic anhydride in 0.1 M trietanolamine (pH 8.0) 
 
Tris/NaCl Buffer: 
0.1 M Tris/HCl (pH 7.5); 0.15 M NaCl; 0.1% Tween20 
 
Blocking Solution: 
1 % blocking powder (Roche Diagnostics) in 1x Tris/NaCl buffer (heat to 65°C to dissolve) 
 
DEPC-H2O: 
1 ml Diethyl-Pyrokarbonat (DEPC) (Sigma) in 1 L H2O (autoclave to inactivate DEPC) 
 
Hybridization solution: 
50% formamide, 5x SSC (pH 4.5); 2% Blocking Powder (Roche Diagnostics); 0.05% CHAPS 
(Sigma); 5 mM EDTA; 50 µg/ml heparin; 1 µg/ml yeast RNA (heat to 65°C to dissolve) 
 
NBT/BCIP Solution: 
10 mg of NBT (Sigma) in 1ml of DEPC-H2O 
 
NTM Buffer: 
0.1 M Tris/HCl (pH 9.5); 0.1 M NaCl, 0.05 M MgCl2 
 
PFA: 
4% Paraformaldedyde (PFA) in PBS (heat to 65°C and add NaOH to dissolve) 
 
1x PBS 
8g NaCl; 0.2g KCl; 1.78g Na2HPO4*2H2O; 0.24g KH2PO4; add DEPC-H2O to 1l 
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SSC, 20X: 
175.3g NaCl; 88.2g sodium citrate*2H2O; add DEPC-H2O to 1l (adjust pH to 7.5 or 4.5) 
 
 
qChiP: 
 
TE buffer: 
10 mM Tris/HCL (pH 7.5); 1 mM EDTA 
 
Glycine buffer: 
1 M glycine in ddH2O 
 
Triton X-100 dilution buffer: 
100 mM Tris/HCl (pH 8.6); 100 mM NaCl; 5 mM EDTA (pH 8.0); 0.2 % NaN3; 5 % Triton X-
100 
 
SDS buffer: 
50 mM Tris (pH 8.1); 0.5% SDS; 100 mM NaCl; 5 mM EDTA 
 
Immunoprecipitation (IP) buffer: 
Mix 1 part of Triton X-100 dilution buffer and 2 parts of SDS buffer 
 
LiCl/detergent wash: 
0,5 % deoxycholic acid (sodium salt); 1 mM EDTA; 250 mM LiCl; 0.5 % NP-40; 10 mM Tris/HCl 
(pH 8.0); 0.2 % NaN3 
 
Buffer 500: 
0.1 % deoxycholic acid; 1 mM EDTA; 50 mM HEPES (pH 7.5); 500 mM NaCl; 1 % Triton X-
100; 0.2 % NaN3 
 
Mixed micelle buffer: 
150 mM NaCl; 20 mM Tris/HCl (pH 8.1); 5 mM EDTA (pH 8.0); 5.2 % Sucrose; 0.02 % NaN3, 
1 % Triton X-100; 0.5 % SDS 
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Elution buffer: 
10 mM EDTA, 1 % SDS; 50 Mm Tris/HCl (pH 8.0) 
 
1x TBS: 
1.5 M NaCl; 0.1 M Tris/HCl (pH 7.4) 
 
1x PBS: 
13.7 mM NaCl; 2.7 mM KCl; 80.9 mM Na2HPO4; 1.5 mM KH2PO4 (pH 7.4) 
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3.6 Oligonucleotides 
3.6.1 Oligonucleotides used for genotyping 
Name  Sequence (5`-3`)  
Ap4 Primer a  
Ap4 Primer b  
Ap4 Primer c  
ApcMin wt  
ApcMin com  
ApcMin mut  
Vil-Cre Fwd  
Vil-Cre Rev 
Lgr5 com                           
Lgr5 wt rev                        
Lgr5 mut rev                    
Cmv-Cre trans1               
Cmv-Cre trans2                 
Cmv Int Con Fwd              
Cmv Int Con Rev 
GCCTAAGAGTAGGTGCTCTGC  
GCGAGCAAATGAACTGTTGAC  
CGTACGCCGGCTTAAGTGTA  
GCCATCCCTTCACGTTAG  
TTCCACTTTGGCATAAGGC  
TTCTGAGAAAGACAGAAGTTA  
CGCGAACATCTTCAGGTTCT  
CAAGCCTGGCTCGACGGCC 
CTGCTCTCTGCTCCCAGTCT 
ATACCCCATCCCTTTTGAGC 
GAACTTCAGGGTCAGCTTGC 
GCGGTCTGGCAGTAAAAACTATC  
GTGAAACAGCATTGCTGTCACTT 
CTAGGCCACAGAATTGAAAGATCT  
GTAGGTGGAAATTCTAGCATCATCC 
3.6.2 Oligonucleotides used for qPCR 
Name  Sequence (5`-3`)  
mouse B2m Fwd CCGGCCTGTATGCTATCC 
mouse B2m Rev CTTGCTGAAGGACATATCTGACA 
mouse Ap4  Fwd        
mouse Ap4  Rev         
mouse Spdef Fwd         
mouse Spdef Rev          
mouse EpCam Fwd    
mouse EpCam Rev    
mouse Lysozyme Fwd                  
mouse Lysozyme Rev                 
mouse Cryptdin Fwd  
mouse Cryptdin Rev  
mouse Gob5 Fwd       
mouse Gob5 Rev       
mouse Muc2 Fwd       
mouse Muc2 Rev       
mouse Smoc2 Fwd    
mouse Smoc2 Rev     
mouse Lgr5 Fwd        
mouse Lgr5 Rev         
mouse Olfm4 Fwd      
mouse Olfm4 Rev      
mouse Cdkn1a (p21) Fwd                       
mouse Cdkn1a (p21)  Rev                  
mouse Ctnnb1 Fwd    
mouse Ctnnb1 Rev    
mouse Sox4 Fwd       
mouse Sox4 Rev        
mouse Axin2 Fwd       
mouse Axin2 Rev        
TCAAGCGCTTTATCCAGGAG 
CAATGCCCTCATCCTTGTCT  
AACATGTATCCCGACGATAGCAGC 
TCAATATCTTTCAGGACCTCGCCC  
TTGCTCCAAACTGGCGTCTA  
ACGTGATCTCCGTGTCCTTGT  
ATGGAATGGCTGGCTACTTATGGAG  
CTCACCACCCTCTTTGCACATTG  
AGGAGCAGCCAGGAGAAG  
ATGTTCAGCGACAGCAGAG               
TGAAATTGTGCTGCTGACCGATGG  
TGCTGCGAAAGCATCAACAAGACC   
TGTGGGACTTTTGCCATGTACT  
GCAAGAGCACCTGTGATCCA  
GAAGAAGATATTGCCTCACG  
TTCCTCAAGAGCTGACTGAT  
GAGGAAGCGCTACAGAATTTGAGA  
GTGGCACGTAGCTGATGTGG  
TGGCCCTTGGAAGCTGTAGT  
ACCTCCTTGGCCATAGCGAA  
AACATCTCAGGGCCGAAA  
TGCGCTTGGAGTGATAGAAA  
TGCTGAAGGTGCTGTCTGTC  
AGTCGCTGCATCTGAAAGGT  
GCTGCATCGTTCTCTCCAGA 
AAACAGGTAGACGCGCTTCA  
ATGCTAGGCGGAATGAAGATG  
GGAGACAACGCTGTTGTTCTC                        
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mouse Ascl2 Fwd       
mouse Ascl2 Rev        
mouse Dll1 Fwd         
mouse Dll1 Rev           
mouse Notch1 Fwd    
mouse Notch1 Rev    
mouse Hes1 Fwd        
mouse Hes1 Rev        
mouse Jag1 Fwd        
mouse Jag1 Rev         
mouse Jag2 Fwd        
mouse Jag2 Rev        
mouse Dll4 Fwd         
mouse Dll4 Rev          
mouse Hey1 Fwd        
mouse Hey1 Rev       
mouse Tcf7 (Tcf1) Fwd                  
mouse Tcf7 (Tcf1) Rev                  
mouse c-Myc Fwd       
mouse c-Myc Rev      
mouse EphB3 Fwd     
mouse EphB3 Rev     
human β-ACTIN Fwd    
human β-ACTIN Rev     
human AP4 Fwd         
human AP4 Rev         
human c-MYC Fwd     
human c-MYC Rev     
human NOTCH1 Fwd    
human NOTCH1 Rev    
human NRARP_Fwd  
human NRARP_Rev  
human HES1 Fwd 
human HES1 Rev 
GCCCGTGAAGGTGCAAAC  
ACAGGAAAAGTGCTCGCGA  
CATGAACAACCTAGCCAATTGC  
GCCCCAATGATGCTAACAGAA  
GCAGATGCTCAGGGTGTCTT  
GCCAGGATCAGTGGAGTTGT  
TCAGCGAGTGCATGAACG  
TGCGCACCTCGGTGTTAAC  
TCTCTGACCCCTGCCATAAC  
TTGAATCCATTCACCAGATCC  
GGCAACTCCTTCTACCTGCC  
GTCATTGTCCCAGTCCCAGG  
CCCTCACCTGGATTACCTAC  
GAATCTGCTTGTTAGGGATG  
TGAGCTGAGAAGGCTGGTAC  
ACCCCAAACTCCGATAGTCC  
TGCAGCTATACCCAGGCTGG  
CCTCGACCGCCTCTTCTTC  
TGACCTAACTCGAGGAGGAGCTGGAATC  
AAGTTTGAGGCAGTTAAAATTATGGCTGAAGC  
AAGAGACTCTCATGGACACGAAAT  
ACTTCCCGCCGCCAGATG  
TGACATTAAGGAGAAGCTGTGCTAC 
GAGTTGAAGGTAGTTTCGTGGATG 
GCAGGCAATCCAGCACAT 
GGAGGCGGTGTCAGAGGT 
GCTGCTTAGACGCTGCTGGATTT 
TAACGTTGAGGGGCATCG 
TGATGAGGTCCTCCAGCAT 
TGATGAGGTCCTCCAGCAT 
TTCGAACCCGAAATCCTG 
GCCACAGAAACCAGGAAGG 
GAAGCACCTCCGGAACCT 
GTCACCTCGTTCATGCACTC 
 
3.6.3 Oligonucleotides used for qCHIP 
Name  Sequence (5`-3`)  
mouse Sox4 (A) Fwd           TTCATGGGCCGCTTGATGT 
mouse Sox4 (A) Rev           CAACAACGCGGAGAACACTG 
mouse Sox4 (B) Fwd           CGCGTGCAATGAGAAGCTC 
mouse Sox4 (B) Fwd           CACACACACAGAGGCAAACG 
mouse Ascl (A) Fwd GCAGAGGTCAGTCAGCACTT 
mouse Ascl (A) Rev TTCTTCACAGCTGCATCCCT 
mouse Ascl (B1) Fwd ACAAACAAACGCCGGTCTTG 
mouse Ascl (B1) Rev GCCTGACACTTAGCGCCA 
mouse Ascl (B2) Fwd CTCCATCGGGCTTAGCTCTC 
mouse Ascl (B2) Rev TCTCTGTCCTGCGCCTCTAC 
mouse Ascl (C1) Fwd GCGTGGCTCCAGAGATGG 
mouse Ascl (C1) Rev TTCTCACACTCAAGGGGCAC 
mouse Ascl (C2) Fwd GTGCCCCTTGAGTGTGAGAA 
mouse Ascl (C2) Rev GCATGAGGGGCTAAATGGGT 
mouse Tcf7 (A) Fwd            TCTTTGGGTAGAAGGCAGCC 
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mouse Tcf7 (A) Rev            GCCTCAGCCAAAGTCATTCTG 
mouse Tcf7 (B) Fwd            AATCAGCCATCACCACCACC 
mouse Tcf7 (B) Rev TGAGGGCAGAGGAGGAAGAA 
mouse Notch1 (A) Fwd           ACACTCAGCTCCCCGGAT 
mouse Notch1 (A) Rev          ACAATGGGCCGCTCTGATTC 
mouse Notch1 (B) Fwd           CCTACCTCTTGCGGCGAG 
mouse Notch1 (B) Rev           CCGGTGGTGTGCGTCAAC 
mouse Dll1 (A) Fwd            GTTTGGTGTGTGTCGTTCGC 
mouse Dll1 (A) Rev            AGCTCTTTCTCTCCGCATTGT 
mouse Dll1 (B) Fwd ACATGAGAAAAGGGGAGGCG 
mouse Dll1 (B) Rev            AGGAAGGAGAGGCATAGGGG 
mouse Jag1 (A) Fwd           CTCGCGCTCCCCTTCTTTTA 
mouse Jag1 (A) Rev            CATTGTGTTACCTGCAGCCG 
mouse Jag1 (B) Fwd           CTTGCAAGCCCCAGGTGTAG 
mouse Jag1 (B) Rev            CTCTGGGCTCGCTTGCTG 
mouse Jag2 (A) Fwd           CAAGAGCACGCGCCCCAGG 
mouse Jag2 (A) Rev            CTTTCAGTTCGCCTGGCCGGTAC 
mouse Jag2 (B) Fwd           CTCAGCAGCTCCCCGTTC 
mouse Jag2 (B) Rev          CACTCTGCGCTGCCTTATTT 
mouse Jag2 (C) Fwd           GGGACGAGACTGACAGCTC 
mouse Jag2 (C) Rev           CTCGCCTCCTTTAAAGCTCG 
mouse Hes1 Fwd            CACACACCCCACACGCAG 
mouse Hes1 Rev            CCAAGAAGGTAAATAGCAGCTG 
mouse Dll4 (A) Fwd            TGTACTCCCTCACTAGCCCG 
mouse Dll4 (A) Rev            GTAATCCAGGTGAGGGCGAC 
mouse Dll4 (B) Fwd            CTCCTTCTCTCGGTCCCTGT 
mouse Dll4 (B) Rev            GCAGATGCGGAAGAAAGTCC 
mouse Dll4 (C) Fwd            GGGACAAGAATAGCGGCAGT 
mouse Dll4 (C) Rev            GAAAGGAGCTCTGGTGTCCC 
mouse Cdkn1a (A1) Fwd           AATTGAAGAGGTGGGGCTGC 
mouse Cdkn1a (A1) Rev           TCTGGGGTCTCTGTCTCCAT 
mouse Cdkn1a (A2) Fwd           TCCCACTTTGCCAGCAGAAT 
mouse Cdkn1a (A2) Rev           CCAGGCACACACACACAGAT 
mouse Cdkn1a (B) Fwd           CCCAGAAGTGTGTGTGTGTG 
mouse Cdkn1a (B) Rev           ACACCCGTCATCCACCTG 
mouse Cdkn1a (C) Fwd           CCCCAGACGCTTCATCTCTT 
mouse Cdkn1a (C) Rev           TACCACACACATACACACGC 
mouse EphB3 Fwd            AAGAGCGGCCAACTGAACTC 
mouse EphB3 Rev            CTGCCCGTCAACACTCAGG 
mouse AchR Fwd 
mouse AchR Rev 
 
 
AGTGCCCCCTGCTGTCAGT 
CCCTTTCCTGGTGCCAAGA 
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3.7 siRNAs 
The following siRNAs were purchased from Ambion: 
AP4-specific siRNA: 5‘-GUGAUAGGAGGGCUCUGUAG-3‘ 
Silencer negative control siRNA: 5-UUGUCUUGCAUUCGACUAAUU-3 
.  
3.8 Vectors 
Name Insert Source 
Bluescript II plasmid 
p695-pBS-mOlfm4 Mouse Olfm4 ORF Prof. Dr. Hans Clevers 
pCMV6-Entry-Lgr5 Mouse Lgr5 ORF Origene, cat.no. MR219702 
pCMV6-Entry-Smoc2 Mouse Smoc2 ORF Origene, cat.no. MR207121 
pBluescriptII-KS empty Promega Corporation 
pRTR empty (Jackstadt et al., 2013c) 
pRTR-Ap4-VSV AP4-VSV ORF (Jackstadt et al., 2013c) 
pGA-RBPJ Human RBPJ-ORF (Oswald et al., 2001) 
pGA empty (Oswald et al., 2001) 
ORF: Open Reading Frame 
 
3.9 Mice 
Genotype Background Source 
Ap4fl/fl 
C57BL/6 
Our lab (Jackstadt et al., 2013a) 
ApcMin Dr. Marlon Schneider (LMU) 
Lgr5-CreERT2 Prof. Dr. Hans Clevers (Hubrecht Institute) 
Vil-Cre Prof. Dr. Klaus-Peter Jannsen (TUM) Vil-CreERT2 
CMV-Cre The Jackson Laboratory Flp 
Prkdc-scid NOD The Jackson Laboratory 
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3.10 Cell lines 
Species Cell lines Medium Supplier 
Human CRC cell lines 
SW620 DMEM Medium +  10% FBS + 1% P/S 
-- 
-- 
DLD-1 McCoy`s 5A Medium + 
10% FBS + 1% P/S 
 
-- 
HCT15 -- 
Colo320 
RPMI1640 w/o glutamax 
+ 1% Glutamax + 
10% FBS + 1% P/S 
-- 
Murine CRC cell line CT26 
RPMI1640 w/o glutamax 
+ 1% Glutamax +  
10% FBS + 1% P/S  
ATCC 
Human kidney cell line HEK293 DMEM Medium +  10% FBS + 1% P/S DSMZ 
ATCC: The Global Bioresource Center; https://www.atcc.org/ 
DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; 
https://www.dsmz.de/ 
 
3.11 Software 
application software Supplier 
Data analysis and 
figure generation 
Excel Microsoft Cooperation 
Prism5  Graphpad Software Inc. 
 
WB 
Varioskan Flash Multimode Reader Thermo Scientific 
KODAK MI SE software Carestream Health 
qPCR ND1000 V3 PEQLAB LightCycler 480 Roche Diagnostics 
Cell Culture cFlow Software Accuri 
Sequencing analysis DNA Sequencing Analysis Software v5 Applied Biosystems BioEdit BioEdit 
IF ZEN 2009 Carl Zeiss 
IHC, ISH,           
tumor counting Axiovision Carl Zeiss 
Organoids Nikon NIS-Elements Nikon 
Luciferase reporter 
assays SIMPLICITY software package DLR 
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3.12 Laboratory equipment 
application Device Supplier 
qPCR ND 1000 NanoDrop Spectrophotometer PEQLAB LightCycler480 Roche Diagnostics 
WB 
Mini-PROTEAN®-electrophoresis system Bio-Rad 
HTU SONI130 
G. Heinemann 
Ultraschall- und 
Labortechnik 
Varioskan Flash Multimode Reader Thermo Scientific 
Mini Trans-Blot® Electrophoretic Transfer Cell Bio-Rad 
Powerpac 300 Power Supply Bio-Rad 
biophotometer plus eppendorf 
EPS 600 power supply Pharmacia Biotech 
440CF imaging system Eastman Kodak 
Cell culture 
Herasafe KS class II safety cabinet Thermo Fisher Scientific 
Neubauer counting chamber Carl Roth 
BD AccuriTM C6 Flow Cytometer Instrument BD Accuri 
Axiovert 25 microscope equipped with an 
Axiocam 105 color camera Carl Zeiss 
Sequencing ABI 3130 genetic analyzer capillary sequencer Applied Biosystems 
IF LSM700 confocal microscope Carl Zeiss 
IHC, ISH Axioplan 2 imaging microscope AxioCam HRc camera Carl Zeiss 
Electron microscopy Libra 120 transmission electron microscope Carl Zeiss 
Organoids 
Stemi 2000-C stereo microscope Carl Zeiss 
Nikon AZ-100 macroscope equipped with a 
Nikon DS-Fi3 color camera equipped with a 
5.9 megapixel CMOS image sensor. 
Nikon 
Tumor counting 
Stemi 2000-C stereo microscope  Carl Zeiss  
Nikon D5100 digital camera equipped with a 
Nikon AF-S Nikkor 18-55mm 1:3.5-5.6G 
objective 
Nikon 
Luciferase reporter 
assays Orion II Luminometer      
Berthold 
Technologies  
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4. Methods 
 
4.1 Generation and husbandry of mice 
   Ap4fl/fl mice and germ-line Ap4 knock-out mice were generated by the Hermeking lab 
as follows: targeted embryonic stem cells (ES-cells) with C57BL/6N background were 
obtained by homologous recombination with a vector containing the Ap4 exons 2-4 
flanked by loxP (locus of X-over P1) sites and an intronic neomycin resistance (Neo) 
cassette flanked by frt (flp recognition target) sites (scheme in (Jackstadt et al., 
2013a)). Ap4+/fl mice were generated by injection of targeted ES cells into C57BL/6N 
blastocyst. The Neo cassette was removed by crossing to flp (Flippase)-mice 
(Gronostajski and Sadowski, 1985) and germ-line Ap4 knock-out mice were generated 
by crossing with CMV (cytomegalovirus)-Cre+/- mice (Schwenk et al., 1995).  
   Ap4-/- mice showed no overt phenotype and were born at normal Mendelian ratio. 
Oligonucleotides used for genotyping are listed in Table 3.6.1. For analysis of the effect 
of Ap4 inactivation on the ISC number we used Lgr5-eGFP-Cre-ERT2+/- mice (Barker 
and Clevers, 2007) (obtained from Hans Clevers, University Medical Center Utrecht, 
The Netherlands) and for specific deletion of Ap4 in intestinal epithelial cells or derived 
organoids we used Villin-Cre+/- or Villin-Cre-ERT2+/- mice (el Marjou et al., 2004) 
(obtained from Klaus-Peter Janssen, Technical University Munich, Germany), 
respectively. ApcMin/+ mice (Moser et al., 1990; Su et al., 1992) (obtained from Marlon 
Schneider, Ludwig-Maximilians-Universität, München, Germany) were used to analyze 
the role of Ap4 in intestinal adenoma development. Mice were kept in individually 
ventilated cages (IVC) with a 12-hour light/dark cycle and ad libitum access to water 
and standard rodent diet. For determination of proliferation rates 75 mg/kg BrdU 
(Bromdesoxyuridin) (Amersham) in PBS (phosphate-buffered saline) was i.p. 
(intraperitoneal) injected 1.5 hours before mice were sacrificed. All animal 
experimentations and analyses were approved by the Government of Upper Bavaria, 
Germany (AZ 55.2-1-54-2532-4-2014). 
 
4.2 Tissue preparation and adenoma counting 
   After isolation of intestinal tissue, the colon and small intestine were separated and 
flushed with PBS to remove stool. The small intestine was dissected into duodenum, 
jejenum and ileum. The colon and small intestine were opened longitudinally and rolled 
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with the mucosa oriented outwards and fixed in formalin, dehydrated and embedded 
into paraffin. For evaluation of tumor numbers each part of the intestine was cut 
longitudinally and spread on Whatman 3 MM paper. After fixation in formalin adenomas 
were counted under a Stemi 2000-C stereo (dissection) microscope (Carl Zeiss) with 
10x magnification. Pictures of intestines were taken with a Nikon D5100 digital camera 
with a Nikon AF-S Nikkor 18-55mm 1:3.5-5.6G objective. 
 
4.3 HE and PAS/Alcian blue staining 
   Formalin-fixed, paraffin-embedded (FFPE) tissue was cut into 2 µm sections on a 
Microm HM355S rotating microtome (Thermo Fisher Scientific). For hematoxylin and 
eosin (HE)-staining the slides were de-paraffinized and stained with hematoxylin 
(Waldeck) for 6 minutes followed by eosin (Sigma-Aldrich) for 2.5 minutes in an 
automated slide staining device (Tissue-Tek, Prisma). Periodic acid Schiff (PAS)-
staining was done by applying Alcian Blue pH 1 (Bio Optica) for 10 minutes followed 
by periodic acid (Merck Millipore) for 5 minutes, Schiff`s reagent (Sigma Aldrich) for 5 
minutes and counterstaining with hematoxylin (Waldeck).  
 
4.4 Immunohistochemistry 
   FFPE tissue was cut into 2 µm sections on a microtome and de-paraffinized. After 
antigen retrieval slides were incubated with primary antibody (the primary antibodies 
used are listed in Table 3.4.1) for 1 hour at room temperature and washed with Tris-
HCL (Tris hydrochloride) buffer (pH 7.5) followed by a secondary antibody. Antibodies 
were detected with the Vectastain Elite ABC (avidin-biotin complex) kit (Vector) using 
DAB (3,3'-diaminobenzidine) (Vector Laboratories and Dako) for brown stainings or 
AEC (3-Amino-9-ethylcarbazole) (Thermo Fisher Scientific) for red stainings. The 
slides were counterstained with hematoxylin (Vector Laboratories) and mounted with 
Roti®-Histokitt II (Carl Roth). All stainings were performed with the respective IgG 
(Immunglobulin G) control (Table 3.4.1) as a negative control and without primary 
antibody as a system control. Images were captured on an Axioplan2 imaging 
microscope (Carl Zeiss) equipped with an AxioCamHRc Camera (Carl Zeiss). For 
analysis of cleaved Caspase-3 the AxioVision Software (Carl Zeiss) was used to 
measure the area for each tumor in mm2.  
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4.5 In situ hybridization 
   For detection of ISCs with an Olfm4 mRNA probe, the Bluescript II plasmid p695-
pBS-mOlfm4 (kindly provided by Prof. Hans Clevers) was linearized by using a NotI 
restriction enzyme (New England Biolabs). The pCMV6 entry plasmids containing the 
Lgr5 or Smoc2 open reading frame (ORF) were obtained from Origene with the catalog 
number MR219702 or MR207121, respectively. Both ORFs were cloned into the pBSII 
KS plasmid (Promega Corporation) by using the restriction enzymes NotI and KpnI. 
The pBSII KS-mSmoc2 was linearized with the KpnI restriction enzyme and the pBSII 
KS-mLgr5 was linearized with the BclI restriction enzyme. The Olfm4, Lgr5 and Smoc2 
(SPARC-related modular calcium-binding protein 2) RNA probe was generated by an 
in vitro transcription reaction with a RNA-T7 Polymerase by using the DIG Northern 
Starter Kit (Roche Diagnostics). During the transcription reaction the probe was labeled 
with digoxigenin (DIG). The in situ hybridization was performed on freshly prepared 8 
µm paraffin sections as described (Gregorieff and Clevers, 2010). 
 
4.6 Isolation of IECs 
   Each part of the intestine was dissected longitudinally and cut into small pieces. IECs 
were isolated by shaking the tissue in Hanks´balanced salt solution (HBSS)/ethylene-
diamine-tetra-acetic acid (EDTA) at 37◦C for 10 minutes. The supernatant including 
IECs was centrifuged and the pellet was washed with ice-cold PBS, frozen in liquid 
nitrogen and stored at -80◦C until RNA isolation.  
 
4.7 Crypt isolation and organoid culture 
   Crypt isolation and organoid culture was performed as described before (Sato et al., 
2009). The small intestine was opened longitudinally, and the villi were scraped off 
under a dissection microscope by using a surgical blade. The intestine was cut into 
small pieces and incubated in 8 mM EDTA in HBSS for 5 minutes to remove the rest 
of the villi followed by an additional incubation in EDTA for 30 minutes at 4◦C. Isolated 
crypts were washed in advanced DMEM (Dulbecco's Modified Eagle's Medium)/F12 
(Gibco / Life Technologies) containing Glutamax (Gibco / Life Technologies) and 
Hepes (Gibco / Life Technologies), passed through a 100 µm cell strainer and either 
frozen in liquid nitrogen (IEC) or counted and pelleted for culturing (organoids). 200 
crypts were mixed with 50 µl of growth factor reduced, phenol red-free matrigel. After 
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polymerization of the Matrigel 600 µl of crypt culture medium was added. Crypt culture 
medium consists of advanced DMEM/F12 supplemented with 1:100 P/S 
(Penicillin/Streptomycin) (Gibco / Life Technologies), 1:100 Hepes, 1:100 Glutamax 
and the following growth factors: 100 ng/ml Noggin (Preprotech), 1:100 N2 (Gibco / 
Life Technologies), 1:50 B27 retinoic acid free (Gibco / Life Technologies), 50 ng/ml 
epidermal growth factor (EGF) (Preprotech), 500 ng/ml R-spondin-1 (RSPO1) 
(Sinobiological), 10 µM Y-27632 (MedBiochem Express) was added only the first 2 
days after isolation/culturing or passaging to avoid anoikis and 100 ng/ml Wnt-3a 
(Abcam) was added only the first two days after isolation/culturing. Crypt culture 
medium was changed every 2 days. Organoids were passaged at a 1:6 ratio once a 
week. For passaging organoids were removed from Matrigel and dissociated 
mechanically into single-crypt domains before they were transferred into fresh Matrigel. 
4-OHT (4-hydroxytamoxifen) (Sigma-Aldrich), diluted in ethanol, was added to the 
crypt culture medium to a final concentration of 500 nM for at least 12 hours. RNA was 
isolated using Trizol (Invitrogen) and the RNeasy Mini Kit (QIAGEN). 
   For generation of tumoroids intestinal adenoma cells from 3 tumors for each ApcMin/+ 
mouse were isolated by lysis in DMEM containing 4000 units Collagenase Type IV 
(Merck Millipore) and 125 µg/ml Dispase Type II (Sigma-Aldrich). Single cells were 
embedded in Matrigel and seeded in 24-well plates (15,000 single cells per 50 µl 
Matrigel per well). The tumor organoid culture medium was formulated as described 
before (Sato et al., 2011a). Crypt culture medium (Advanced DMEM/F12 
supplemented with 1:100 Penicillin/Streptomycin, 1:100 Hepes and 1:100 Glutamax 
and growth factors (1:100 N2, 1:50 B27, 50 ng/ml EGF)). 10 µM Y-27632 was added 
only the first 2 days after isolation/culturing or passaging to avoid anoikis. Counting of 
the number of organoids per well (6 wells per mouse) was performed 6 days after 
isolation before the first passaging. Passaging was performed as described above for 
normal organoids. RNA was isolated using Trizol and the RNeasy Mini Kit. For Western 
blot analysis tumor organoids were lysed in RIPA lysis buffer (50 mM Tris/HCl, pH 8.0, 
150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecylsulfate, 
Complete Mini protease inhibitors (Roche Diagnostics)). 
   For tumoroid formation after acute loss of Apc or Apc and Ap4 crypts were isolated 
as described above. For each well in a 6-well plate approximately 8 drops of 25µl 
matrigel and 50 crypts each were plated and overlaid with ENR media (containing EGF, 
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Noggin and RSPO1) as described above. 48 hours after isolation organoids were 
treated with 100 nM 4-OHT in ENR media for 48 hours. After passaging and additional 
48 hours, the culture conditions were switched to EN devoid of RSPO1 to select for 
tumoroid growth. Pictures of tumoroids were taken with a Nikon AZ-100 macroscope 
equipped with a Nikon DS-Fi3 color camera equipped with a 5.9 megapixel CMOS 
image sensor. 
 
4.8 Tissue microarrays and IHC (immunohistochemistry) analysis of clinical 
samples 
   Colon cancer specimens from patients that underwent surgical resection at the 
University of Munich (LMU) were drawn from the archives of the Institute of Pathology. 
Specimens were anonymized, and the need for consent was waived by the institutional 
ethics committee of the Medical Faculty of the LMU. Tissue microarrays (TMAs) with 
samples of 225 (220 evaluable) stage II primary colorectal cancer cases were 
generated with 6 representative 1 mm cores of each case. 5 µm TMA sections were 
deparaffinized and stained with primary antibodies (listed in Table 3.4.1) on a Ventana 
Benchmark XT Autostainer with UltraView Universal DAB and alkaline phosphatase 
detection kits (Ventana Medical Systems). The stainings were evaluated according to 
the score shown in Figure 30a.  
 
4.9 RNA expression profiling by RNA-Seq 
   Total RNA from organoids or adenomas was used for RNA-Seq (RNA-sequencing). 
Random primed cDNA libraries were constructed and sequenced using the HiSeq2500 
(Illumina) platform by GATC (Konstanz, Germany). Each sample was covered by at 
least 30 million single reads of 50 bp length.  
 
4.10 Bioinformatics analyses of RNA-Seq and ChIP-Seq data 
   RNA-Seq FASTQ files were processed using the RNA-Seq module implemented in 
the CLC Genomics Workbench v8.0 software (QIAGEN Bioinformatics) with default 
settings and were mapped to the GRCm38/mm10 mouse reference genome and its 
associated gene and transcript annotation (ENSEMBL). RNA-Seq data were filtered to 
exclude weakly expressed transcripts with less than 5 mapped exon reads in all 
samples from the analysis and subjected to upper quartile normalization using the 
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R/Bioconductor RUVSeq (remove unwanted variation from RNA-Seq data) package 
as described in (Risso et al., 2014). Differential gene expression analysis was 
performed with edgeR (McCarthy et al., 2012; Robinson et al., 2010) or DESeq2 (Love 
et al., 2014) after further normalization using the RUVg approach to remove variation 
between RNA samples resulting from differences in library preparation. Gene Set 
Enrichment Analysis (GSEA) was performed using the GSEA software (Subramanian 
et al., 2005). Lgr5+ or EphB2high stem cell gene sets were obtained from (Merlos-
Suarez et al., 2011; Munoz et al., 2012; van der Flier et al., 2009). The Wnt/β-catenin 
target gene sets were obtained from (Fevr et al., 2007). The Notch target gene set was 
obtained from (Li et al., 2012). Additional gene sets representing genes involved in 
Wnt/β-catenin signaling, EMT or c-Myc target genes were obtained from the Molecular 
Signatures database (MSigDB) (Liberzon et al., 2015). Enrichment of Hallmark gene 
sets or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways among 
differentially regulated genes was analyzed with the Molecular Signatures database 
program (MSigDB) (Liberzon et al., 2015). Heatmaps were generated with GENE-E 
(Broad Institute). 
   ChIP-Seq (Chromatin immunoprecipitation-sequencing) data of genome-wide Ap4 
occupancy in murine B and T cells (GEO accession nos. GSE80669 and GSE58075) 
and human CRC cells (GEO accession no. GSE46935) were obtained from previously 
published studies (Chou et al., 2014; Chou et al., 2016; Jackstadt et al., 2013c) and 
were analyzed with the UCSC genome browser (Kent et al., 2002). 
 
4.11 In silico analysis of human colorectal patient samples 
   Normalized RNA expression (RNA-Seq by Expectation Maximization; RSEM) data 
from colorectal cancer patient samples were obtained from the publically available 
TCGA datasets (Cancer Genome Atlas, 2012) at https://cancergenome.nih.gov/. 
Association of TCGA patient samples with the different CMS (consensus molecular 
subtypes) categories was obtained from the Cancer Subtyping Consortium (CRCSC) 
at www.synapse.org. The CMS sub-types were described in (Guinney et al., 2015). 
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4.12 Indirect immunofluorescence detection and confocal laser-scanning 
microscopy  
   FITC (Fluorescein isothiocyanate) conjugated donkey anti-rabbit (Jackson Immuno 
Research) and AlexaFluor 555 conjugated goat anti-mouse (Invitrogen) antibodies 
were used for detection of primary rabbit or mouse antibodies, respectively. DNA was 
stained using DAPI (4′,6-diamidino-2-phenylindole) (Carl Roth). Slides were mounted 
with ProLong Gold antifade reagent (Life technologies). Images were captured with a 
confocal microscope (LSM 700, Carl Zeiss) using a Plan Apochromat 20x/0.8 M27 
objective, ZEN 2009 software (Carl Zeiss) and the following settings: Image size 
2048x2048 and 16 bit; pixel/dwell of 25.2 µs; pixel size 0.31 µm; laser power 2%; 
master gain 600-1000. After image capturing the original LSM files were converted into 
TIFF files. Conditions for primary antibodies used here are listed in Table 3.4.1. 
 
4.13 Electron microscopy  
   Small pieces from the middle of ileum were fixed in 6.25% glutaraldehyde, post-fixed 
with osmium tetroxide, dehydrated, embedded in EPON 812 (Serva Electrophoresis), 
polymerized at 80◦C and cut into 60-80 nm sections with an ultra-microtome (Ultracut, 
Reichert Jung). The sections were stained with lead citrate and uranyl acetate. Images 
were captured on a transmission electron microscope (Libra 120, Carl Zeiss). 
 
4.14 RNA isolation and quantitative real-time PCR (qPCR) 
   Total RNA was isolated using the High Pure RNA Isolation Kit (Roche Diagnostics) 
or RNAeasy Kit (QIAGEN). 5 adenomas per mouse were used for each ApcMin tumor 
sample. cDNA was generated from 1 µg total RNA per sample using anchored oligo-
dT primers (Reverse-iT First Strand Synthesis; ABgene). qPCR was performed by 
using the LightCycler 480 (Roche Diagnostics) and the Fast SYBR Green Master Mix 
(Applied Biosystems) as described previously (Siemens et al., 2011). Oligonucleotides 
used as qPCR primers are provided in Table 3.6.2. 
 
4.15 DBZ treatment of mice  
   DBZ (dibenzazepine) treatment was described elsewhere (van Es et al., 2005b). The 
γ-secretase inhibitor DBZ (Axon Medchem) was suspended in water with 0.5% 
Methocel and 0.1% Tween-80 (Sigma-Aldrich), and 40 µmol/kg were injected i.p. on 5 
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consecutive days into NOD/SCID mice. The mice were sacrificed at day 6 for tissue 
collection.  
 
4.16 Cell lines / culture and reagents  
   SW480, SW620, HT29 and HEK293T cell lines were maintained in Dulbecco`s 
Modified Eagles Medium (DMEM, Gibco / Life Technologies). Colo320 and the mouse 
colon carcinoma cell line CT26 were cultured in RPMI (Roswell Park Memorial 
Institute) 1640 (Sigma-Aldrich, Gibco / Life Technologies). The colorectal cancer cell 
lines DLD-1 and HCT15 were maintained in McCoy`s 5A Medium (Gibco / Life 
Technologies). The identity of SW480, SW620, Colo320, HT29, HCT15 and DLD-1 cell 
lines was confirmed by PCR-single-locus technology using 21 independent PCR 
amplicons (Eurofins Medigenomics, Ebersberg, Germany). CT26 cells were purchased 
from ATCC (the American Type Culture Collection) and HEK293T cells from DSMZ 
(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH). All cells were 
cultivated in presence of 100 units/ml penicillin and 0.1 mg/ml streptomycin and 10% 
fetal bovine serum (FBS) (Invitrogen). Doxycycline (DOX) (Sigma-Aldrich) was 
dissolved in water (100 µg/ml stock solution) and always used at 100 ng/ml final 
concentration.  
 
4.17 Chromatin immunoprecipitation (ChIP) assay  
   Cross-linking and harvesting of cells was performed as previously described 
(Jackstadt et al., 2013b). Briefly, cross-linking was performed by incubation of cells in 
1% formaldehyde (Merck Millipore) and terminated after 5 minutes by addition of 
glycine at a final concentration of 0.125 M. Cells were harvested with SDS buffer (50 
mM Tris/HCL pH 8.1, 0.5% SDS, 100 mM NaCl, 5 mM EDTA) and after pelleting 
resuspended in IP (Immunoprecipitation) buffer (2 parts of SDS buffer and 1 part Triton 
dilution buffer (100 mM Tris/HCl pH 8.6, 100 mM NaCl, 5 mM EDTA (pH 8.0), 0.2%  
NaN3, 5% Triton X-100)). Chromatin was sheered by sonication (HTU SONI 130, G. 
Heinemann) to generate DNA fragments with an average size of 500 bp. Pre-clearing 
and incubation with an AP4-specific antibody or the respective IgG control (the 
antibodies used are listed in Table 3.4.1) was performed for 16 hours as previously 
described (Menssen et al., 2007). Washing and reversal of cross-linking was 
performed as described (Frank et al., 2001). Immunoprecipitated DNA was analyzed 
 Methods 
40 
 
by qPCR and the enrichment was expressed as percentage of the input for each 
condition (Frank et al., 2001). The sequences of oligonucleotides used as qChIP 
primers are listed in Table 3.6.3.  
 
4.18 Generation of cell pools stably expressing conditional alleles  
   DLD-1 colorectal cancer cells were transfected with pRTR plasmids using 
Lipofectamin 2000 (Invitrogen) or FuGENE (Promega Corporation). After 24 hours 
cells were transferred into media containing 4 µg/ml Puromycin (Sigma-Aldrich) for one 
week. Homogeneity of the derived cell pools was determined by addition of 100 ng/ml 
DOX (Sigma-Aldrich) for 48 hours and evaluation of GFP expression by fluorescence 
microscopy by using an Axiovert 25 microscope equipped with an Axiocam 105 color 
camera (Carl Zeiss) and by flow cytometry using a BD AccuriTM C6 flow cytometer 
instrument (BD Accuri). 
 
4.19 Plasmids and RNAi  
   The generation of pRTR-AP4-VSV was previously described (Jackstadt et al., 
2013c). siRNAs (silencerRNAs) were transfected at a 40 nM final concentration using 
HiPerFect reagent (QIAGEN). siRNA target sequences were as follows: AP4-specific 
siRNA (Ambion): (5‘-GUGAUAGGAGGGCUCUGUAG-3‘) as described in (Jung et al., 
2008). As a control the Silencer negative control siRNA #1 (Ambion) was used. 
 
4.20 Cell-Based Reporter Assays  
   HEK293T cells were seeded in 24-well format dishes at 50% confluence and 
transfected with FuGENE Reagent (Roche Diagnistics) for 24 hours with 100 ng of the 
indicated firefly luciferase reporter plasmid (pGA-RBPJ (Oswald et al., 2001)) and the 
respective control vector (pGA (Oswald et al., 2001)), 100 ng of the effector (dBR-AP4, 
AP4) or the respective control vector and 10 ng of Renilla reporter plasmid as a 
normalization control. The analyses were performed with the Dual Luciferase Reporter 
assay (Promega Corporation) according to manufacturer’s instructions. Luminescence 
intensities were measured with an Orion II Luminometer (Berthold) in 96-well format 
and analyzed with the SIMPLICITY software package (DLR).   
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4.21 Western blot analysis  
   Cells or tumoroids were lysed in RIPA lysis buffer (50 mM Tris/HCl, pH 8.0, 150 mM 
NaCl, 1% NP40, 0.5% (w/v) sodium deoxycholate, 0.1% sodium dodecylsulfate, 
Complete Mini protease inhibitors (Roche Diagnostics)). Lysates were sonicated and 
centrifuged at 16.060 x g for 15 min at 4°C. Per lane 30 – 80 µg of whole cell lysate 
was separated using 10% or 12% SDS-acrylamide gels and transferred on Immobilon 
PVDF membranes (Merck Millipore). For immuno-detection membranes were 
incubated with primary antibodies (the primary antibodies used are listed in Table 
3.4.1). Signals from HRP (horse-radish-peroxidase)-coupled secondary antibodies 
were generated by enhanced chemiluminescence (Perkin Elmer Life Sciences, 
Boston, MA) and recorded with a CCD camera (440CF imaging system, Eastman 
Kodak Co., Rochester, NY). Uncropped Western blot membranes are provided in 
Supplemental Data 3. 
 
4.22 Statistical analysis  
   The Graph Pad Prism software was used for statistical analyses. A Student’s t test 
(unpaired, two-tailed) was used for calculation of significant differences between two 
groups of samples or mice, with p<0.05 considered significant. Asterices generally 
indicate: *: p<0.05, **: p<0.01 and ***: p<0.001, n.s. = not significant. For calculation 
of correlation coefficients, Pearson´s or Spearman´s correlation analyses were 
applied. Kaplan Meier curves were analyzed by log-rank (Mantel-Cox) test. 
 
4.23 Data availability statement  
   RNA-Seq data that support the findings of this study have been deposited in Gene 
Expression Omnibus (GEO) with the accession codes „GSE99434” and “GSE99437”.  
All other data are available from the corresponding author on reasonable request. 
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5. Results 
 
5.1 Role of Ap4 in intestinal adenoma formation 
   Here we determined the effect of Ap4-deficiency on adenoma formation in the 
intestine of ApcMin mice, which harbour an inactivating mutation in one adenomatous 
polyposis coli (Apc) allele (Jaeckel et al., 2018). Upon spontaneous loss of the second 
Apc allele these mice develop ~50-100 adenomas in the small intestine by the age of 
4-6 months. As expected, adenomas in ApcMin/+/Ap4-/- mice did not display Ap4 
expression, whereas adenomas of ApcMin mice showed elevated expression of Ap4 
(Figure 9a). ~50% of ApcMin mice succumbed to intestinal adenomas by ~180 days of 
age (Figure 9b) which was in line with previous reports (Guillen-Ahlers et al., 2010; 
Hoshiko et al., 2013). However, in Ap4-deficient ApcMin mice intestinal cancer-related 
death was delayed on average by 110 days, with heterozygous mice showing an 
intermediate delay. 
 
 
Figure 9 Deletion of Ap4 in ApcMin/+ mice prolongs survival. a Immunohistochemical 
detection of Ap4 in adenomas of moribund ApcMin/+ mice with the indicated genotype. 
Counterstaining with hematoxylin.  Scale bar = 50 µm. b Kaplan-Meier survival analysis of 
ApcMin/+ mice with the indicated genotypes. Censored mice without intestinal tumor related 
death are indicated on the Kaplan-Meier curve as tick marks. Results were subjected to a log 
rank test with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = not significant 
 
Ap4-deficiency was associated with a ~4-fold decrease in the number of adenomas in 
the small intestines of moribund ApcMin mice, while the size of adenomas increased 
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(Figure 10a-c). Unexpectedly, the proliferation rate within small intestinal adenomas of 
moribund ApcMin mice was not affected by loss of Ap4 (Figure 10d).  
 
Figure 10 Deletion of Ap4 in ApcMin/+ mice decreases the frequency of adenomas.  
a Macroscopic pathology of representative polyps in the small intestine (ileum) of moribund 
ApcMin/+ mice with the indicated genotype, scale in cm. b Representative sections through rolls 
of the small intestine stained for hematoxylin and eosin (HE). Scale bar = 500 µm. c 
Quantification of adenoma number/mouse (left panel) and tumor diameter (right panel) in the 
intestine of 6 male and 6 female (ApcMin/+/Ap4+/+), 5 male and 5 female (ApcMin/+/Ap4+/-) or 4 
male and 4 female (ApcMin/+/Ap4-/-) moribund ApcMin/+ mice. The box plot extends from the 25th 
to 75th percentiles. The line in the middle of the box is plotted at the median. The whiskers 
underneath or above the boxes range from min. to max. value, respectively. d Left panel: 
Immunohistochemical detection of Ki67 in adenomas from moribund ApcMin/+ mice, scale bar 
= 200 µm. Counterstaining with hematoxylin. Right panel: Ki67-positive cells were counted in 
at least 8 adenomas from 1 male and 2 female mice per genotype. c, d: Results represent the 
mean +/- SD. Results were subjected to an unpaired, two tailed Student’s t-test with p-values 
* < 0.05, ** < 0.01, *** < 0.001, n.s. = not significant. 
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When adenomas of age-matched, 120 days old ApcMin mice were compared, the Ap4-
deficient mice showed a ~5-fold decrease in the number of adenomas, whereas the 
size of the adenomas was not affected (Figure 11a-c). A decreased number of tumors 
was also detected in the colon of Ap4-deficient ApcMin mice when compared to Ap4-
wild-type ApcMin mice (Figure 11d). However, due to the low incidence of adenomas in 
the colon of ApcMin mice these differences did not reach statistical significance. The 
uniform tumor size and the unchanged proliferation rate of tumors in the small intestine 
(Figure 11e) in 120 days old mice suggested that the increase in adenoma size seen 
in moribund animals was most likely due to the increased lifespan of Ap4-deficient 
ApcMin mice. 
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Figure 11 Ap4 deletion decreases frequency but not size of adenomas in age-matched 
ApcMin/+ mice. a Macroscopic pathology of representative polyps in the small intestine (ileum) 
of 120 days old ApcMin/+ mice with the indicated genotype, scale in cm. b Representative 
sections through rolls of the small intestine were stained for β-catenin. Scale bar = 500 µm 
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(upper pictures) or 250 µm (lower pictures). c Quantification of adenoma number/mouse (left 
panel) and tumor diameter (right panel) in the intestine of 4 male and 4 female 120 days old 
ApcMin/+ mice per genotype. The box extends from the 25th to 75th percentiles. The line in the 
middle of the box is plotted at the median. The whiskers represent the minimal and maximal 
values. d Left panel: Macroscopic pathology of representative polyps in the colon of 120 days 
old ApcMin/+ mice with the indicated genotype, scale in cm. Right panel: Quantification of colonic 
adenomas of 120 days old ApcMin/+ mice with the indicated genotype. e Left panel: 
Immunohistochemical detection of Ki67 in adenomas of 120 days old ApcMin/+ mice of the 
indicated genotype. Scale bar = 100 µm. Counterstaining with hematoxylin. Right panel: Ki67-
positive cells were counted in at least 9 adenomas derived from 1 male and 2 female mice per 
genotype.  c, d, e: Results represent the mean +/- SD. Results were subjected to an unpaired, 
two tailed Student’s t-test with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = not significant. 
 
The effects of Ap4 loss on tumorigenesis observed in ApcMin mice were independent 
of the gender (Figure 12a-c). When we analyzed ApcMin mice with intestinal epithelial 
cell (IEC)-specific deletion of Ap4, which was achieved by crossing Villin-Cre with 
Ap4fl/fl mice, we obtained similar results as for ApcMin mice with germ-line deletion of 
Ap4: i.e. in Ap4∆IEC/ApcMin mice intestinal cancer-related death was significantly 
delayed by 110 days, with heterozygous mice showing an intermediate delay (Figure 
13a). Ap4∆IEC/ApcMin mice showed a 6-fold decrease in the number of adenomas in the 
small intestines of moribund and a 5-fold decrease in the small intestine of 120 days 
old ApcMin mice, whereas the size of adenomas increases in moribund mice and the 
size of the adenomas was not affected in 120 days old mice (Figure 13b, c). Epithelial-
specific deletion of Ap4 in ApcMin mice also resulted in a decreased number of 
adenomas in the colon, although this effect was not statistically significant (Figure 13d). 
Interestingly, deletion of Ap4 in epithelial cells did not affect the proliferation rate of 
established adenomas of ApcMin mice (Figure 13e). Therefore, the effects of Ap4 
deletion in the germ-line on adenoma formation are presumably intestinal epithelial 
cell-autonomous. Taken together, these results show that Ap4 is rate limiting for 
adenoma initiation in ApcMin mice. Since c-Myc is a required mediator of intestinal 
tumor formation in Apc-mediated tumorigenesis, the results imply a pivotal role of Ap4 
among the many known c-Myc target genes in mediating intestinal tumor formation. 
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Figure 12 Effects of gender-specific deletion of Ap4 on adenoma formation in ApcMin/+ 
mice. a Kaplan-Meier survival analysis of ApcMin/+ mice with the indicated genotypes. Male and 
female mice have been analyzed separately. Censored mice without intestinal tumor related 
death are indicated on the Kaplan-Meier curve as tick marks. b Quantification of adenoma 
number per mouse (left panel) and tumor diameter (right panel) in the intestine of 6 male and 
6 female (ApcMin/+/Ap4+/+), 5 male and 5 female (ApcMin/+/Ap4+/-)) or 4 male and 4 female 
(ApcMin/+/Ap4-/-) moribund ApcMin/+ mice. Male and female mice have been analyzed separately. 
The box extends from 25th to 75th percentile. The line in the middle of the box represents the 
median. The whiskers underneath or above the boxes depict the min. and max. value, 
respectively. c Enumeration of adenomas per mouse (left panel) and tumor diameter (right 
panel) in the intestine of 4 male and 4 female 120 days old ApcMin/+ mice per genotype as in 
(b). Male and female mice were analyzed separately. a: Results were subjected to a log rank 
test. b, c: Results represent the mean +/- SD with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. 
= not significant.  
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Figure 13 Effects of epithelial-specific deletion of Ap4 on adenoma formation in ApcMin/+ 
mice. a Kaplan-Meier survival analysis of ApcMin/+ mice with the indicated genotypes. b 
Enumeration of adenomas/mouse (left panel) and tumor diameter (right panel) in the intestine 
of 7 male and 7 female (ApcMin/+/Ap4fl/fl) or 5 male and 5 female (ApcMin/+/Ap4+/∆IEC, 
ApcMin/+/Ap∆IEC) moribund ApcMin/+ mice per genotype. c Enumeration of adenomas/mouse (left 
panel) and tumor diameter (right panel) in the intestine of 6 male and 6 female (ApcMin/+/Ap4fl/fl) 
or 4 male and 4 female (ApcMin/+/Ap4+/∆IEC, ApcMin/+/Ap∆IEC) 120 days old ApcMin/+ mice per 
genotype. d Quantification of colonic adenomas of 120 days old ApcMin/+ mice with the indicated 
genotype. e Left panel: Immunohistochemical detection of BrdU incorporation in adenomas of 
120 days old ApcMin/+ mice of the indicated genotype. Counterstaining with hematoxylin. Scale 
bar = 100 µm. Right Panel: Quantification of BrdU-positive cells in at least 9 adenomas of the 
ileum from 1 male and 2 female mice per genotype. a: Results were subjected to a log rank 
test. b, c, d, e: Results represent the mean +/- SD with p-values * < 0.05, ** < 0.01, *** < 0.001, 
n.s. = not significant. 
 
5.2 mRNA expression profiling of Ap4-deficient adenomas 
   To identify pathways mediating the effects of Ap4 we compared the mRNA 
expression profiles of intestinal adenomas that formed in ApcMin mice with and without 
Ap4 deletion. By applying next-generation sequencing (NGS) we identified 1459 
mRNAs that were differentially regulated with a fold change in expression > 1.5 
(p<0.05) due to deletion of Ap4 (Figure 14a). Out of these, 954 mRNAs were 
significantly down-regulated, and 505 mRNAs were up-regulated in Ap4-deficient 
ApcMin mice (Figure 14b, c). Notably, pathway analysis showed that mRNAs encoding 
for proteins involved in EMT (epithelial-mesenchymal transition), as well as cell-cycle 
regulatory proteins (e.g. E2f targets) were significantly enriched among the down-
regulated mRNAs (Figure 14d, Supplemental Data 1).  
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Figure 14 Expression analyses of Ap4-deficient adenomas from ApcMin/+ mice. a Venn 
diagram displaying differentially regulated RNAs (fold change > 1.25, p<0.05) in Ap4fl/fl and 
Ap4∆IEC ApcMin/+ adenomas as determined by edgeR and DESeq2. b Volcano plot depicting 
expression changes between ApcMin/+/Ap4fl/fl and ApcMin/+/Ap4∆IEC tumors from 120 days old 
mice derived from 3 female mice (5 tumors per mouse) per genotype detected by RNA-Seq. 
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P-values are plotted against the log2 of the corresponding RNA expression changes in Ap4∆IEC 
versus Ap4fl/fl adenomas. Differentially expressed RNAs (p-value < 0.05) with a log2 fold 
change ≥ 0.58 are indicated in red, with a log2 fold change ≤ −0.58 are marked in blue. RNAs 
with 0,58 > log2 fold change > −0.58 and/or with a p-value ≥ 0.05 are represented by grey dots. 
Dashed vertical lines indicate cut-offs for differential expression. Dashed horizontal line 
indicates the cut-off for adjusted p-values < 0.05 as determined with DESeq2. c Heat map 
depicting expression changes of differentially expressed mRNAs (fold change > 1.5 and p< 
0.05 as determined by edgeR and DESeq2) as relative expression levels normalized to the 
mean expression in the control, ApcMin/+/Ap4fl/fl, samples for each indicated mRNA. Colors 
indicate relative expression values from minimum (blue) to maximum (red) for each RNA 
sample per differentially regulated mRNA. Three biological replicates per genotype were 
analyzed. d Upper panel: Hallmark gene set (mSigDB: molecular Signature Database 
(Liberzon et al., 2015)) and KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis from 
down-regulated mRNAs after conditional ablation of Ap4 in intestinal ApcMin/+ adenomas. The 
10 most significantly enriched pathways among down-regulated mRNAs are shown. Lower 
panel: Hallmark gene set (mSigDB: molecular Signature Database) and KEGG (Kyoto 
Encyclopedia of Genes and Genomes) analysis from up-regulated mRNAs. The 10 most 
significantly enriched pathways among up-regulated mRNAs after conditional ablation of Ap4 
in intestinal ApcMin/+ adenomas are shown. See also Supplemental Data 1.  All data analyses 
were performed by Dr. Markus Kaller. 
 
Furthermore, Gene Set Enrichment Analysis (GSEA) showed that mRNAs 
characteristic for Lgr5-positive or EphB2high ISCs (intestinal stem cells) (Merlos-Suarez 
et al., 2011; Munoz et al., 2012; van der Flier et al., 2009) were preferentially down-
regulated in Ap4-deficient adenomas (Figure 15a, b). Moreover, mRNAs encoding for 
proteins involved in Wingless/Int-1(Wnt)/β-catenin and Notch signaling, which control 
the homeostasis of ISCs (Beumer and Clevers, 2016; Sancho et al., 2004), were also 
preferentially down-regulated in Ap4-deficient adenomas (Figure 15a, b, Supplemental 
Data 2). Genes down-regulated upon deletion of Ap4 included ISC markers induced 
by Wnt/β-catenin signaling, such as Lgr5 and Ascl2 (Barker et al., 2007; de Lau et al., 
2011; Van der Flier et al., 2007), or by Notch signaling, such as Olfm4 (VanDussen et 
al., 2012), as well as additional direct Wnt/β-catenin and/or Notch target genes with 
critical functions in the Wnt and Notch signaling pathways, such as Sox4, Tcf7/Tcf1, 
Axin2, EphB3, Jag1, Jag2, Hes1 and c-Myc (Figure 15b). Furthermore, Notch1 itself 
was down-regulated in Ap4-deficient adenomas. Taken together, these results imply 
that Ap4 regulates the homeostasis of ISCs via activating Wnt/β-catenin and/or Notch 
signaling pathways.  
   Recently, Ap4 was shown to maintain a c-Myc-induced transcriptional program in 
activated T-cells (Chou et al., 2014) and germinal center B-cells (Chou et al., 2016) . 
In line with these findings, c-Myc target genes were preferentially down-regulated in 
Ap4-deficient adenomas (Figure 15a; Supplemental Data 2). However, the changes in 
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expression of c-Myc target genes observed after deletion of Ap4 were rather modest 
compared to the regulations observed in ISC signature or Notch signaling components 
(Figure 15c). Likewise, E2f targets, though significantly enriched among the down-
regulated RNAs (Figure 15a), displayed only modest changes in expression that were 
comparable to those of c-Myc targets (Figure 15c). These modest regulations of c-Myc 
and E2f targets may explain the lacking influence of Ap4-deletion on cell proliferation 
within adenomas. Also mRNAs involved in EMT were preferentially down-regulated in 
Ap4-deficient adenomas (Figure 15a), which matches our previous study about the 
role of AP4 in EMT in human colorectal cancer (CRC) cell lines (Jackstadt et al., 
2013c). We exemplarily confirmed the differential regulation detected by NGS using 
qPCR. Thereby, we validated the down-regulation of the stem cell markers Smoc2, 
Lgr5 and Olfm4, as well as the repression of several genes involved in the Wnt/β-
catenin signaling and/or Notch signaling in Ap4-deficient adenomas (Figure 15d). 
Consistent with its previously reported repression by AP4 (Jung et al., 2008), 
Cdkn1a/p21 was up-regulated in Ap4-deficient adenomas. Interestingly, we did not 
detect a change in mRNA or protein levels of Ctnnb1 (β-catenin) in ApcMin adenomas 
(Figure 15d, e), suggesting that Ap4 directly regulates Wnt/β-catenin target genes. 
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Figure 15 Ap4-dependent expression profiles in ApcMin/+ adenomas. a GSEA comparing 
gene expression profiles from ApcMin/+/Ap4fl/fl and ApcMin/+/Ap4∆IEC adenomas from 120 days old 
mice with Lgr5-positive or EphB2high stem cell signatures (Munoz et al., 2012) (Merlos-Suarez 
et al., 2011; van der Flier et al., 2009), Wnt/β-catenin signaling (mSigDB: molecular Signatures 
Database ), mRNAs significantly enriched genes down-regulated mRNAs in β-catenin-knout-
out crypts which overlap with genes characteristic for other stem cell populations and intestinal 
tumors (Fevr et al., 2007), β-catenin target genes differentially regulated after Ctnnb1 loss 
(Fevr et al., 2007),Notch target genes (Li et al., 2012), c-Myc target genes (mSigDB), E2f target 
genes (mSigDB) and hallmark EMT (mSigDB). NES: Normalized Enrichment Score, Nom. P-
value: Nominal p-value. b Heatmap of selected differentially expressed mRNAs (p-value < 
0.05) from intestinal stem cell gene signatures, Wnt/β-catenin signaling and/or Notch signaling 
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gene signatures analyzed in (a). The heatmap displays relative fold changes in expression 
levels normalized to the mean expression in the control, ApcMin/+/Ap4fl/fl, samples for each 
indicated mRNA. Three biological replicates per genotype were analyzed. c Cumulative 
distribution plots comparing RNA expression changes as determined by DESeq2 of gene set 
members of the indicated gene signatures upon loss of AP4 in ApcMin/+ - induced adenomas. 
d qPCR analysis of the indicated mRNA derived from tumors from 3 female mice (5 tumors 
per mouse) per genotype. e Immunohistochemical detection of β-catenin in adenomas of 120 
days old ApcMin/+ mice of the indicated genotype. Scale bar = 100 µm. Counterstaining with 
hematoxylin. At least 16 adenomas from 2 male and 2 female mice per genotype were stained. 
d: Results represent the mean +/- SD. Results were subjected to an unpaired, two tailed 
Student’s t-test with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = not significant. a, b: See 
also Supplemental Data 2. a, b, c: Figures and analyses were made by Dr. Markus Kaller. 
 
   Next, we analyzed whether Ap4 directly regulates the expression of ISC markers and 
components of the Wnt/β-catenin and/or Notch signaling pathways. Our analysis of 
Ap4 DNA binding patterns in murine T and B cells (Chou et al., 2014; Chou et al., 2016) 
revealed Ap4 occupancy within the promoter regions of Ascl2, Axin2, c-Myc, Dll1, Dll4, 
EphB3, Hes1, Hey1, Jag1, Jag2, Notch1, Sox4, and Tcf7 (Figure 16a). We performed 
quantitative chromatin-immunoprecipitation (qChIP) analysis to confirm Ap4 
occupancy in the murine CRC cell line CT26 at the promoters of the following genes: 
Ascl2, Dll1, Dll4, EphB3, Hes1, Jag1, Jag2, Notch1, Sox4, and Tcf7 (Figure 16b). 
Similar to the promoter of human CDKN1A/P21, the murine Cdkn1a/p21 promoter also 
contains Ap4 binding sites that showed occupancy by Ap4 (Figure 16b). Therefore, 
Cdkn1a/p21 is a conserved, direct Ap4 target. Taken together, these results suggest 
that the differential regulation of genes involved in Wnt/β-catenin and/or Notch 
signaling observed in Ap4-deficient ApcMin adenomas is a direct consequence of the 
absence of Ap4 at the respective promoters.  
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Figure 16 Ap4 binding to promoters of selected genes. a BedGraph histogram plots 
showing examples of occupancy by Ap4 within promoters of genes involved in Wnt/β-catenin 
and/or Notch pathways in murine T-cells and/or B-cells according to previously published 
ChIP-Seq analysis (Chou et al., 2014; Chou et al., 2016). The following datasets deposited at 
https://www.ncbi.nlm.nih.gov/geo/ were used: GSM1400434, GSM1400430 (T-cells) and 
GSM2132680, GSM2132681, GSM2132682, GSM2132683 (B cells). Orange and blue vertical 
bars denote the genomic positions of CAGCTG and CAGGTG E-boxes, respectively. Red 
boxes indicate genomic coordinates of high confidence Ap4 peaks (p < 1e-10) identified with 
Homer (Hypergeometric Optimization of Motif EnRichment) (Heinz et al., 2010). Numbers on 
the y-axis indicate read-numbers as determined by ChIP-Seq analysis. Gene structures are 
indicated schematically with exons represented by thick rectangles. E-Boxes used for qChIP 
analysis in (b) are marked. Lz: light zone, dz: dark zone. b The murine CRC cells CT26 were 
subjected to qChIP analysis with Ap4 or IgG specific antibodies for ChIP. The mouse 
acetylcholine receptor (AchR) promoter, which lacks Ap4-binding motifs, served as a negative 
control. E-Boxes used for qChIP analysis are marked in (a). b: Results were subjected to an 
unpaired, two tailed Student’s t-test with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = not 
significant. a: Figures and analyses were made by Dr. Markus Kaller. 
 
5.3 Analysis of tumor organoids from Ap4-deficient ApcMin mice 
   Our NGS results suggested that Ap4 is involved in maintaining a stem cell like 
expression pattern in tumor cells. This was confirmed by in situ hybridization with a 
probe detecting the mRNA expression of Lgr5 or Smoc2 in small intestinal adenomas 
of ApcMin mice (Figure 17a). Indeed, Ap4-deficient adenomas displayed less cells 
positive for Lgr5 or Smoc2 mRNA expression when compared to adenomas 
expressing Ap4. Therefore, the number of tumor stem cells is presumably decreased 
in the absence of Ap4. Next, we generated tumor organoids using single cells derived 
from adenomas of ApcMin mice. Indeed, cells directly isolated from Ap4-deficient 
adenomas formed tumor organoids ex vivo with a significantly lower frequency than 
those derived from Ap4 wild-type adenomas (Figure 17b). However, after the first 
passage ex vivo the Ap4-deficient and proficient tumoroids re-built new tumor 
organoids with a comparable frequency and growth rate (Figure 17b). Therefore, Ap4 
0
1
2
3
*
*
CT26
Ap4
IgG
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
n
.
s.
Wnt/β-catenin components Notch components
%
 
in
pu
t
b
*
*
IP
 Results 
58 
 
appears to be required for the initiation, but not for the maintenance of ex vivo cultured 
intestinal tumoroids. The deletion of Ap4 in these tumor organoids was accompanied 
by lower levels of the ISC markers Smoc2, Lgr5 and Olfm4 when compared to Ap4 
wild-type adenomas (Figure 17c). Additional genes involved in Wnt/β-catenin signaling 
and/or Notch signaling, including Notch1 itself, were also down-regulated in Ap4-
deficient tumor organoids (Figure 17d). Also, at the protein level the cleaved, active 
form of Notch1 (Nicd1) and Hes1, which is encoded by a Notch target gene, were 
decreased in Ap4-deficient tumor organoids indicating a decrease in Notch signaling 
(Figure 17e). Therefore, the reduced de novo tumor organoid formation capacity may 
be caused by the down-regulation of genes required for in vivo ISC function upon Ap4 
loss. 
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Figure 17 Deletion of Ap4 decreases stemness in adenomas and tumor organoids. a Left 
panel: In situ hybridization of Lgr5 or Smoc2 mRNA. Scale bars represent 100 µm. Right panel: 
Quantification of Lgr5-positive or Smoc2-positive area in percent (%) in the adenomas from 2 
male and 1 female mice in at least 6 adenomas per genotype. b Left panel: representative 
pictures of small intestinal tumor organoids 6 days after isolation (passage 0), upper pictures, 
or 4 days after passaging (passage 1), lower pictures. Organoids were isolated from 3 tumors 
per mouse from 2 female and 2 male mice per genotype. Scale bars represent 500 µm. right 
panels: number of tumor organoids per drop of 50 µl matrigel. A total of 24 drops (passage 0) 
or 15 drops (passage 1) was analyzed per genotype. c, d qPCR analysis of the indicated 
mRNA derived from tumor organoids. e Western blot analysis of the indicated proteins. 
Uncropped Western blot membranes are shown in Supplemental Data 3. a, b, c, d: Results 
represent the mean +/- SD. Results were subjected to an unpaired, two tailed Student’s t-test 
with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = not significant. 
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   Subsequently, we isolated small intestinal crypts from Lgr5-CreERT2/Apcfl/fl and Lgr5-
CreERT2/Apcfl/fl/Ap4fl/fl mice. After plating of crypts in matrigel overlaid with ENR media 
(containing EGF, Noggin and RSPO1) we acutely deleted Apc or Apc in combination 
with Ap4 in Lgr5-positive stem cells of newly formed intestinal organoids by addition of 
4-hydroxy-tamoxifen (4-OHT). After passaging (passage 1) and seeding the same 
amount of cells per drop of matrigel we switched culture conditions to EN media devoid 
of RSPO1, in which only Apc-deficient tumoroids can grow. We obtained less de novo 
formed tumoroids after Ap4 deletion when compared to Ap4-proficient tumoroids 
(Figure 18a, b). This supports the notion that Ap4 has an important role during tumor 
initiation and confirms the result we previously obtained in vivo. Reassuringly, 
tumoroids did not form in the absence of RSPO1 and 4-OHT (Figure 18a). During serial 
passaging the amount and size of tumoroids was not influenced by the deletion of Ap4 
(Figure 18a, b, c). To exclude the possibility that Ap4-deficient tumoroids grew due to 
incomplete deletion of Ap4, the complete deletion of Ap4 was confirmed by genomic 
PCR (Figure 18d). Taken together, these results confirm a critical role of Ap4 in the 
initiation, but not for the maintenance of the tumoroids. These results are in line with 
the observations initially obtained with ApcMin mice, where Ap4 loss decreased the 
number of adenomas but not their size.  
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Figure 18 Deletion of Ap4 is not impotant for the maintenance of tumors.  
a Representative pictures of tumor organoids derived from small intestinal epithelial cells 
obtained from Lgr5-CreERT2+/-/Apcfl/fl and Lgr5-CreERT2+/-/Apcfl/fl/Ap4fl/fl mice after treatment 
with 4-OHT. After isolation organoids were kept in ENR Media (contains EGF, Noggin and 
RSPO1). 48 hours after isolation organoids were treated with 4-OHT in a concentration of 100 
nM for 48 hours to delete Apc or Apc in addition to Ap4 in Lgr5-positive intestinal stem cells 
(ISC). Additional 48 hours later organoids were passaged and EN media (containing EGF and 
Noggin, but without RSPO-1) was used, which selectively allowed Apc-deficient tumoroids to 
expand (passage 1-5). Pictures were taken 7 days after passaging in case of passage 1, 4 
days after passaging for passage 2 and 6 days after passaging for both passage 3, 4.and 5. b 
Mean tumor organoid number per drop of 25 µl matrigel calculated as a mean of a total of 20 
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drops for passage 1 and passage 3-5 or a total of 11 drops (Ap4 wt) and 6 drops (Ap4 ko) for 
passage 2. c Mean tumor organoid size was measured and calculated from matrigel drops as 
depicted exemplarily in (b). d Analysis of Ap4 status of tumoroids by genomic PCR at passage 
4. b, c: Results were subjected to an unpaired, two tailed Student’s t-test with p-values                  
* < 0.05, ** < 0.01, *** < 0.001, n.s. = not significant. 
 
5.4 Ap4 regulates the homeostasis of intestinal stem cells  
   Next, we analyzed the expression of Ap4 and the effect of Ap4 deletion in the normal, 
murine intestine. Ap4 protein was detected at the crypt base and in transient amplifying 
(TA) cells located above the crypt base in the small intestine (Figure 19a, left panel). 
As expected, Ap4 expression was not detectable in the intestinal epithelia of Ap4 
knock-out mice, indicating that the antibody used here is specific for Ap4 (Figure 19a, 
right panel). In mice expressing enhanced green flourescent protein (eGFP) from an 
Lgr5-promoter Ap4 expression was detected in eGFP-positive ISCs and TA cells, but 
not in the adjacent Lysozyme-positive Paneth cells (Figure 19b). In Ap4-deficient mice 
the number of eGFP-positive ISCs was significantly decreased, indicating that Ap4 is 
necessary for ISC maintenance (Figure 19c). Notably, Ap4-deficient mice displayed a 
significant decrease in the number of ISCs positive for Olfm4 mRNA expression (Figure 
19d).  
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Figure 19 Inactivation of Ap4 causes decrease of ISC numbers. a Immunohistochemical 
detection of Ap4 (brown) in small intestinal tissue, ileum of 1 male and 1 female mouse per 
genotype. Scale bar = 50 µm (25 µm insert), white arrow: site of specific Ap4 expression. Mast 
cells in the villi display an unspecific staining. Counterstaining with hematoxylin. b Confocal 
immunofluorescence analysis of Ap4, GFP = Lgr5 (top panel) and Ap4, Lysozyme (bottom 
panel) expression in intestinal (ileum) mucosa of 63 days old Lgr5-eGFP mice (Barker et al., 
2007). Nuclear DNA was stained with DAPI. Scale bars represent 25 µm. c Left panel: 
Immuno-histochemical analyses of Lgr5-eGFP in intestinal sections of 63 days old Lgr5-eGFP 
mice. Scale bars represent 25 µm. Right panel: Lgr5-eGFP positive cells in the crypt base of 
the ileum from 2 male and 2 female mice (130 crypts) per genotype. d Left panel: In situ 
hybridization of Olfm4 mRNA. Scale bars represent 25 µm. Right panel: Olfm4 positive cells in 
the crypt base from 2 male and 2 female mice (316 crypts) per genotype. c, d: Results were 
subjected to an unpaired, two tailed Student’s t-test with p-values * < 0.05, ** < 0.01, *** < 
0.001, n.s. = not significant. b: Stainings were performed by Ursula Götz; pictures were taken 
by Dr. Rene Jackstadt.  
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Furthermore, they showed an increased number of Paneth cells in all regions of the 
small intestine (Figure 20a): in the ileum each crypt section contained ~8 Paneth cells 
compared to ~5 Paneth cells in wild-type mice. As determined by electron microscopy, 
Paneth cells of Ap4-deficient mice also displayed an increased number of vesicles, 
which contain antimicrobial proteins, such as Lysozyme and Cryptdin (Figure 20b). 
The length of the small intestine was increased in Ap4-deficient mice, presumably as 
a result of widened crypt bases (Figure 20c). The length of the villi in the ileum was 
slightly decreased when compared to wild-type mice (Figure 20c). However, the 
number of TA cells in small intestinal crypts (Figure 20c), the length of the colon and 
the width of colonic crypts remained unchanged (Figure 20d). The latter presumably 
due to the absence of classical Paneth cells in the colon. Ap4-deficiency also resulted 
in a decreased number of secretory goblet cells in villi of the small intestine (Figure 
20e) and in crypts of the small intestine and colon (Figure 20f). Accordingly, mRNA 
expression of stem cell markers (Smoc2, Lgr5, Olfm4) and the goblet cell markers 
(Gob5, Muc2) was significantly decreased, whereas Paneth cell markers (Lysozyme, 
Cryptdin) were significantly increased in the epithelia of the small intestine of Ap4-
deficient mice (Figure 20g). We did not detect an effect of Ap4-deletion on the rate of 
apoptosis or proliferation in the small intestine (Figure 20h, i). Therefore, these 
processes did presumably not cause the changes in the numbers of Paneth cells, 
goblet cells and ISCs observed in Ap4-deficient mice. In addition, the effects of Ap4 
deletion described here were independent of the gender of the mice (Figure 20j, k).  
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Figure 20 Effects of Ap4-deletion on the small intestine and the colon. a Left: 
Immunohistochemical detection of Lysozyme (brown) expressed in Paneth cells. 
Counterstaining with hematoxylin. Scale bar: 50 µm (25 µm insert). Right: The small 
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intestine/ileum from 2 male and 2 female mice (100 crypts) per genotype was analyzed for 
Paneth cells per crypt. b Electron microscopic analysis of small intestinal crypt base; white 
arrow: Paneth cells. Scale bar: 25 µm. c Analysis of small intestine/ileum for length of small 
intestine from 4 male and 4 female mice per genotype, width of crypts of the ileum from 2 male 
and 2 female mice (260 crypts) per genotype, length of villi from 2 male and 2 female mice 
(100 villi) per genotype and the number of TA cells per crypt from 2 male and 2 female mice 
(160 crypts) per genotype. d The colon was analyzed for the length of colon from 4 male and 
4 female mice per genotype or for the width of crypts from 2 male and 2 female mice in a total 
of 200 crypts per genotype. e Left panel: The ileum of 63 days old mice was stained with 
periodic acid-Schiff (PAS)/Alcian Blue (pH1.0) and counterstained with hematoxylin. Scale bar 
= 100 µm. Right panel: Goblet cells were counted in ileum of 2 male and 2 female mice (225 
villi) per genotype. f Goblet cells in the ileum or colon were detected by PAS/Alcian Blue (pH1) 
staining. Counterstaining with hematoxylin. Goblet cells in the crypts (indicated by a white 
arrow) were counted from 2 male and 2 female mice (125 crypts) per genotype. Scale bar: 25 
µm. g qPCR analysis of the indicated mRNAs in IECs of the ileum of 2 male and 1 female mice 
per genotype. h Immunohistochemical detection of cleaved caspase-3 in small intestinal 
(ileum) crypts or villi from mice of the indicated genotype.  Left panel: scale bar = 25 µm. Right 
panel: scale bar = 100 µm. Counterstaining with hematoxylin. 200 crypts or villi of the ileum 
from 2 male and 2 female mice per genotype were analyzed for cleaved caspase-3 positive 
cells. i Left panel: Immunohistochemical detection of Ki67 of the ileum of mice of the indicated 
genotype, scale bar = 25 µm. Counterstaining with hematoxylin. Right panel: Quantification of 
Ki67-positive cells per crypt base or TA unit in 2 male and 2 female mice and a total of 102 
crypts per genotype. j Left panel: Number of Paneth cells in the ileum divided into gender: 2 
male and 2 female mice per genotype (50 crypts per gender and genotype). Central panel: 
length of small intestine divided into gender: 4 male and 4 female mice per genotype. Right 
panel: width of crypts of the ileum divided into gender: 2 male and 2 female mice per genotype 
(140 crypts per gender and genotype). k Left panel: Quantification of Lgr5-eGFP-positive cells 
in the crypt base of the ileum detected in 2 male and 2 female mice per genotype (65 crypts 
per gender and genotype). Right panel: Quantification of Olfm4-positive cells in the crypt base 
of the ileum in 2 male and 2 female mice per genotype (158 crypts per gender and genotype). 
a, b, c, d, e, f, g, h, i, j, k: Results represent the mean +/- SD. Results were subjected to an 
unpaired, two tailed Student’s t-test with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = not 
significant. b: Pictures were taken by Dr. Susanna Müller. 
 
Furthermore, IEC (intestinal epithelial cell)-specific deletion of Ap4 had the same 
effects on the small intestinal and colonic architecture as the germ-line deletion of Ap4 
(Figure 21a-h). Therefore, the effects of Ap4 loss on ISCs and their derivatives were 
intestinal epithelial cell-autonomous. Interestingly, Ap4-deficiency also decreased the 
number of stem cells in the colon (Figure 21i, j).  
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Figure 21 Effects of conditional deletion of Ap4 on the small intestine and colon.  
a Immunohistochemical detection of Ap4 (brown) in small intestinal tissue, ileum (upper panel) 
or in the stomach (lower panel) of 1 male and 1 female 63 days old mouse per genotype. Scale 
bar = 50 µm, white arrow: site of specific Ap4 expression. Mast cells in the villi display an 
unspecific staining. Counterstaining with hematoxylin. b The small intestine, ileum, was 
analyzed for the indicated parameters by analyzing the intestine from 4 male and 4 female 
mice per genotype for length of small intestine, 2 male and 2 female mice and a total of 200 
crypts per genotype for width of crypts, 2 male and 2 female mice and a total of 120 villi per 
genotype for length of villi, 2 male and 2 female mice and a total of 120 crypts per genotype 
for Paneth cells per crypt. c 2 male and 1 female mice and a total of 30 Paneth cells per 
genotype were analyzed for the number of vesicles per Paneth cell. d 2 male and 2 female 
mice and a total of 130 villi per genotype were analyzed for goblet cells per villi in small intestine 
(ileum). 2 male and 2 female mice and a total of 120 crypts per genotype were analyzed for 
goblet cells per small intestinal crypts. 2 male and 2 female mice and a total of 115 crypts per 
genotype were analyzed for goblet cells per colonic crypts. e The small intestine (ileum) was 
analyzed for the Lgr5-GFP positive cells in 3 male and 3 female mice and a total of 160 crypts 
per genotype (Ap4fl/fl and Ap4∆IEC) or from 2 male and 3 female mice and a total of 130 crypts 
per genotype (Ap4+/∆IEC). f Quantification of Olfm4 positive cells in the crypt base of the ileum. 
280 crypts were evaluated from 2 male and 2 female mice per genotype. g 200 crypts or villi 
from the ileum of 2 male and 2 female mice were analyzed for cleaved caspase-3 positive 
cells. h Left panel: Immunohistochemical detection of BrdU in the ileum of mice with the 
indicated genotype, scale bar = 25 µm. Counterstaining with hematoxylin. Right panel: BrdU-
positive cells per crypt base or TA unit were counted by analyzing 2 male and 2 female mice 
and a total of 100 crypts. i Left panel: Detection of Smoc2 mRNA by in situ hybridization. Scale 
bars represent 25 µm. Right panel: Quantification of Smoc2-positive cells in the crypt base 
from 1 male and 2 female mice (150 crypts) per genotype. j Left panel: Detection of Lgr5 mRNA 
by in situ hybridization. Scale bars represent 25 µm. Right panel: Quantification of Lgr5-positive 
cells in the crypt base from 1 male and 2 female mice (80 crypts) per genotype. b, c, d, e, f, g, 
h, i, j: Results represent the mean +/- SD. Results were subjected to an unpaired, two tailed 
Student’s t-test with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = not significant 
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Age-matched ApcMin mice deficient for Ap4 also displayed a decreased number of 
Lgr5- and Smoc2-positive ISCs per crypt, an increase in Paneth cells, increased length 
of the small intestine and enlargement of the crypt base of normal intestine, without 
any change in proliferation or apoptosis in normal epithelium (Figure 22a-h) 
independent of the gender (Figure 22i). Notably, ISCs have been shown to efficiently 
form intestinal tumors upon deletion of Apc (Barker et al., 2009) and play a critical role 
in adenoma and cancer cell self-renewal (de Sousa e Melo et al., 2017; Schepers et 
al., 2012). Taken together, these results suggest that the decreased rate of tumor 
formation in Ap4-deficient ApcMin mice is due to the lower number of functional ISCs in 
the intestinal crypts. 
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Figure 22 Effects of Ap4 loss on the small intestine and colon in ApcMin/+ mice. a The 
amount of Lgr5-positive stem cells per crypt within the ileum was determined in 2 male and 2 
female mice and a total of 150 crypts per genotype. b The small intestine (ileum) was analyzed 
for Lgr5-GFP positive cells in 2 male and 2 female mice in a total of 85 crypts per genotype. c 
Left panel: In situ hybridization of Smoc2 mRNA. Scale bars represent 25 µm. Right panel: 
Detection of Smoc2 positive cells in the crypt base from 2 male and 1 female mice (90 crypts) 
per genotype. d Left panel: In situ hybridization of Lgr5 mRNA. Scale bars represent 25 µm. 
Right panel: Detection of Lgr5-positive cells in the crypt base from 2 male and 1 female mice 
(75 crypts) per genotype. e The ileum was analyzed for the indicated parameters by analyzing 
the intestine from 2 male and 2 female mice and a total of 100 crypts per genotype for Paneth 
cells per crypt, 4 male and 4 female mice per genotype for length of small intestine and 2 male 
and 2 female mice and a total of 310 crypts per genotype for width of crypt. f Left panel: 
Immunohistochemical detection of Ki67 of the ileum of mice of the indicated genotype, scale 
bar = 25 µm. Counterstaining with hematoxylin. Right panel: Ki67 positive cells per crypt base 
or TA unit were counted within 140 crypts of 2 male and 2 female mice. g Left panel: 
Immunohistochemical detection of BrdU incorporation in crypts of 120 days old ApcMin/+ mice 
of the indicated genotype. Counterstaining with hematoxylin. Scale bar = 25 µm. Right Panel: 
Quantification of BrdU-positive cells in crypts of the small intestine from 1 male and 2 female 
mice and a total of 76 crypts per genotype. h Immunohistochemical detection of cleaved 
caspase-3 in normal ileum from mice of the indicated genotype. Left panel: scale bar = 25 µm. 
Right panel: scale bar = 50 µm. Counterstaining with hematoxylin. 200 crypts or villi of the 
ileum from 2 male and 2 female mice were analyzed for cleaved caspase-3 positive cells. i 
Quantification of Paneth cells per crypt in the ileum in 2 male and 2 female mice per genotype 
(50 crypts per gender and genotype), length of small intestine of 4 male and 4 female mice per 
genotype, width of crypts of the ileum of 2 male and 2 female mice per genotype (155 crypts 
per gender and genotype) or the amount of Lgr5-eGFP positive cells in the crypt base of the 
ileum divided into gender: 2 male and 2 female mice per genotype (75 crypts per gender and 
genotype). a, b, c, d, e, f, g, h, i: Results represent the mean +/- SD. Results were subjected 
to an unpaired, two tailed Student’s t-test with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = 
not significant. 
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5.5 Analysis of Ap4 function in intestinal organoids 
   To further analyze the functional relevance of Ap4 for ISCs, we generated small 
intestinal organoids by ex vivo culture of small intestinal crypts derived from Villin-Cre-
ERT2/Ap4fl/fl mice. After addition of 4-OHT to established organoids, Ap4 expression 
was decreased by ~90% within three days, which demonstrates efficient, Cre-
mediated deletion of the floxed Ap4 allele in these organoids (Figure 23a). Upon acute 
Ap4 inactivation, organoids showed a pronounced decrease of ISC markers, an 
increase of Paneth cell markers, as well as a decrease of goblet cell markers within 3 
days after exposure to 4-OHT, whereas organoids derived from Villin-Cre-ERT2/Ap4 
wild-type mice exposed to 4-OHT did not display significant changes in the expression 
of these markers (Figure 23a). Importantly, Ap4-deficient organoids formed less 
protrusions (crypt-like-structures), when compared to the Ap4-expressing organoids 
(Figure 23b). Since the number of protrusions corresponds to the number of self-
renewing ISCs within organoids (Wolfe et al., 2017), the decrease in the number of 
protrusions in Ap4-deficient organoids is presumably caused by a decrease in 
functional ISCs. Taken together, these results suggest that Ap4 is essential for 
maintaining ISCs in their undifferentiated state and plays an important role in the 
homeostasis of ISCs and Paneth cells.  
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Figure 23 Effects of Ap4 deletion in intestinal organoids. a qPCR analysis of the indicated 
mRNA from organoids isolated from 3 female mice per genotype after passaging and 7 days 
after Cre activation by 4-OHT. b Left panel: representative pictures of small intestinal organoids 
7 days after passaging and Cre activation by 4-OHT. Scale bars represent 20 µm. Right panel: 
Quantification of protrusions (crypt-like structures) per organoid derived from 3 female mice 
per genotype. A total of 81 organoids were evaluated per genotype. a, b: Results represent 
the mean +/- SD. Results were subjected to an unpaired, two tailed Student’s t-test with p-
values * < 0.05, ** < 0.01, *** < 0.001, n.s. = not significant. 
 
5.6 Gene expression profiling of Ap4-deficient organoids  
   Next, we obtained RNA expression profiles of Ap4-deficient and Ap4 wild-type 
organoids 7 days after 4-OHT treatment using NGS. Changes in gene expression 
observed after deletion of Ap4 were considerably less pronounced in organoids when 
compared to adenomas. By setting the cut-off for differential expression to a fold-
change > 1.5 (p<0.05) we identified 693 mRNAs as differentially regulated as a 
consequence to deletion of Ap4 (Figure 24a), with 319 mRNAs being significantly 
down-regulated, and 374 showing up-regulation (Figure 24b, c). Remarkably, factors 
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involved in Notch signaling and Wnt/β-catenin signaling were significantly over-
represented among the down-regulated mRNAs (Figure 24d, Supplemental Data 1). 
 
 
Figure 24 Expression analyses of Ap4-deficient organoids. a Venn diagram displaying 
differentially regulated mRNAs (fold change > 1.5, p<0.05) in Ap4fl/fl and Ap4∆IEC organoids as 
determined by edgeR and DESeq2. b, c Volcano plot (b) and heat map (c) depicting 
expression changes of differentially expressed mRNAs between Vil-Cre-ERT2 and Vil-Cre-
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ERT2/Ap4 fl/fl organoids, 7 days after Cre activation by 4-OHT, detected by RNA-Seq. b: 
Volcano plot depicting expression changes of differentially expressed mRNAs (fold change > 
1.5) from Ap4fl/fl and Ap4∆IEC organoids. Down-regulated mRNAs are depicted in blue, up-
regulated mRNAs are depicted in red. RNAs with fold changes < 1.5 and/or statistically non-
significant changes in expression are indicated in black. Dashed vertical lines indicate 1.5 fold 
change cutoff. Dashed horizontal line indicates the cutoff for adjusted p-values < 0.05 as 
determined with DESeq2. c: Heat-map depicting expression changes of differentially 
expressed mRNAs (fold change > 1.5 p< 0.05 as determined by edgeR and DESeq2) from 
Ap4fl/fl and Ap4∆IEC organoids. Colors indicate relative expression values from minimum (blue) 
to maximum (red) for each RNA sample per differentially regulated mRNA. d Upper panel: 
Hallmark gene set (mSigDB: molecular Signature Database (Liberzon et al., 2015)) and KEGG 
(Kyoto Encyclopedia of Genes and Genomes) analysis from down-regulated mRNAs after 
conditional ablation of Ap4 in intestinal organoids. The 10 most significantly enriched pathways 
among down-regulated mRNAs are shown. Lower Panel: Hallmark gene set (mSigDB: 
molecular Signature Database) and KEGG (Kyoto Encyclopedia of Genes and Genomes) 
analysis from up-regulated mRNAs. The 10 most significantly enriched pathways among up-
regulated mRNAs after conditional ablation of AP4 in intestinal organoids are shown. See also 
Supplemental Data 1. All data analyses were performed by Dr. Markus Kaller. 
 
   In line with the effect of Ap4 deletion in adenomas GSEA indicated that mRNAs 
characteristic for Lgr5-positive or EphB2high ISCs and several factors involved in Wnt/β-
catenin and Notch signaling pathways were preferentially down-regulated upon 
deletion of Ap4 (Figure 25a, Supplemental Data 2): For example Sox4, Axin2, EphB3 
were down-regulated (Figure 25b, Supplemental Data 2). Down-regulated components 
of the Notch signaling pathway included Notch1, and the Notch target gene Hes1, as 
well as the Notch activating ligands Dll1, Dll3, Dll4 and Jag2 (Figure 25b, Supplemental 
Data 2). Exemplary confirmations of mRNA down-regulations of genes important in 
Wnt/β-catenin signaling and/or Notch signaling upon acute deletion of Ap4 in intestinal 
epithelial cell derived organoids are shown in Figure 25c. The decreased activity of the 
Notch pathway after Ap4 loss was confirmed by immunohistochemical detection of 
Nicd1 (Notch intracellular domain 1) in normal crypts in the small intestine (Figure 25d, 
e). Not only was the frequency of Nicd1-positive cells per crypt lower, but also the 
intensity of the Nicd1 signal was decreased, which indicates a lower activity of the 
Notch signaling pathway in these cells. Taken together, these results show that Ap4 
contributes to the Wnt/β-catenin and Notch transcriptional program in normal intestinal 
tissue. 
   Interestingly, the transcription factor Spdef (SAM pointed domain containing ETS 
factor) was down-regulated in Ap4-deficient organoids according to NGS analysis and 
validated by qPCR (Figure 25b, c). Spdef regulates the differentiation and maturation 
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of goblet cells (Noah et al., 2010). Down-regulation of Spdef may therefore contribute 
to the decreased number of goblet cells observed in Ap4-deficient mice.  
   As observed in adenomas, c-Myc and E2f target genes were significantly enriched 
among the down-regulated RNAs in Ap4-deficient organoids (Figure 25a, 
Supplemental Data 2) albeit with rather modest fold changes in expression that were 
considerably less pronounced compared to those of ISC signature and Notch target 
genes (Figure 25f, Supplemental Data 2). Interestingly, the differential mRNA 
expression caused by deletion of Ap4 was similar in organoids and adenomas as 
determined by correlation analysis (Figure 25g). As the organoid derived expression 
profiles were obtained in the absence of non-epithelial cells or stroma, these findings 
indicate that gene expression changes resulting from the inactivation of Ap4 are largely 
epithelial cell autonomous. These results suggest that the differential regulation of 
factors involved in Wnt/β-catenin and/or Notch signaling observed after deletion of Ap4 
in ApcMin mice occur in normal intestinal epithelial stem cells prior to adenoma 
development.  
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Figure 25 NGS analysis of intestinal organoids after deletion of Ap4. a GSEA  comparing 
gene expression profiles from Vil-Cre-ERT2 and Vil-Cre-ERT2/Ap4fl/fl organoids 7 days after 
Cre activation (change in GSEA Curves to Ap4 ∆IEC in a and to Ap4 wt and Ap4 IEC in b) by 
4-OHT with Lgr5-positive or EphB2high stem cell signatures (Munoz et al., 2012) (Merlos-
Suarez et al., 2011; van der Flier et al., 2009), mRNAs differentially regulated after Ctnnb1 
loss (Fevr et al., 2007), β-catenin regulated / ISC specific genes (Fevr et al., 2007), Notch 
targets genes (Li et al., 2012), c-Myc target genes (mSigDB: molecular Signatures Database) 
or E2f target genes (mSigDB). NES: Normalized Enrichment Score, Nom. p-value: Nominal p-
value. b Heat-map depicting expression changes of selected differentially expressed mRNAs 
(p-value < 0.05) from stem cell gene signatures, Wnt signaling and/or Notch signaling gene 
signatures analyzed in (a). The heatmap displays relative expression levels normalized to the 
mean expression in the control (Vil-CreERT2) samples for each mRNA. Three biological 
replicates per genotype were analyzed. c qPCR analysis of the indicated mRNA of organoids 
with the indicated genotypes 3 days and 7 days after 4-OHT induction. d Left panel: 
Immunohistochemical detection of Nicd1 of the ileum from mice of the indicated genotype, 
scale bar = 25 µm. Counterstaining with hematoxylin. Right panel: Quantification of Nicd1-
positive cells per crypt in 2 male and 2 female mice and a total of 120 crypts per genotype. e 
Relative Nicd1 protein expression was measured as the intensity of staining in Nicd1-positive 
cells in the crypt base (left panel) and the TA unit (right panel). For the intensity, a score from 
1-3 was used (1 = weak, 2 = moderate, 3 = strong staining). f Cumulative distribution plots 
comparing RNA expression changes as determined by DESeq2 of gene set members of the 
indicated gene signatures upon loss of Ap4 in organoids. g Scatter plot displaying the 
correlation of expression changes of the 424 mRNAs significantly (p < 0.05) downregulated in 
both adenomas and organoids (shown in grey). The mRNAs from stem cell gene signatures, 
Notch target gene signatures and c-Myc target genes analyzed in Figure 15a and 25a in both 
adenomas and organoids are highlighted with the indicated colors. The Pearson correlation 
coefficient of all 424 mRNAs down-regulated in both adenomas and organoids and statistical 
significance are indicated. c, d, e: Results represent the mean +/- SD. Results were subjected 
to an unpaired, two tailed Student’s t-test with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = 
not significant. a, b: See also Supplemental Data 2. a, b, f, g: Figures and analyses were made 
by Dr. Markus Kaller. 
 
5.7 Regulation of the NOTCH pathway by AP4 in human CRC cells 
   In order to determine whether the connection between Ap4 and Notch detected here 
is conserved between species and relevant to human CRCs, we performed expression 
and functional analyses in human CRC cell lines. In line with the results described 
above, the expression of AP4 and NICD1 proteins positively correlated in a panel of 5 
CRC cell lines (Figure 26a). After ectopic AP4 expression in DLD-1 cells 
NOTCH1/NICD1 and the NOTCH-target genes HES1 and NRARP were induced at the 
protein and mRNA levels (Figure 26b, c). Down-regulation of AP4 by RNA interference 
decreased NICD1 protein expression in Colo320 cells (Figure 26d). Furthermore, a 
NOTCH activity reporter plasmid was induced by ectopic AP4 expression, but not by a 
mutant AP4 protein, which lacks the basic DNA-binding region (Figure 26e). In 
addition, analysis of public ChIP-Seq data showed open and active chromatin 
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surrounding the sites of AP4 occupancy at the NOTCH1 promoter, since histone 
H3K4me1 and H3K27Ac modifications were increased in their vicinity (Figure 26f).  
 
 
Figure 26 AP4 regulates NOTCH1 in human CRC cell lines. a Western blot analysis of AP4 
and NICD1 protein expression in CRC lines. Detection of α-TUBULIN served as a loading 
control. b Western blot analysis of the indicated proteins after ectopic expression of AP4 in 
DLD-1 cells for the indicated periods. c qPCR analysis of the indicated mRNAs after activation 
of ectopic AP4 expression in DLD-1 CRC cells by addition of doxycycline (DOX) for the 
indicated periods. Gene expression changes after DOX treatment for the indicated time points 
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(fold change) were normalized to untreated cells (0h DOX) and β-actin. Results are given as 
mean +/- s.d. (n=3) d Colo320 cells were transfected with an AP4-specific siRNA. 72 h later, 
protein lysates were subjected to immunoblot analysis of the indicated proteins. e RBPJk 
reporter activity was determined in HEK293T cells 24 hours after transfection with the indicated 
vectors. f Representative AP4 ChIP-seq result for the NOTCH1 promoter in DLD-1 cells. 
H3K4me1 and H3K27Ac ChIP-seq results were obtained from the ENCODE Consortium of the 
UCSC Genome Browser. a, b, d: Uncropped western blot membranes are shown in 
Supplemental Data 3. c, e: n = 3, results represent the mean +/- SD. Results were subjected 
to an unpaired, two-tailed Student’s t-test with p-values * < 0.05, ** < 0.01, *** < 0.001, n.s. = 
not significant. All analyses were performed by Dr. Rene Jackstadt. 
 
 
When we analyzed ChIP-Seq data, which we had previously obtained after ectopic 
AP4 expression in the CRC cell line DLD-1 (Jackstadt et al., 2013c), we detected AP4 
occupancy at the ASCL2, DLL1, DLL4, EPHB3, HES1, JAG1, JAG2, NOTCH1, SOX4 
and TCF7 promoters in human DLD-1 CRC cells (Figure 27). Therefore, AP4 regulates 
genes involved in WNT/β-CATENIN and/or NOTCH signaling directly by binding to 
their promoters in CRC cells.  
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Figure 27 AP4 regulates directly WNT/β-CATENIN and/or NOTCH pathway 
componenents in human CRC cell lines. Histogram plots showing examples of occupancy 
by AP4 within promoters of genes involved in WNT/β-CATENIN and/or NOTCH pathways in 
the human DLD-1 cell line upon ectopic expression of AP4 or vector control. ChIP-seq data 
were adapted from our NGS analysis published in (Jackstadt et al., 2013c). Orange and blue 
vertical bars denote the genomic positions of CAGCTG and CAGGTG E-boxes, respectively. 
Figures and analyses were made by Dr. Markus Kaller. 
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   In addition, inhibition of NOTCH signaling by exposure to the γ-secretase inhibitor 
Dibenzazepine (DBZ) resulted in a decrease of AP4 and c-MYC expression in SW620 
CRC cells (Figure 28a). As expected, the NOTCH-target genes NRARP and HES1 
were also repressed. Notably, DBZ suppressed Ap4 protein expression in the small 
and large intestine of mice (Figure 28b). As expected, inhibition of Notch signaling led 
to an increase in the number of Paneth cells and goblet cells as well as to a decrease 
of Hes1 and c-Myc expression. Since we could not obtain experimental evidence for a 
direct regulation of AP4 by NICD1 (data not shown), the regulation of AP4 by the 
NOTCH pathway is presumably mediated by c-MYC, which represents a known target 
of the NOTCH pathway (Palomero et al., 2006; Weng et al., 2006). Therefore, AP4, 
the NOTCH pathway and c-MYC form a positive feed-back loop.    
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Figure 28 Inhibition of Notch signaling leads to down-regulation of Ap4. a qPCR analysis 
of the indicated mRNAs in SW620 cells 96 hours after DBZ (5 mM) treatment. Results 
represent the mean +/- SD. b Immunohistochemical analysis of small intestine (Ileum) and 
colon from ~ 6 months old mice treated with vehicle (DMSO) or DBZ for 5 consecutive days 
with the indicated antibodies or PAS staining; scale bar indicates 100 µm. n represents the 
number of mice analyzed per genotype. a: n = 3, results represent the mean +/- SD. Results 
were subjected to an unpaired, two-tailed Student’s t-test with p-values * < 0.05, ** < 0.01, *** 
< 0.001, n.s. = not significant. a: Figure and analysis was made by Dr. Rene Jackstadt. b: DBZ 
treatment of mice was performed by Prof. Dr. David Horst, stainings of Ap4, c-Myc and Hes1 
were performed by Ursula Götz, pictures (except the pictures of Lysozyme) were taken by Dr. 
Rene Jackstadt. 
 
5.8 Role of AP4 in human CRCs  
   To obtain further evidence for a clinical relevance of AP4 in CRC initiation and 
progression we analyzed patient-derived expression data that were generated by the 
TCGA consortium (Cancer Genome Atlas, 2012). Indeed, AP4 mRNA expression was 
significantly increased in primary CRCs when compared to normal mucosa in 41 
matched normal versus CRC patient samples, as well as in unmatched patient samples 
representing normal mucosa (n=41) and primary CRCs (n=462) (Figure 29a). 
Recently, CRCs were shown to belong to four different molecular sub-groups, the so-
called consensus molecular subtypes (CMS) 1-4 (Guinney et al., 2015). In line with the 
results obtained here, CRCs belonging to the CMS2 subtype, which is characterized 
by high WNT and c-MYC activity, showed significantly elevated expression of AP4 
when compared to the three other CMS subtypes (Figure 29b). Moreover, in CRCs 
from the TCGA cohort AP4 expression showed a positive correlation with the 
expression of mRNAs characteristic for Lgr5-positive intestinal stem cells (van der Flier 
et al., 2009), as well as with mRNAs encoding factors involved in WNT/β-CATENIN 
signaling and c-MYC target genes (mSigDB, molecular Signature Database: (Liberzon 
et al., 2015)) (Figure 29c). Furthermore, AP4 expression showed a significant positive 
correlation with ASCL2, TCF7, NOTCH1 and JAG2 expression in 462 primary CRCs 
in the TCGA cohort (Figure 29d). As expected, AP4 expression was also positively 
associated with c-MYC and negatively associated with CDKN1A/p21 expression.  
 Results 
87 
 
 
 
 Results 
88 
 
Figure 29 Ap4 expression and associations in human CRCs deposited within TCGA.  
a Ap4 RNA expression levels from matched patient samples from normal mucosa and tumor 
tissue (left), or unmatched normal mucosa and tumor tissues (right). RNA expression data 
were obtained from publically available TCGA colorectal adenocarcinoma (COAD) datasets 
(Cancer Genome Atlas, 2012). Left panel: matched samples, 41 normal mucosa and 41 tumor 
tissue samples. Right panel: 41 normal mucosa samples and 462 tumor tissue samples were 
used. b Box plots showing Ap4 RNA expression levels in 462 COAD samples from (a) 
associated with the different CRC consensus molecular subtypes (CMS) as defined in 
(Guinney et al., 2015). c Expression of human homologues of the LGR5-positive stem cell 
signature (van der Flier et al., 2009), members of the HALLMARK WNT signaling gene set 
(Liberzon et al., 2015) or c-MYC target genes (Liberzon et al., 2015) are strongly linked with 
AP4 expression in human tumors. All genes within the TCGA datasets from human colorectal 
tumors were pre-ranked by expression correlation coefficient (Pearson r) with Ap4 in 
descending order from left (positive correlation) to right (negative correlation) and analyzed by 
GSEA. d Scatter plots displaying pairwise comparisons of mRNA expression levels [RSEM] of 
the indicated genes for 462 TCGA COAD samples. The correlation coefficients and p-values 
of Pearson´s and Spearman´s correlations, as well as the linear regression trend line are 
indicated. a, left panel: Results were subjected to a paired, two tailed Student’s t-test with p-
values * < 0.05, ** < 0.01, *** < 0.001. a, right panel and c: Results represent the mean +/- SD. 
Results were subjected to an unpaired, two tailed Student’s t-test with p-values * < 0.05, ** < 
0.01, *** < 0.001, n.s. = not significant. All analyses were made by Dr. Markus Kaller.  
 
   In order to determine whether the positive correlation between AP4 and 
NOTCH1/NICD1/HES1 also exists on the level of protein expression in human CRCs, 
we determined AP4, NICD1 and HES1 expression levels by immunohistochemical 
analysis of 220 primary CRC samples. For the evaluation of AP4, NICD1 and HES1 
expression we established a 4-stage scoring scheme (Figure 30a). AP4 expression 
was highly concordant with both NICD1 and HES1 expression (Figure 30b) indicating 
that the reciprocal regulation between AP4 and the NOTCH pathway also occurs in 
primary, human CRCs.    
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Figure 30 Correlative analysis of AP4, NICD1 and HES1 protein expression in human 
CRCs. a The intensity of nuclear AP4, NICD1 and HES1 staining in human CRC TMA (Tumor 
Microarray) samples was assigned the following scores: none = −, weak = +, moderate = ++, 
and strong = +++ expression. Examples of representative immunohistochemistry results were 
shown. Scale bar: 100 µm. b Left: Dot plots displaying pairwise comparisons of IHC staining 
scores explained in (a) for AP4, NICD and HES1 from 220 human CRC TMA samples. Dot 
sizes represent tumor sample numbers. Right: Heatmap displaying Pearson r correlation 
coefficients of IHC scores obtained from 220 tumor samples stained for AP4, NICD1 and HES1 
expression. b: Figures were made by Dr. Markus Kaller.  
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6. Discussion 
 
   This study identified Ap4 as an important, rate limiting mediator of intestinal adenoma 
initiation (Jaeckel et al., 2018; summarizing model in Figure 31): Deletion of Ap4 in the 
germ-line and in intestinal epithelial cells resulted in a reduced number of Lgr5+ 
intestinal stem cells (ISCs) and a reciprocal increase in Paneth cells. Ap4 loss 
decreased intestinal adenoma formation in ApcMin mice, presumably due to the 
reduced number of functional ISCs amenable for adenoma initiating mutational events. 
The Wnt- and Notch-pathways were identified as important mediators of Ap4 function 
in the healthy intestine and during adenoma formation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31 Model summarizing the results of this study. Schematic model summarizing the 
results of this study. The dots in the Paneth cells represent vesicles containing antimicrobial 
proteins such as Lysozyme and Cryptdin. The dots in the lumen represent antimicrobial 
proteins excreted by Paneth cells. 
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   Since inactivation of Ap4 led to a decrease in the number of ISCs and an increase in 
Paneth cells, it is conceivable that the decreased formation of adenomas in the 
absence of Ap4 is due to the smaller number of bona-fide ISCs that are able to initiate 
adenomas after acquiring genetic and epigenetic alterations. This hypothesis is in 
accordance with the observation that tumor-promoting mutations in ISCs are more 
efficient in generating tumors than mutations in other, more differentiated intestinal 
epithelial cells. This may be because ISCs are long-lived and self-renewing (e.g. have 
a high proliferation rate), which results in a high probability to accumulate mutations 
(Barker et al., 2009; Powell et al., 2012). In addition, recent analyses have provided 
further support for a direct role of stem cell abundance in the determination of tumor 
frequencies (Tomasetti and Vogelstein, 2015): i.e. a strong correlation was found 
between the tissue-specific stem cell number and the risk to develop a tumor for this 
particular tissue. Furthermore, cancer cells with stem cell characteristics are present 
in tumors of human colorectal cancer (CRC). Human CRC cells expressing the stem 
cell markers CD133 (O'Brien et al., 2007; Ricci-Vitiani et al., 2007) or CD44/CD166 
(Dalerba et al., 2007) are able to induce tumors when injected into mice. These results 
show that tumors may have their origin in the stem cells of the intestinal crypt or at 
least in cells with stem cell like characteristics. Indeed, mutations in progenitor cells in 
the transit amplifying unit of the intestinal crypt are much less effective in tumor 
initiation than the stem cells in the crypt base, since Apc deletion in the transit 
amplifying (TA) cells are only causing microadenomas and very rarely 
macroadenomas (Barker et al., 2009). However, also differentiated cells may function 
as the origin of intestinal cancer as soon as they dedifferentiate into a stem-cell-like 
phenotype (Schwitalla et al., 2013).  
   Unexpectedly, deletion of Ap4 in intestinal epithelial cells (IECs) had no effect on 
cellular proliferation. In contrast, acute deletion of c-Myc using Ah-Cre or Villin-CreER 
alleles in post-natal IECs resulted in defects in proliferation and biosynthetic activity in 
the small intestine (Bettess et al., 2005; Muncan et al., 2006). These divergent results 
may be due to the different timing of gene inactivation. Here we used either germ-line 
or Villin-Cre mediated deletion of Ap4. The latter leads to deletion of Ap4 at embryonic 
day E12.5. However, the two studies on c-Myc employed deletion at least 7 days after 
birth and later which was necessary since c-Myc is essential during embryogenesis. 
They observed that IEC proliferation is at least in part independent of c-Myc. Therefore, 
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IECs may rely on alternative pathways for promoting cell proliferation. In addition, 
these differences indicate that Ap4 is responsible for mediating a distinct aspect of c-
Myc function and does not simply perform all functions of c-Myc. c-Myc is a target gene 
of both the Wnt pathway (He et al., 1998) and the Notch pathway (Klinakis et al., 2006; 
Palomero et al., 2006; Sharma et al., 2006; Weng et al., 2006). Direct activation of c-
Myc gene expression by using tamoxifen in Villin-MycERTAM mice induces loss of 
Paneth and goblet cells (Finch et al., 2009). Since we showed that Ap4-deficiency 
leads to an increased Paneth cell number and AP4 represents a direct target of c-MYC 
(Jung et al., 2008), the decrease of Paneth cells after c-Myc activation may be due to 
activation of Ap4. However, further analysis are necessary to support this hypothesis.  
   Notably, the deletion of Ap4 resulted in decreased expression of Notch pathway 
components including Notch1 itself. Interestingly, Notch pathway inactivation promotes 
differentiation of intestinal stem cells into Paneth cells (VanDussen et al., 2012), 
leading to Paneth cell hyperplasia and a decrease in ISCs (Carulli et al., 2015; 
VanDussen et al., 2012). However, the number of goblet cells increases after Notch 
inhibition, whereas it decreased after Ap4 inactivation in our study. Therefore, Ap4 loss 
does not simply recapitulate inhibition of the Notch pathway suggesting that Ap4 
regulates additional pathways/genes, which contribute to the differentiation of goblet 
cells. For example, Ap4-deficiency resulted in a decrease in expression of the 
transcription factor Spdef (SAM pointed domain-containing Ets transcription factor). 
Interestingly, ectopic expression of Spdef in the murine intestine promotes the 
differentiation of goblet cells, while it decreases the number of Paneth cells (Noah et 
al., 2010). Accordingly, the decrease of Spdef observed in Ap4-deficient organoids 
could potentially also contribute to the decreased number of goblet cells detected after 
Ap4 deletion. Alternatively, the decrease in goblet cells may have been a 
compensatory response to the increase in Paneth cells caused by Ap4 deletion.  
   Additionally, a controlled balance of the Notch and Wnt pathway activity is important 
for the homeostasis of stem cells and cell fate decisions in the intestine and these two 
pathways regulate each other at multiple points (Tian et al., 2015). For example, 
activated Notch signaling does not lead to the expected cell proliferation after inhibition 
of Wnt signaling in Tcf4 knock-out mice (Fre et al., 2009), showing the dependence on 
Wnt signaling for the effect of activated Notch signaling. The Notch and the Wnt 
signaling are linked to each other, since the expre
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(Rodilla et al., 2009) and other genes involved in Notch signaling (Ungerback et al., 
2011) are regulated by Wnt signaling. Thereby, Wnt signaling can indirectly activate 
Notch signaling. Specifically, inhibition of Notch1/2 receptors induces Wnt-signaling, 
which then promotes goblet cell differentiation (Tian et al., 2015). The decrease of Wnt-
pathway component expression after Ap4 deletion may therefore alter the expected 
outcome of a Notch inhibition (i.e. increase of all secretory cell numbers) unto the 
decrease of goblet cell differentiation observed here.  
   In addition, the increased number of Paneth cells in Ap4-deficient mice might result 
from an increased propensity of Ap4-deficient ISCs to generate Paneth cell precursors 
during asymmetric stem cell division. Interestingly, LGR5 represents an AP4 target 
gene in human CRC cell lines (Jackstadt et al., 2013c) and Lgr5-deficiency promotes 
Paneth cell differentiation in mice (Garcia et al., 2009). 
   Recently, it was shown that ablation of Lgr5-positive cells does not affect the tumor 
growth upon orthotopic transplantation of syngeneic tumor cells to the colon mucosal 
wall (de Sousa e Melo et al., 2017). Hence, Lgr5-positive cells seem to be dispensable 
after the initiation of adenomas. The tumor TA cells or, hypothetically, Lgr5-negative 
tumor stem cells, seem to be sufficient to maintain adenoma growth in the colon. Lgr5- 
positive cells are only indispensable to establish and maintain liver metastasis in this 
model. This is in agreement with the effects of Ap4 inactivation observed here: a 
decreased number of ISCs and adenomas, whereas tumor cell proliferation and tumor 
size was not affected by Ap4 deletion. In accordance, the results obtained in tumoroids 
derived from ApcMin mice and in tumoroids generated by acute deletion of Apc imply 
that Ap4 is important for the initiation but not required for the maintenance of tumoroids. 
Interestingly, Lgr5 gene expression has been reported previously to be dispensable for 
ex vivo tumor organoid maintenance (Sato et al., 2011a).  
   NOTCH signaling is involved in many different types of tumors including colon cancer 
(Akiyoshi et al., 2008; Sureban et al., 2008), pancreatic cancer (Kimura et al., 2007; 
Miyamoto et al., 2003; Terris et al., 2002; Wang et al., 2006), breast cancer (Reedijk 
et al., 2005; Stylianou et al., 2006), liver cancer (Gao et al., 2007; Qi et al., 2003) and 
lung cancer (Konishi et al., 2007). This may be due to regulation of important cancer-
specific pathways, such as the Akt pathway (Efferson et al., 2010; Meurette et al., 
2009), the Ras pathway (Fitzgerald et al., 2000) as well as the NF-κB pathway (Cheng 
et al., 2001; Espinosa et al., 2002; Oswald et al., 1998; Wang et al., 2001). In CRC 
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Notch signaling is important for intestinal tumor initiation, but not for tumor progression 
(Fre et al., 2009). A 20-fold increase in the number of adenomas was observed in mice 
with Apc mutation combined with Notch activation compared to Apc mutation alone. 
The acceleration of adenoma growth due to Notch activation may also be the case in 
human CRC, since NOTCH activation occurs in most adenomas in humans (Fre et al., 
2009). Inhibition of NOTCH signaling leads to mitotic arrest and apoptosis in human 
colon cancer cells (Akiyoshi et al., 2008) as well as less tumor growth through inhibition 
of the formation of blood vessels by angiogenesis (Li et al., 2007; Noguera-Troise et 
al., 2006; Ridgway et al., 2006). Taken all these results in consideration, the Notch 
pathway may represent a route via which Ap4 promotes intestinal adenoma initiation.  
   Ectopic AP4 expression is sufficient to activate the WNT pathway in human CRC cell 
lines (Jackstadt et al., 2013c). Our NGS analysis presented here further supports these 
findings with in vivo evidence, since numerous components of the Wnt/β-catenin 
signaling pathway were down-regulated in Ap4-deficient adenomas and derived 
organoids. In support of this conjecture, a comprehensive study has recently shown 
that Ap4 is an important component of Wnt signaling during X. laevis development and 
acts down-stream of the β-catenin destruction complex to regulate expression of 
Wnt/β-catenin target genes (Lebensohn et al., 2016). Furthermore, AP4 is upregulated 
in human hepatocellular carcinoma (HCC), where it activates WNT/β-CATENIN 
signaling to promote tumor growth and by this decreasing survival time (Song et al., 
2018). Therefore, Ap4 presumably represents an integral component of the Wnt 
pathway and its activities during development and tumorigenesis. The down-regulation 
of genes involved in Wnt signaling observed here may critically contribute to the 
decreased number of ISCs observed in Ap4-deficient mice, since an activated Wnt 
pathway is necessary for the maintenance of stemness and suppression of 
differentiation in ISCs (Andreu et al., 2005; Pinto et al., 2003; van Es et al., 2005a).  
   Furthermore, Notch and Wnt signaling cooperate in tumorigenesis. Activation of 
Notch signaling works together with Apc mutation to induce adenoma formation in 
ApcMin mice by maintenance of highly proliferative undifferentiated cells (van Es et al., 
2005b). In addition, activation of Notch signaling increases the tumor load of Wnt-
induced tumors and shortens the survival time in mice heterozygous for mutated Apc 
allele. This may be a result of the increased proliferation after Notch activation 
increasing the possibility of cancer promoting mutations in cancer initiating precursor 
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cells as well as higher proliferation rate of already transformed cancer cells (Fre et al., 
2009). Also, in human tumorigeneses, active WNT and NOTCH signaling cooperate in 
the initiation of CRC (Fre et al., 2009). The regulation of both pathways by Ap4 may 
contribute to the effects of Ap4-deletion in this study. 
   Recent studies identified Ap4 as important for maintaining a c-Myc-induced 
transcriptional program, which is critical for the function of activated B- and T-cells 
(Chou et al., 2014; Chou et al., 2016). Interestingly, we found that Ap4 may act up-
stream of c-Myc, as c-Myc expression in adenomas was decreased after deletion of 
Ap4. This effect is most likely due to a decrease in Wnt and/or Notch activity that 
resulted from the inactivation of Ap4, since c-Myc is a target gene of both pathways. 
c-Myc is known to be necessary for adenoma formation caused by deletion of Apc 
(Sansom et al., 2007; Sur et al., 2012). Furthermore, moderately reduced expression 
of c-Myc is sufficient to decrease the tumor load in ApcMin mice without affecting 
adenoma size (Sur et al., 2012). Interestingly, this phenotype is reminiscent to the 
effect of Ap4 deletion on adenoma formation described here. Therefore, the effects of 
Ap4 deletion on adenoma formation in ApcMin mice may at least in part result from a 
decrease in c-Myc expression. 
   AP4 has been shown to induce EMT (epithelial-mesenchymal-transition) in human 
CRC cells by regulating genes controlling this process and to promote metastasis in a 
xenograft model (Jackstadt et al., 2013c). The next-generation sequencing (NGS) 
results in this study show a tendency towards a decreased expression of genes 
involved in EMT in Ap4-deficient adenomas derived from ApcMin mice. In addition, our 
results indicate a decrease of tumor stem cells in these adenomas. Interestingly, 
passage through an EMT is associated with the acquisition of stem cell traits (Mani et 
al., 2008). In line with this, cancer stem cells (CSCs) of the primary tumor may be the 
precursor for metastasis in different cancer types (Lawson et al., 2015; Odoux et al., 
2008). These results suggest that Ap4 may promote EMT and metastasis by the 
maintenance of the stem cell-like characteristics of cancer cells. However, ApcMin mice 
in a C57BL/6 background are not the adequate mouse model to analyze metastasis, 
since these mice do not develop metastasis (Halberg et al., 2009). In future, it will be 
necessary to analyse the role of Ap4 in the initiation of metastasis and the underlying 
mechanism. 
 Discussion 
96 
 
   In addition, the ApcMin mouse model has the limitation that most tumors are located 
in the small intestine rather than in the colon. We assume that the decrease in the 
number of colonic stem cells in the absence of Ap4 would also translate into a 
decreased number of colorectal cancers if studied in a suitable mouse model. Similarly, 
in humans AP4 may also have a critical function in the control of colonic stem cell 
number and thereby influence the incidence of colorectal cancer. Since many 
mechanisms and pathways are conserved between small intestinal and colonic 
tumors, the results obtained in the mouse model used here may also provide insights 
into the biology of human CRCs and FAP, the inherited syndrome associated with 
germ-line APC mutations. Since the up-regulation of AP4 in human CRC samples was 
associated with activation of the same signaling pathways that we identified in the 
mouse model, the findings presented here are likely to play a role in human CRC.   
   In conclusion, our study demonstrates an unexpected, central role of Ap4 in ISC and 
Paneth cell homeostasis and reveals, that Ap4 function is critical for adenoma initiation 
in a preclinical model of inherited colon cancer. Besides illuminating an important 
aspect of CRC biology our results indicate that Ap4 represents a candidate therapeutic 
target for the treatment of CRCs. 
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7. Summary 
   The gene encoding the transcription factor TFAP4/AP4 represents a direct target of 
the c-MYC oncoprotein. AP4 contributes to the progression of colorectal cancer by 
regulating genes involved in proliferation and EMT (epithelial-mesenchymal transition). 
Previously we reported that AP4 is expressed in proliferating cells in human colonic 
crypts in a pattern similar to c-MYC. Also in human colorectal cancer, AP4 is highly 
expressed in proliferating cells. Taken together, these results suggested that AP4 may 
have an important function in intestinal homeostasis and carcinogenesis. In this study 
we deleted Ap4 in ApcMin mice, a preclinical model of inherited colorectal cancer. Ap4-
deficiency extended their average survival by 110 days and decreased the formation 
of intestinal adenomas and tumor-derived organoids. Deletion of Ap4 in the germ-line 
and in intestinal epithelial cells resulted in a reduced number of intestinal stem cells 
and a reciprocal increase in Paneth cells. The effects of Ap4 deletion in ApcMin mice 
are presumably due to the reduced number of functional intestinal stem cells amenable 
to adenoma initiating mutational events. Deletion of Ap4 also decreased the number 
of colonic stem cells leading to a decrease of adenomas also in the colon. Expression 
profiling revealed that intestinal stem cell signatures, as well as the Wnt/β-catenin and 
Notch signaling pathways are down-regulated in Ap4-deficient adenomas and 
intestinal organoids. Both the Wnt/β-catenin and Notch signaling pathway are 
important for the maintenance of intestinal stem cells. The down-regulation of these 
pathways may be the cause of the lower number of intestinal stem cells in the crypt 
base in Ap4-deficient mice. Ap4-associated gene expression signatures are conserved 
between murine adenomas and human colorectal cancer samples. Our results 
establish Ap4 as a rate limiting mediator of adenoma initiation as well as a regulator of 
intestinal stem cell and Paneth cell homeostasis. 
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8. Zusammenfassung 
   Das für den Transkriptionsfaktor TFAP4/AP4 kodierende Gen stellt ein direktes Ziel 
des c-MYC-Onkoproteins dar. AP4 trägt zur Progression von kolorektalem Krebs bei, 
indem es Gene reguliert, welche Proliferation und EMT (Epithial-mesenchymale-
Transition) steuern. Zuvor berichteten wir, dass AP4 in proliferierenden Zellen in 
humanen Kolonkrypten ein ähnliches Expressionsmuster wie c-MYC hat. Auch beim 
kolorektalen Krebs im Menschen wird AP4 in proliferierenden Zellen stark exprimiert. 
Zusammenfassend legen diese Ergebnisse nahe, dass AP4 eine wichtige Funktion in 
der intestinalen Homöostase und Karzinogenese haben könnte. In der vorliegenden 
Studie haben wir Ap4 in ApcMin-Mäusen, einem präklinischen Modell des erblichen 
Kolorektalkarzinoms, deletiert. Der Verlust von Ap4 verlängerte das durchschnittliche 
Überleben um 110 Tage und verringerte die Bildung von Adenomen im Darm und von 
Tumorzellen abgeleiteten Organoiden. Die Deletion von Ap4 in der Keimbahn und in 
Darmepithelzellen führte zu einer verminderten Anzahl an intestinalen Stammzellen 
und einem reziproken Anstieg der Paneth-Zellen. Die Auswirkungen der Ap4-Deletion 
in ApcMin Mäusen sind vermutlich auf die verringerte Anzahl von funktionellen 
intestinalen Stammzellen zurückzuführen, die für Adenom-initiierende 
Mutationsereignisse zugänglich sind. Die Deletion von Ap4 verringerte auch die Anzahl 
von Kolonstammzellen, was auch im Dickdarm zu einer Abnahme von Adenomen 
führte. Die Erstellung von Expressionsprofilen zeigte, dass intestinale Stammzell-
Signaturen, sowie die Wnt/β-Catenin- und Notch-Signalwege, in Ap4-defizienten 
Adenomen und intestinalen Organoiden herabreguliert sind. Sowohl der Wnt/β-
Catenin- als auch der Notch-Signalweg ist wichtig für den Erhalt von intestinalen 
Stammzellen. Die Herunterregulierung dieser Signalwege könnte die Ursache für die 
geringere Anzahl von intestinalen Stammzellen an der Kryptenbase in Ap4-defizienten 
Mäusen sein. Ap4-assoziierte Gen-Expressions-Signaturen sind zwischen murinen 
Adenomen und humanen kolorektalen Krebsproben konserviert. Unsere Ergebnisse 
etablieren Ap4 als limitierenden Mediator der Adenom-Initiation, sowie als Regulator 
der Homöostase von intestinalen Stammzellen und Paneth-Zellen. 
 
 Acknowledgements 
99 
 
9. Acknowledgements 
   My deepest gratitude goes to my supervisor Prof. Dr. Heiko Hermeking for the 
interesting project and his advice, support and scientific input during my doctorial 
study.  
Many thanks go to Dr. Markus Kaller for the bioinformatics analyses and associated 
figures as well as for advices and discussions about my project. 
I would like to thank Ursula Götz for her technical support in the laboratory and her 
support in breeding of mice as well as for her help in the establishment of primary 
antibodies for immunohistochemistry and in performing immunohistochemical 
stainings. 
I also would like to thank Dr. Peter Jung for the organoid culture protocols, the advices 
and supports for organoid experiments as well as for discussions about my results. 
   In addition, I would like to acknowledge all the other people supporting my doctoral 
work: 
Prof. Dr. med. David Horst for the paraffin slides from human CRC cohorts and the 
DBZ treatment of mice. 
Dr. Rene Jackstadt for the human CRC cell culture work and the associated figures. 
People working in the pathological entrance laboratory for the dehydration of the 
mouse tissues, help with histological staining, performing immunohistochemistry on 
slides from human CRC cohorts and for allowing me to cut my paraffin blocks at their 
microtomes. 
Andrea Sendelhofert and Anja Heier for their help in immunohistochemistry in 
establishment primary antibodies. 
Dr. med. Susanna Müller and Sabine Schäfer for electron microscopic analysis and 
preparation of intestinal tissue for electron microscopy, respectively. 
   Additionally, I would like to thank all colleagues from AG Hermeking and all other 
people from the institute for a good time during my doctorial work. Many thanks to my 
mother and grandmother always motivating me during my doctorial time. 
  
 References 
100 
 
10. References 
Akiyoshi, T., Nakamura, M., Yanai, K., Nagai, S., Wada, J., Koga, K., Nakashima, H., 
Sato, N., Tanaka, M., and Katano, M. (2008). Gamma-secretase inhibitors enhance 
taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology 
134, 131-144. 
 
Andreu, P., Colnot, S., Godard, C., Gad, S., Chafey, P., Niwa-Kawakita, M., Laurent-
Puig, P., Kahn, A., Robine, S., Perret, C., et al. (2005). Crypt-restricted proliferation 
and commitment to the Paneth cell lineage following Apc loss in the mouse intestine. 
Development 132, 1443-1451. 
 
Barker, N. (2014). Adult intestinal stem cells: critical drivers of epithelial homeostasis 
and regeneration. Nat Rev Mol Cell Biol 15, 19-33. 
 
Barker, N., and Clevers, H. (2007). Tracking down the stem cells of the intestine: 
strategies to identify adult stem cells. Gastroenterology 133, 1755-1760. 
 
Barker, N., Ridgway, R.A., van Es, J.H., van de Wetering, M., Begthel, H., van den 
Born, M., Danenberg, E., Clarke, A.R., Sansom, O.J., and Clevers, H. (2009). Crypt 
stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611. 
 
Barker, N., van Es, J.H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., 
Haegebarth, A., Korving, J., Begthel, H., Peters, P.J., et al. (2007). Identification of 
stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007. 
 
Batlle, E., Henderson, J.T., Beghtel, H., van den Born, M.M., Sancho, E., Huls, G., 
Meeldijk, J., Robertson, J., van de Wetering, M., Pawson, T., et al. (2002). Beta-
catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the 
expression of EphB/ephrinB. Cell 111, 251-263. 
 
Bettess, M.D., Dubois, N., Murphy, M.J., Dubey, C., Roger, C., Robine, S., and 
Trumpp, A. (2005). c-Myc is required for the formation of intestinal crypts but 
dispensable for homeostasis of the adult intestinal epithelium. Mol Cell Biol 25, 7868-
7878. 
 
Beumer, J., and Clevers, H. (2016). Regulation and plasticity of intestinal stem cells 
during homeostasis and regeneration. Development 143, 3639-3649. 
 
Buczacki, S.J., Zecchini, H.I., Nicholson, A.M., Russell, R., Vermeulen, L., Kemp, R., 
and Winton, D.J. (2013). Intestinal label-retaining cells are secretory precursors 
expressing Lgr5. Nature 495, 65-69. 
 
Cancer Genome Atlas, N. (2012). Comprehensive molecular characterization of 
human colon and rectal cancer. Nature 487, 330-337. 
 
Carulli, A.J., Keeley, T.M., Demitrack, E.S., Chung, J., Maillard, I., and Samuelson, 
L.C. (2015). Notch receptor regulation of intestinal stem cell homeostasis and crypt 
regeneration. Dev Biol 402, 98-108. 
 
 References 
101 
 
Cheng, P., Zlobin, A., Volgina, V., Gottipati, S., Osborne, B., Simel, E.J., Miele, L., 
and Gabrilovich, D.I. (2001). Notch-1 regulates NF-kappaB activity in hemopoietic 
progenitor cells. J Immunol 167, 4458-4467. 
 
Chou, C., Pinto, A.K., Curtis, J.D., Persaud, S.P., Cella, M., Lin, C.C., Edelson, B.T., 
Allen, P.M., Colonna, M., Pearce, E.L., et al. (2014). c-Myc-induced transcription 
factor AP4 is required for host protection mediated by CD8+ T cells. Nat Immunol 15, 
884-893. 
 
Chou, C., Verbaro, D.J., Tonc, E., Holmgren, M., Cella, M., Colonna, M., 
Bhattacharya, D., and Egawa, T. (2016). The Transcription Factor AP4 Mediates 
Resolution of Chronic Viral Infection through Amplification of Germinal Center B Cell 
Responses. Immunity 45, 570-582. 
 
Chu, D., Zhang, Z., Zhou, Y., Wang, W., Li, Y., Zhang, H., Dong, G., Zhao, Q., and Ji, 
G. (2011). Notch1 and Notch2 have opposite prognostic effects on patients with 
colorectal cancer. Ann Oncol 22, 2440-2447. 
 
Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127, 
469-480. 
 
Clevers, H., Loh, K.M., and Nusse, R. (2014). Stem cell signaling. An integral 
program for tissue renewal and regeneration: Wnt signaling and stem cell control. 
Science 346, 1248012. 
 
Clevers, H., and Nusse, R. (2012). Wnt/beta-catenin signaling and disease. Cell 149, 
1192-1205. 
 
Clevers, H.C., and Bevins, C.L. (2013). Paneth cells: maestros of the small intestinal 
crypts. Annu Rev Physiol 75, 289-311. 
 
D'Annibale, S., Kim, J., Magliozzi, R., Low, T.Y., Mohammed, S., Heck, A.J., and 
Guardavaccaro, D. (2014). Proteasome-dependent Degradation of Transcription 
Factor Activating Enhancer-binding Protein 4 (TFAP4) Controls Mitotic Division. J 
Biol Chem 289, 7730-7737. 
 
Dalerba, P., Dylla, S.J., Park, I.K., Liu, R., Wang, X., Cho, R.W., Hoey, T., Gurney, 
A., Huang, E.H., Simeone, D.M., et al. (2007). Phenotypic characterization of human 
colorectal cancer stem cells. Proc Natl Acad Sci U S A 104, 10158-10163. 
 
de Lau, W., Barker, N., Low, T.Y., Koo, B.K., Li, V.S., Teunissen, H., Kujala, P., 
Haegebarth, A., Peters, P.J., van de Wetering, M., et al. (2011). Lgr5 homologues 
associate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293-
297. 
 
de Sousa e Melo, F., Kurtova, A.V., Harnoss, J.M., Kljavin, N., Hoeck, J.D., Hung, J., 
Anderson, J.E., Storm, E.E., Modrusan, Z., Koeppen, H., et al. (2017). A distinct role 
for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature 543, 676-680. 
 
 References 
102 
 
Efferson, C.L., Winkelmann, C.T., Ware, C., Sullivan, T., Giampaoli, S., Tammam, J., 
Patel, S., Mesiti, G., Reilly, J.F., Gibson, R.E., et al. (2010). Downregulation of Notch 
pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of 
rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer 
model. Cancer Res 70, 2476-2484. 
 
el Marjou, F., Janssen, K.P., Chang, B.H., Li, M., Hindie, V., Chan, L., Louvard, D., 
Chambon, P., Metzger, D., and Robine, S. (2004). Tissue-specific and inducible Cre-
mediated recombination in the gut epithelium. Genesis 39, 186-193. 
 
Espinosa, L., Santos, S., Ingles-Esteve, J., Munoz-Canoves, P., and Bigas, A. 
(2002). p65-NFkappaB synergizes with Notch to activate transcription by triggering 
cytoplasmic translocation of the nuclear receptor corepressor N-CoR. J Cell Sci 115, 
1295-1303. 
 
Fearon, E.R., and Vogelstein, B. (1990). A genetic model for colorectal 
tumorigenesis. Cell 61, 759-767. 
 
Fevr, T., Robine, S., Louvard, D., and Huelsken, J. (2007). Wnt/beta-catenin is 
essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell 
Biol 27, 7551-7559. 
 
Finch, A.J., Soucek, L., Junttila, M.R., Swigart, L.B., and Evan, G.I. (2009). Acute 
overexpression of Myc in intestinal epithelium recapitulates some but not all the 
changes elicited by Wnt/beta-catenin pathway activation. Mol Cell Biol 29, 5306-
5315. 
 
Fitzgerald, K., Harrington, A., and Leder, P. (2000). Ras pathway signals are required 
for notch-mediated oncogenesis. Oncogene 19, 4191-4198. 
 
Frank, S.R., Schroeder, M., Fernandez, P., Taubert, S., and Amati, B. (2001). 
Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 
and gene activation. Genes Dev 15, 2069-2082. 
 
Fre, S., Huyghe, M., Mourikis, P., Robine, S., Louvard, D., and Artavanis-Tsakonas, 
S. (2005). Notch signals control the fate of immature progenitor cells in the intestine. 
Nature 435, 964-968. 
 
Fre, S., Pallavi, S.K., Huyghe, M., Lae, M., Janssen, K.P., Robine, S., Artavanis-
Tsakonas, S., and Louvard, D. (2009). Notch and Wnt signals cooperatively control 
cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci U S A 106, 
6309-6314. 
 
Gao, J., Chen, C., Hong, L., Wang, J., Du, Y., Song, J., Shao, X., Zhang, J., Han, H., 
Liu, J., et al. (2007). Expression of Jagged1 and its association with hepatitis B virus 
X protein in hepatocellular carcinoma. Biochem Biophys Res Commun 356, 341-347. 
 
Garcia, M.I., Ghiani, M., Lefort, A., Libert, F., Strollo, S., and Vassart, G. (2009). 
LGR5 deficiency deregulates Wnt signaling and leads to precocious Paneth cell 
differentiation in the fetal intestine. Dev Biol 331, 58-67. 
 References 
103 
 
 
Gong, H., Han, S., Yao, H., Zhao, H., and Wang, Y. (2014). AP4 predicts poor 
prognosis in nonsmall cell lung cancer. Mol Med Rep 10, 336-340. 
 
Gregorieff, A., and Clevers, H. (2005). Wnt signaling in the intestinal epithelium: from 
endoderm to cancer. Genes Dev 19, 877-890. 
 
Gregorieff, A., and Clevers, H. (2010). In situ hybridization to identify gut stem cells. 
Curr Protoc Stem Cell Biol Chapter 2, Unit 2F 1. 
 
Gronostajski, R.M., and Sadowski, P.D. (1985). The FLP recombinase of the 
Saccharomyces cerevisiae 2 microns plasmid attaches covalently to DNA via a 
phosphotyrosyl linkage. Mol Cell Biol 5, 3274-3279. 
 
Guillen-Ahlers, H., Suckow, M.A., Castellino, F.J., and Ploplis, V.A. (2010). Fas/CD95 
deficiency in ApcMin/+ mice increases intestinal tumor burden. PLoS One 5, e9070. 
 
Guinney, J., Dienstmann, R., Wang, X., de Reynies, A., Schlicker, A., Soneson, C., 
Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015). The 
consensus molecular subtypes of colorectal cancer. Nat Med 21, 1350-1356. 
 
Halberg, R.B., Waggoner, J., Rasmussen, K., White, A., Clipson, L., Prunuske, A.J., 
Bacher, J.W., Sullivan, R., Washington, M.K., Pitot, H.C., et al. (2009). Long-lived 
Min mice develop advanced intestinal cancers through a genetically conservative 
pathway. Cancer Res 69, 5768-5775. 
 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. 
Cell 144, 646-674. 
 
He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., Morin, 
P.J., Vogelstein, B., and Kinzler, K.W. (1998). Identification of c-MYC as a target of 
the APC pathway. Science 281, 1509-1512. 
 
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., 
Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-
determining transcription factors prime cis-regulatory elements required for 
macrophage and B cell identities. Mol Cell 38, 576-589. 
 
Hoshiko, S., Kawaguchi, M., Fukushima, T., Haruyama, Y., Yorita, K., Tanaka, H., 
Seiki, M., Inatsu, H., Kitamura, K., and Kataoka, H. (2013). Hepatocyte growth factor 
activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. Cancer Res 73, 
2659-2670. 
 
Hu, B.S., Zhao, G., Yu, H.F., Chen, K., Dong, J.H., and Tan, J.W. (2013). High 
expression of AP-4 predicts poor prognosis for hepatocellular carcinoma after 
curative hepatectomy. Tumour Biol 34, 271-276. 
 
 References 
104 
 
Huels, D.J., Bruens, L., Hodder, M.C., Cammareri, P., Campbell, A.D., Ridgway, 
R.A., Gay, D.M., Solar-Abboud, M., Faller, W.J., Nixon, C., et al. (2018). Wnt ligands 
influence tumour initiation by controlling the number of intestinal stem cells. Nat 
Commun 9, 1132. 
 
Jackstadt, R., Jung, P., and Hermeking, H. (2013a). AP4 directly downregulates p16 
and p21 to suppress senescence and mediate transformation. Cell Death Dis 4, 
e775. 
 
Jackstadt, R., Menssen, A., and Hermeking, H. (2013b). Genome-wide analysis of c-
MYC-regulated mRNAs and miRNAs, and c-MYC DNA binding by next-generation 
sequencing. Methods Mol Biol 1012, 145-185. 
 
Jackstadt, R., Roh, S., Neumann, J., Jung, P., Hoffmann, R., Horst, D., Berens, C., 
Bornkamm, G.W., Kirchner, T., Menssen, A., et al. (2013c). AP4 is a mediator of 
epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med 
210, 1331-1350. 
 
Jaeckel, S., Kaller, M., Jackstadt, R., Gotz, U., Muller, S., Boos, S., Horst, D., Jung, 
P., and Hermeking, H. (2018). Ap4 is rate limiting for intestinal tumor formation by 
controlling the homeostasis of intestinal stem cells. Nat Commun 9, 3573. 
 
Jarriault, S., Brou, C., Logeat, F., Schroeter, E.H., Kopan, R., and Israel, A. (1995). 
Signalling downstream of activated mammalian Notch. Nature 377, 355-358. 
 
Jarriault, S., Le Bail, O., Hirsinger, E., Pourquie, O., Logeat, F., Strong, C.F., Brou, 
C., Seidah, N.G., and Isra l, A. (1998). Delta-1 activation of notch-1 signaling results 
in HES-1 transactivation. Mol Cell Biol 18, 7423-7431. 
 
Jensen, J., Pedersen, E.E., Galante, P., Hald, J., Heller, R.S., Ishibashi, M., 
Kageyama, R., Guillemot, F., Serup, P., and Madsen, O.D. (2000). Control of 
endodermal endocrine development by Hes-1. Nat Genet 24, 36-44. 
 
Jung, P., and Hermeking, H. (2009). The c-MYC-AP4-p21 cascade. Cell Cycle 8, 
982-989. 
 
Jung, P., Menssen, A., Mayr, D., and Hermeking, H. (2008). AP4 encodes a c-MYC-
inducible repressor of p21. Proc Natl Acad Sci U S A 105, 15046-15051. 
 
Kayahara, T., Sawada, M., Takaishi, S., Fukui, H., Seno, H., Fukuzawa, H., Suzuki, 
K., Hiai, H., Kageyama, R., Okano, H., et al. (2003). Candidate markers for stem and 
early progenitor cells, Musashi-1 and Hes1, are expressed in crypt base columnar 
cells of mouse small intestine. FEBS Lett 535, 131-135. 
 
Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M., and 
Haussler, D. (2002). The human genome browser at UCSC. Genome Res 12, 996-
1006. 
 
 
 
 References 
105 
 
Kimura, K., Satoh, K., Kanno, A., Hamada, S., Hirota, M., Endoh, M., Masamune, A., 
and Shimosegawa, T. (2007). Activation of Notch signaling in tumorigenesis of 
experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer 
Sci 98, 155-162. 
 
Kinzler, K.W., and Vogelstein, B. (1996). Lessons from hereditary colorectal cancer. 
Cell 87, 159-170. 
 
Klinakis, A., Szabolcs, M., Politi, K., Kiaris, H., Artavanis-Tsakonas, S., and 
Efstratiadis, A. (2006). Myc is a Notch1 transcriptional target and a requisite for 
Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A 103, 
9262-9267. 
 
Konishi, J., Kawaguchi, K.S., Vo, H., Haruki, N., Gonzalez, A., Carbone, D.P., and 
Dang, T.P. (2007). Gamma-secretase inhibitor prevents Notch3 activation and 
reduces proliferation in human lung cancers. Cancer Res 67, 8051-8057. 
 
Korinek, V., Barker, N., Moerer, P., van Donselaar, E., Huls, G., Peters, P.J., and 
Clevers, H. (1998). Depletion of epithelial stem-cell compartments in the small 
intestine of mice lacking Tcf-4. Nat Genet 19, 379-383. 
 
Kuhnert, F., Davis, C.R., Wang, H.T., Chu, P., Lee, M., Yuan, J., Nusse, R., and Kuo, 
C.J. (2004). Essential requirement for Wnt signaling in proliferation of adult small 
intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad 
Sci U S A 101, 266-271. 
 
Lawson, D.A., Bhakta, N.R., Kessenbrock, K., Prummel, K.D., Yu, Y., Takai, K., 
Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.Y., et al. (2015). Single-cell analysis 
reveals a stem-cell program in human metastatic breast cancer cells. Nature 526, 
131-135. 
 
Lebensohn, A.M., Dubey, R., Neitzel, L.R., Tacchelly-Benites, O., Yang, E., Marceau, 
C.D., Davis, E.M., Patel, B.B., Bahrami-Nejad, Z., Travaglini, K.J., et al. (2016). 
Comparative genetic screens in human cells reveal new regulatory mechanisms in 
WNT signaling. Elife 5. 
 
Li, J.L., Sainson, R.C., Shi, W., Leek, R., Harrington, L.S., Preusser, M., Biswas, S., 
Turley, H., Heikamp, E., Hainfellner, J.A., et al. (2007). Delta-like 4 Notch ligand 
regulates tumor angiogenesis, improves tumor vascular function, and promotes 
tumor growth in vivo. Cancer Res 67, 11244-11253. 
 
Li, Y., Hibbs, M.A., Gard, A.L., Shylo, N.A., and Yun, K. (2012). Genome-wide 
analysis of N1ICD/RBPJ targets in vivo reveals direct transcriptional regulation of 
Wnt, SHH, and hippo pathway effectors by Notch1. Stem Cells 30, 741-752. 
 
Li, Y., Yang, Y., Li, J., Liu, H., Chen, F., Li, B., Cui, B., and Liu, Y. (2017). USP22 
drives colorectal cancer invasion and metastasis via epithelial-mesenchymal 
transition by activating AP4. Oncotarget 8, 32683-32695. 
 
 References 
106 
 
Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J.P., and Tamayo, 
P. (2015). The Molecular Signatures Database (MSigDB) hallmark gene set 
collection. Cell Syst 1, 417-425. 
 
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change 
and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550. 
 
Ma, W., Liu, B., Li, J., Jiang, J., Zhou, R., Huang, L., Li, X., He, X., and Zhou, Q. 
(2018). MicroRNA-302c represses epithelial-mesenchymal transition and metastasis 
by targeting transcription factor AP-4 in colorectal cancer. Biomed Pharmacother 
105, 670-676. 
 
Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., 
Reinhard, F., Zhang, C.C., Shipitsin, M., et al. (2008). The epithelial-mesenchymal 
transition generates cells with properties of stem cells. Cell 133, 704-715. 
 
McCarthy, D.J., Chen, Y., and Smyth, G.K. (2012). Differential expression analysis of 
multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids 
Res 40, 4288-4297. 
 
Menssen, A., Epanchintsev, A., Lodygin, D., Rezaei, N., Jung, P., Verdoodt, B., 
Diebold, J., and Hermeking, H. (2007). c-MYC delays prometaphase by direct 
transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-
induced DNA damage and chromosomal instability. Cell Cycle 6, 339-352. 
 
Merlos-Suarez, A., Barriga, F.M., Jung, P., Iglesias, M., Cespedes, M.V., Rossell, D., 
Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Munoz, P., et al. (2011). The 
intestinal stem cell signature identifies colorectal cancer stem cells and predicts 
disease relapse. Cell Stem Cell 8, 511-524. 
 
Meurette, O., Stylianou, S., Rock, R., Collu, G.M., Gilmore, A.P., and Brennan, K. 
(2009). Notch activation induces Akt signaling via an autocrine loop to prevent 
apoptosis in breast epithelial cells. Cancer Res 69, 5015-5022. 
 
Miyamoto, Y., Maitra, A., Ghosh, B., Zechner, U., Argani, P., Iacobuzio-Donahue, 
C.A., Sriuranpong, V., Iso, T., Meszoely, I.M., Wolfe, M.S., et al. (2003). Notch 
mediates TGF alpha-induced changes in epithelial differentiation during pancreatic 
tumorigenesis. Cancer Cell 3, 565-576. 
 
Moser, A.R., Pitot, H.C., and Dove, W.F. (1990). A dominant mutation that 
predisposes to multiple intestinal neoplasia in the mouse. Science 247, 322-324. 
 
Muncan, V., Sansom, O.J., Tertoolen, L., Phesse, T.J., Begthel, H., Sancho, E., Cole, 
A.M., Gregorieff, A., de Alboran, I.M., Clevers, H., et al. (2006). Rapid loss of 
intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol 
Cell Biol 26, 8418-8426. 
 
 
 
 References 
107 
 
Munoz, J., Stange, D.E., Schepers, A.G., van de Wetering, M., Koo, B.K., Itzkovitz, 
S., Volckmann, R., Kung, K.S., Koster, J., Radulescu, S., et al. (2012). The Lgr5 
intestinal stem cell signature: robust expression of proposed quiescent '+4' cell 
markers. EMBO J 31, 3079-3091. 
 
Noah, T.K., Kazanjian, A., Whitsett, J., and Shroyer, N.F. (2010). SAM pointed 
domain ETS factor (SPDEF) regulates terminal differentiation and maturation of 
intestinal goblet cells. Experimental Cell Research 316, 452-465. 
 
Noah, T.K., and Shroyer, N.F. (2013). Notch in the intestine: regulation of 
homeostasis and pathogenesis. Annu Rev Physiol 75, 263-288. 
 
Noguera-Troise, I., Daly, C., Papadopoulos, N.J., Coetzee, S., Boland, P., Gale, 
N.W., Lin, H.C., Yancopoulos, G.D., and Thurston, G. (2006). Blockade of Dll4 
inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032-
1037. 
 
O'Brien, C.A., Pollett, A., Gallinger, S., and Dick, J.E. (2007). A human colon cancer 
cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-
110. 
 
Odoux, C., Fohrer, H., Hoppo, T., Guzik, L., Stolz, D.B., Lewis, D.W., Gollin, S.M., 
Gamblin, T.C., Geller, D.A., and Lagasse, E. (2008). A stochastic model for cancer 
stem cell origin in metastatic colon cancer. Cancer Res 68, 6932-6941. 
 
Oswald, F., Liptay, S., Adler, G., and Schmid, R.M. (1998). NF-kappaB2 is a putative 
target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 18, 2077-2088. 
 
Oswald, F., Tauber, B., Dobner, T., Bourteele, S., Kostezka, U., Adler, G., Liptay, S., 
and Schmid, R.M. (2001). p300 acts as a transcriptional coactivator for mammalian 
Notch-1. Mol Cell Biol 21, 7761-7774. 
 
Palomero, T., Lim, W.K., Odom, D.T., Sulis, M.L., Real, P.J., Margolin, A., Barnes, 
K.C., O'Neil, J., Neuberg, D., Weng, A.P., et al. (2006). NOTCH1 directly regulates c-
MYC and activates a feed-forward-loop transcriptional network promoting leukemic 
cell growth. Proc Natl Acad Sci U S A 103, 18261-18266. 
 
Payne, J.E. (1990). Colorectal carcinogenesis. Aust N Z J Surg 60, 11-18. 
 
Pellegrinet, L., Rodilla, V., Liu, Z., Chen, S., Koch, U., Espinosa, L., Kaestner, K.H., 
Kopan, R., Lewis, J., and Radtke, F. (2011). Dll1- and dll4-mediated notch signaling 
are required for homeostasis of intestinal stem cells. Gastroenterology 140, 1230-
1240 e1231-1237. 
 
Pinto, D., Gregorieff, A., Begthel, H., and Clevers, H. (2003). Canonical Wnt signals 
are essential for homeostasis of the intestinal epithelium. Genes Dev 17, 1709-1713. 
 
 
 
 References 
108 
 
Powell, A.E., Wang, Y., Li, Y., Poulin, E.J., Means, A.L., Washington, M.K., 
Higginbotham, J.N., Juchheim, A., Prasad, N., Levy, S.E., et al. (2012). The pan-
ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a 
tumor suppressor. Cell 149, 146-158. 
 
Powell, S.M., Petersen, G.M., Krush, A.J., Booker, S., Jen, J., Giardiello, F.M., 
Hamilton, S.R., Vogelstein, B., and Kinzler, K.W. (1993). Molecular diagnosis of 
familial adenomatous polyposis. N Engl J Med 329, 1982-1987. 
 
Qi, R., An, H., Yu, Y., Zhang, M., Liu, S., Xu, H., Guo, Z., Cheng, T., and Cao, X. 
(2003). Notch1 signaling inhibits growth of human hepatocellular carcinoma through 
induction of cell cycle arrest and apoptosis. Cancer Res 63, 8323-8329. 
 
Reedijk, M., Odorcic, S., Chang, L., Zhang, H., Miller, N., McCready, D.R., 
Lockwood, G., and Egan, S.E. (2005). High-level coexpression of JAG1 and 
NOTCH1 is observed in human breast cancer and is associated with poor overall 
survival. Cancer Res 65, 8530-8537. 
 
Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., and 
De Maria, R. (2007). Identification and expansion of human colon-cancer-initiating 
cells. Nature 445, 111-115. 
 
Riccio, O., van Gijn, M.E., Bezdek, A.C., Pellegrinet, L., van Es, J.H., Zimber-Strobl, 
U., Strobl, L.J., Honjo, T., Clevers, H., and Radtke, F. (2008). Loss of intestinal crypt 
progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by 
derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep 9, 377-383. 
 
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.C., Chanthery, Y., Kowalski, 
J., Watts, R.J., Callahan, C., Kasman, I., et al. (2006). Inhibition of Dll4 signalling 
inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083-1087. 
 
Risso, D., Ngai, J., Speed, T.P., and Dudoit, S. (2014). Normalization of RNA-seq 
data using factor analysis of control genes or samples. Nature biotechnology 32, 
896-902. 
 
Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor 
package for differential expression analysis of digital gene expression data. 
Bioinformatics 26, 139-140. 
 
Rodilla, V., Villanueva, A., Obrador-Hevia, A., Robert-Moreno, A., Fernandez-
Majada, V., Grilli, A., Lopez-Bigas, N., Bellora, N., Alba, M.M., Torres, F., et al. 
(2009). Jagged1 is the pathological link between Wnt and Notch pathways in 
colorectal cancer. Proc Natl Acad Sci U S A 106, 6315-6320. 
 
Sancho, E., Batlle, E., and Clevers, H. (2004). Signaling pathways in intestinal 
development and cancer. Annu Rev Cell Dev Biol 20, 695-723. 
 
Sangiorgi, E., and Capecchi, M.R. (2008). Bmi1 is expressed in vivo in intestinal stem 
cells. Nat Genet 40, 915-920. 
 
 References 
109 
 
Sansom, O.J., Meniel, V.S., Muncan, V., Phesse, T.J., Wilkins, J.A., Reed, K.R., 
Vass, J.K., Athineos, D., Clevers, H., and Clarke, A.R. (2007). Myc deletion rescues 
Apc deficiency in the small intestine. Nature 446, 676-679. 
 
Sasaki, N., Sachs, N., Wiebrands, K., Ellenbroek, S.I., Fumagalli, A., Lyubimova, A., 
Begthel, H., van den Born, M., van Es, J.H., Karthaus, W.R., et al. (2016). Reg4+ 
deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon. 
Proc Natl Acad Sci U S A 113, E5399-5407. 
 
Sato, T., and Clevers, H. (2013). Growing self-organizing mini-guts from a single 
intestinal stem cell: mechanism and applications. Science 340, 1190-1194. 
 
Sato, T., Stange, D.E., Ferrante, M., Vries, R.G., Van Es, J.H., Van den Brink, S., 
Van Houdt, W.J., Pronk, A., Van Gorp, J., Siersema, P.D., et al. (2011a). Long-term 
expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and 
Barrett's epithelium. Gastroenterology 141, 1762-1772. 
 
Sato, T., van Es, J.H., Snippert, H.J., Stange, D.E., Vries, R.G., van den Born, M., 
Barker, N., Shroyer, N.F., van de Wetering, M., and Clevers, H. (2011b). Paneth cells 
constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469, 415-418. 
 
Sato, T., Vries, R.G., Snippert, H.J., van de Wetering, M., Barker, N., Stange, D.E., 
van Es, J.H., Abo, A., Kujala, P., Peters, P.J., et al. (2009). Single Lgr5 stem cells 
build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262-
265. 
 
Schepers, A.G., Snippert, H.J., Stange, D.E., van den Born, M., van Es, J.H., van de 
Wetering, M., and Clevers, H. (2012). Lineage tracing reveals Lgr5+ stem cell activity 
in mouse intestinal adenomas. Science 337, 730-735. 
 
Schwenk, F., Baron, U., and Rajewsky, K. (1995). A cre-transgenic mouse strain for 
the ubiquitous deletion of loxP-flanked gene segments including deletion in germ 
cells. Nucleic Acids Res 23, 5080-5081. 
 
Schwitalla, S., Fingerle, A.A., Cammareri, P., Nebelsiek, T., Goktuna, S.I., Ziegler, 
P.K., Canli, O., Heijmans, J., Huels, D.J., Moreaux, G., et al. (2013). Intestinal 
tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like 
properties. Cell 152, 25-38. 
 
Serafin, V., Persano, L., Moserle, L., Esposito, G., Ghisi, M., Curtarello, M., Bonanno, 
L., Masiero, M., Ribatti, D., Sturzl, M., et al. (2011). Notch3 signalling promotes 
tumour growth in colorectal cancer. J Pathol 224, 448-460. 
 
Sharma, V.M., Calvo, J.A., Draheim, K.M., Cunningham, L.A., Hermance, N., 
Beverly, L., Krishnamoorthy, V., Bhasin, M., Capobianco, A.J., and Kelliher, M.A. 
(2006). Notch1 contributes to mouse T-cell leukemia by directly inducing the 
expression of c-myc. Mol Cell Biol 26, 8022-8031. 
 
 
 References 
110 
 
Shi, L., Jackstadt, R., Siemens, H., Li, H., Kirchner, T., and Hermeking, H. (2014). 
p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to 
regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. 
Cancer Res 74, 532-542. 
 
Siemens, H., Jackstadt, R., Hunten, S., Kaller, M., Menssen, A., Gotz, U., and 
Hermeking, H. (2011). miR-34 and SNAIL form a double-negative feedback loop to 
regulate epithelial-mesenchymal transitions. Cell Cycle 10. 
 
Song, J., Xie, C., Jiang, L., Wu, G., Zhu, J., Zhang, S., Tang, M., Song, L., and Li, J. 
(2018). Transcription factor AP-4 promotes tumorigenic capability and activates the 
Wnt/beta-catenin pathway in hepatocellular carcinoma. Theranostics 8, 3571-3583. 
 
Stylianou, S., Clarke, R.B., and Brennan, K. (2006). Aberrant activation of notch 
signaling in human breast cancer. Cancer Res 66, 1517-1525. 
 
Su, L.K., Kinzler, K.W., Vogelstein, B., Preisinger, A.C., Moser, A.R., Luongo, C., 
Gould, K.A., and Dove, W.F. (1992). Multiple intestinal neoplasia caused by a 
mutation in the murine homolog of the APC gene. Science 256, 668-670. 
 
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, 
M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide 
expression profiles. Proc Natl Acad Sci U S A 102, 15545-15550. 
 
Sur, I.K., Hallikas, O., Vaharautio, A., Yan, J., Turunen, M., Enge, M., Taipale, M., 
Karhu, A., Aaltonen, L.A., and Taipale, J. (2012). Mice lacking a Myc enhancer that 
includes human SNP rs6983267 are resistant to intestinal tumors. Science 338, 
1360-1363. 
 
Sureban, S.M., May, R., George, R.J., Dieckgraefe, B.K., McLeod, H.L., 
Ramalingam, S., Bishnupuri, K.S., Natarajan, G., Anant, S., and Houchen, C.W. 
(2008). Knockdown of RNA binding protein musashi-1 leads to tumor regression in 
vivo. Gastroenterology 134, 1448-1458. 
 
Terris, B., Blaveri, E., Crnogorac-Jurcevic, T., Jones, M., Missiaglia, E., Ruszniewski, 
P., Sauvanet, A., and Lemoine, N.R. (2002). Characterization of gene expression 
profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 160, 
1745-1754. 
 
Tian, H., Biehs, B., Chiu, C., Siebel, C.W., Wu, Y., Costa, M., de Sauvage, F.J., and 
Klein, O.D. (2015). Opposing activities of notch and wnt signaling regulate intestinal 
stem cells and gut homeostasis. Cell Rep 11, 33-42. 
 
Tian, H., Biehs, B., Warming, S., Leong, K.G., Rangell, L., Klein, O.D., and de 
Sauvage, F.J. (2011). A reserve stem cell population in small intestine renders Lgr5-
positive cells dispensable. Nature 478, 255-259. 
 
 References 
111 
 
Tomasetti, C., and Vogelstein, B. (2015). Cancer etiology. Variation in cancer risk 
among tissues can be explained by the number of stem cell divisions. Science 347, 
78-81. 
 
Ungerback, J., Elander, N., Grunberg, J., Sigvardsson, M., and Soderkvist, P. (2011). 
The Notch-2 gene is regulated by Wnt signaling in cultured colorectal cancer cells. 
PLoS One 6, e17957. 
 
Van der Flier, L.G., Sabates-Bellver, J., Oving, I., Haegebarth, A., De Palo, M., Anti, 
M., Van Gijn, M.E., Suijkerbuijk, S., Van de Wetering, M., Marra, G., et al. (2007). 
The Intestinal Wnt/TCF Signature. Gastroenterology 132, 628-632. 
 
van der Flier, L.G., van Gijn, M.E., Hatzis, P., Kujala, P., Haegebarth, A., Stange, 
D.E., Begthel, H., van den Born, M., Guryev, V., Oving, I., et al. (2009). Transcription 
factor achaete scute-like 2 controls intestinal stem cell fate. Cell 136, 903-912. 
 
van Es, J.H., de Geest, N., van de Born, M., Clevers, H., and Hassan, B.A. (2010). 
Intestinal stem cells lacking the Math1 tumour suppressor are refractory to Notch 
inhibitors. Nat Commun 1, 18. 
 
van Es, J.H., Haegebarth, A., Kujala, P., Itzkovitz, S., Koo, B.K., Boj, S.F., Korving, 
J., van den Born, M., van Oudenaarden, A., Robine, S., et al. (2012). A critical role 
for the Wnt effector Tcf4 in adult intestinal homeostatic self-renewal. Mol Cell Biol 32, 
1918-1927. 
 
van Es, J.H., Jay, P., Gregorieff, A., van Gijn, M.E., Jonkheer, S., Hatzis, P., Thiele, 
A., van den Born, M., Begthel, H., Brabletz, T., et al. (2005a). Wnt signalling induces 
maturation of Paneth cells in intestinal crypts. Nat Cell Biol 7, 381-386. 
 
van Es, J.H., van Gijn, M.E., Riccio, O., van den Born, M., Vooijs, M., Begthel, H., 
Cozijnsen, M., Robine, S., Winton, D.J., Radtke, F., et al. (2005b). Notch/gamma-
secretase inhibition turns proliferative cells in intestinal crypts and adenomas into 
goblet cells. Nature 435, 959-963. 
 
VanDussen, K.L., Carulli, A.J., Keeley, T.M., Patel, S.R., Puthoff, B.J., Magness, 
S.T., Tran, I.T., Maillard, I., Siebel, C., Kolterud, A., et al. (2012). Notch signaling 
modulates proliferation and differentiation of intestinal crypt base columnar stem 
cells. Development 139, 488-497. 
 
Wang, J., Shelly, L., Miele, L., Boykins, R., Norcross, M.A., and Guan, E. (2001). 
Human Notch-1 inhibits NF-kappa B activity in the nucleus through a direct 
interaction involving a novel domain. J Immunol 167, 289-295. 
 
Wang, Z., Banerjee, S., Li, Y., Rahman, K.M., Zhang, Y., and Sarkar, F.H. (2006). 
Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, 
vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic 
cancer cells. Cancer Res 66, 2778-2784. 
 
 
 References 
112 
 
Weng, A.P., Millholland, J.M., Yashiro-Ohtani, Y., Arcangeli, M.L., Lau, A., Wai, C., 
Del Bianco, C., Rodriguez, C.G., Sai, H., Tobias, J., et al. (2006). c-Myc is an 
important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. 
Genes Dev 20, 2096-2109. 
 
Wolfe, A.R., Ernlund, A., McGuinness, W., Lehmann, C., Carl, K., Balmaceda, N., 
and Neufeld, K.L. (2017). Suppression of intestinal tumorigenesis in Apc mutant mice 
by Musashi-1 deletion. J Cell Sci. 
 
Wu, W.K., Wang, X.J., Cheng, A.S., Luo, M.X., Ng, S.S., To, K.F., Chan, F.K., Cho, 
C.H., Sung, J.J., and Yu, J. (2013). Dysregulation and crosstalk of cellular signaling 
pathways in colon carcinogenesis. Crit Rev Oncol Hematol 86, 251-277. 
 
Xinghua, L., Bo, Z., Yan, G., Lei, W., Changyao, W., Qi, L., Lin, Y., Kaixiong, T., 
Guobin, W., and Jianying, C. (2012). The overexpression of AP-4 as a prognostic 
indicator for gastric carcinoma. Med Oncol 29, 871-877. 
 
Zhang, Y., Li, B., Ji, Z.Z., and Zheng, P.S. (2010). Notch1 regulates the growth of 
human colon cancers. Cancer 116, 5207-5218. 
 
Zhang, Z., Bu, X., Yang, J., Zhu, S., He, S., Zheng, J., Wang, W., and Chu, D. 
(2018). NOTCH4 regulates colorectal cancer proliferation, invasiveness, and 
determines clinical outcome of patients. J Cell Physiol 233, 6975-6985. 
 
Zhu, L., Gibson, P., Currle, D.S., Tong, Y., Richardson, R.J., Bayazitov, I.T., 
Poppleton, H., Zakharenko, S., Ellison, D.W., and Gilbertson, R.J. (2009). Prominin 1 
marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 
457, 603-607. 
 
 113 
 
11. Supplements  
 
11.1 Supplemental Data 1  
Related to Figure 14d and 24d.  
Differential gene expression resulting from AP4 deletion was subjected to comparative 
analysis with mSigDB Hallmark gene sets and KEGG pathways. 
 
Related to Figure 14d:  
Functional categories (mSigDB Hallmark gene sets) overrepresented among mRNAs 
down-regulated in adenomas of ApcMin/Ap4∆IEC vs ApcMin/Ap4fl/fl mice 
 
EMT  
Igfbp3, Col3a1, Col1a1, Col4a2, Tgfb1, Sparc, Col6a2, Col6a3, Adam12, Spp1, Igfbp4, Itgb3, 
Col5a2, Col1a2, Lamc1, Itga5, Flna, Mmp2, Myl9, Slit2, Fn1, Cd59, Igfbp2, Gas1, Postn, Fstl1, 
Col4a1, Dcn, Col5a1, Lox, Tnc, Lgals1, Cadm1, Serpinh1, Basp1, Fermt2, Glipr1, Col12a1, 
Eln, Pcolce2, Loxl2, Mgp, Col5a3, Serpine2, Pthlh, Sntb1, Thbs2, Vim 
 
Myogenesis  
Igfbp3, Col3a1, Col1a1, Col4a2, Tgfb1, Sparc, Col6a2, Col6a3, Adam12, Tnnt2, Sphk1, Aplnr, 
Kcnh2, Speg, Cd36, Nos1, Ckm, Stc2, Nav2, Prnp, Notch1, Tnni1, Col15a1, Itga7, Dtna, 
Cacna1h, Wwtr1, Cnn3, Cryab, Aebp1, Dmpk, Ephb3, Igfbp7, Fxyd1, Smtn, Casq2 
 
KRAS signaling 
Igfbp3, Col3a1, Spp1, Tnnt2, Cpe, Pcp4, Tfpi, Dcbld2, Il1b, Mmp9, Pecam1, Plat, Fcer1g, 
Etv4, Mmp10, Sparcl1, Ptgs2, Arg1, Eng, Etv5, F13a1, Flt4, Tmem158, Gng11, Trib2, 
Tmem176a, Tph1, Laptm5 
 
E2F targets 
Top2a, Cenpe, Brca2, Cdkn2c, Mcm2, Pds5b, Mybl2, Pole, Ccp110, Hmgb2, Msh2, Ung, 
Nap1l1, Cit, Psip1, Kif18b, Dnmt1, Atad2, Hells, Bub1b, Ncapd2  
 
Estrogen response late 
Igfbp4, Cpe, Pcp4, Top2a, Atp2b4, Prkar2b, Slc7a5, Celsr2, Krt13, Scarb1, Slc27a2, Slc1a4, 
Foxc1, Slc24a3, Kif20a, Homer2, Slc29a1, Fabp5, Plxnb1, Tpsab1, Cxcl14 
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UV response 
Col3a1, Col1a1, Itgb3, Col5a2, Col1a2, Lamc1, Tfpi, Atp2b4, Prkar2b, Nek7, Celf2, Rbpms, 
Fzd2, Kit, Ltbp1, Plcb4, Ptprm, Mta1 
  
Inflammatory response 
Itgb3, Itga5, Sphk1, Aplnr, Dcbld2, Il1b, Olr1, Pik3r5, Edn1, Slc7a2, Abca1, Gpc3, Ifitm1, 
Calcrl, Sema4d, Ffar2, Itgb8, P2rx7, Ccl24, C5ar1  
 
Mitotic spindle 
Flna, Top2a, Cenpe, Brca2, Fscn1, Dock4, Bub1, Kif11, Kif20b, Bcl2l11, Cep250, Kif3c, Pkd2, 
Anln, Cep192, Arap3, Alms1, Sorbs2, Wasf1, Kntc1  
 
Apical junction 
Mmp2, Myl9, Slit2, Kcnh2, Speg, Mmp9, Pecam1, Fscn1, Gnai1, Sdc3, Dsc3, Itga9, Msn, Nrtn, 
Evl, Amigo1, Rac2, Actg2, Cd34  
 
Complement 
Col4a2, Fn1, Cd59, Cd36, Plat, Fcer1g, Olr1, Pik3r5, Dock4, Plek, Serping1, Csrp1, Timp2, 
Ctsl1, Hspa1a, Mmp12, Mmp13, Pik3cg, Zeb1 
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Related to Figure 14d:  
Functional categories (KEGG pathways) overrepresented among mRNAs down-
regulated in adenomas of ApcMin/Ap4∆IEC vs ApcMin/Ap4fl/fl mice 
 
ECM receptor interaction 
Itga2b, Fn1, Lamc1, Col4a1, Col4a2, Lama4, Lama5, Lamb1, Lamb2, Itga1, Itga5, Itgb3, Itga9, 
Itgb8, Itga8, Itga7, Thbs2, Spp1, Col1a1, Col1a2, Col3a1, Col5a1, Col5a2, Col6a1, Col6a2, 
Col6a3, Tnc, Col5a3, Tnxb, Cd36, Sdc3, Sv2c, Hspg2 
 
Focal adhesion 
Itga2b, Fn1, Lamc1, Col4a1, Col4a2, Lama4, Lama5, Lamb1, Lamb2, Itga1, Itga5, Itgb3, Itga9, 
Itgb8, Itga8, Itga7, Thbs2, Spp1, Col1a1, Col1a2, Col3a1, Col5a1, Col5a2, Col6a1, Col6a2, 
Col6a3, Tnc, Col5a3, Tnxb, Rac2, Pik3cg, Pik3r5, Pdgfra, Prkcb, Pak3, Pak6, Myl9, Vav1, 
Pip5k1c, Flt1, Flt4, Flna, Parvb, Cav2  
 
Pathways in Cancer  
Itga2b, Fn1, Lamc1, Col4a1, Col4a2, Lama4, Lama5, Lamb1, Lamb2, Rac2, Pik3cg, Pik3r5, 
Pdgfra, Prkcb, Tgfb1, Fgfr2, Ptgs2, Ccne2, Skp2, Rarb, Kit, Kitlg, Tcf7, Fzd10, Fzd2, Fzd4, 
Mmp2, Mmp9, Ptch1, Smo, Msh2, Brca2 
 
Axon guidance 
Rac2, Pak3, Pak6, Gnai1, Sema4f, Sema4d, Epha7, Ephb3, Ephb4, Srgap2, Plxnb1, Sema4c, 
Sema3g, Ntn4, Robo1, Sema3f, Sema5a, Slit2, Ntn1, Srgap3  
 
Dilated cardiomyopathy  
Itga2b, Itga1, Itga5, Itgb3, Itga9, Itgb8, Itga8, Itga7, Tgfb1, Prkacb, Adcy8, Adcy1, Adcy3, 
Adcy5, Cacna1c, Slc8a1, Tnnt2  
 
Regulation of actin cytoskeleton 
Itga2b, Fn1, Itga1, Itga5, Itgb3, Itga9, Itgb8, Itga8, Itga7, Rac2, Pik3cg, Pik3r5, Pdgfra, Pak3, 
Pak6, Myl9, Vav1, Pip5k1c, Fgfr2, F2r, Msn, Wasf1, Rdx  
 
Small cell lung cancer 
Itga2b, Fn1, Lamc1, Col4a1, Col4a2, Lama4, Lama5, Lamb1, Lamb2, Pik3cg, Pik3r5, Ptgs2, 
Ccne2, Skp2, Rarb 
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Melanogenesis 
Prkcb, Kit, Kitlg, Tcf7, Fzd10, Fzd2, Fzd4, Gnai1, Prkacb, Adcy8, Adcy1, Adcy3, Adcy5, Plcb4, 
Edn1 
 
Calcium signaling pathway 
Pdgfra, Prkcb, Prkacb, Adcy8, Adcy1, Adcy3, Cacna1c, Slc8a1, F2r, Plcb4, Itpr1, Itpkb, Sphk1, 
Nos3, Cacna1h, Nos1, P2rx7, Slc25a4, Atp2b4 
 
Vascular smooth muscle contraction 
Prkcb, Myl9, Prkacb, Adcy8, Adcy1, Adcy3, Adcy5, Cacna1c, Plcb4, Itpr1, Npr1, Calcrl, Mrvi1, 
Actg2, Ppp1r14a  
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Related to 14d:  
Functional categories (mSigDB Hallmark gene sets) overrepresented among mRNAs 
up-regulated in adenomas of ApcMin/Ap4∆IEC vs ApcMin/Ap4fl/fl mice 
 
Interferon gamma response 
Irf7, Tap1, B2m, Rtp4, Bst2, Nmi, Casp1, Casp8, Ube2l6, Ifih1, Stat2, Psmb9, Psmb8, Rsad2, 
Ifi44, Usp18, Batf2, Tdrd7, Ifi27, Ifi35, Sp110, Parp14, Herc6, Ddx60, Psme2, Parp12, Dhx58, 
Oasl, Epsti1, Isg15, Stat1, Hla-Dqa1, Cdkn1a, Upp1, Cd38, Casp7, Casp4, Ddx58, Cd274, 
Ifit1, Il18bp, Gbp6, Ido1, Mx2, Oas2, Oas3, Xaf1, Rnf213, Zbp1, Nlrc5 
 
Interferon alpha response 
Irf7, Tap1, B2m, Rtp4, Bst2, Nmi, Casp1, Casp8, Ube2l6, Ifih1, Stat2, Psmb9, Psmb8, Rsad2, 
Ifi44, Usp18, Batf2, Tdrd7, Ifi27, Ifi35, Sp110, Parp14, Herc6, Ddx60, Psme2, Parp12, Dhx58, 
Oasl, Epsti1, Isg15, Mov10, Oas1, Tmem140, Uba7, Parp9, Trim5  
 
Cholesterol homeostasis 
Ldlr, Idi1, Hmgcs1, Hmgcr, Sqle, Cyp51a1, Hsd17b7, Mvd, Fdft1, Pmvk, Antxr2, Anxa13, Lss  
 
Allograft rejection 
Irf7, Tap1, B2m, Stat1, Hla-Dqa1, Il18, Tlr1, Ccnd2, Cdkn2a, C2, Gcnt1, Hla-Dmb, Hla-E, 
Nos2, Tap2, Cd3g, Cd8a 
 
Inflammatory response 
Irf7, Rtp4, Bst2, Nmi, Cdkn1a, Ldlr, Il18, Tlr1, Cd82, Mep1a, Hrh1, Slc4a4 
 
Xenobiotic metabolism 
Upp1, Slc35d1, Tnfrsf1a, Acox2, Enpep, Slc46a3, Gsta3, Abhd6, Ccl25, Xdh, Abcc3, Entpd5 
 
MTORC1 signaling 
Cdkn1a, Ldlr, Idi1, Hmgcs1, Hmgcr, Sqle, Cyp51a1, Dhcr24, Insig1, Elovl6, Ifrd1  
 
p53 pathway 
Tap1, Casp1, Cdkn1a, Upp1, Ccnd2, Cdkn2a, Cd82, Slc35d1, S100a10, Stom, Eps8l2  
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Apoptosis 
Tap1, Casp1, Casp8, Cdkn1a, Cd38, Casp7, Casp4, Il18, Ccnd2 
  
Fatty acid metabolism 
Ube2l6, Idi1, Hmgcs1, Hsd17b7, Dhcr24, S100a10, Aldh1a1, Acsl5 
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Related to Figure 14d:  
Functional categories (KEGG pathways) overrepresented among mRNAs up-regulated 
in adenomas of ApcMin/Ap4∆IEC vs ApcMin/Ap4fl/fl mice 
 
Steroid biosynthesis  
Hsd17b7, Cyp51a1, Dhcr24, Fdft1, Lss, Sqle, Soat2  
 
Antigen processing and presentation 
Hla-Dmb, Hla-Dqa1, Hla-Dqb1, Hla-E, Tap1, Tap2, Cd8a, Psme2, B2m 
  
Terpenoid backbone biosynthesis 
Pmvk, Hmgcs1, Hmgcr, Idi1, Mvd  
 
Rig I like receptor signaling pathway 
Casp8, Irf7, Ddx58, Ifih1, Dhx58, Isg15  
 
Viral myocarditis 
Hla-Dmb, Hla-Dqa1, Hla-Dqb1, Hla-E, Casp8, Actb  
 
ABC transporters 
Tap1, Tap2, Abcb11, Abcc3, Abcg2 
 
Glycerophospholipid metabolism 
Dgkq, Mboat1, Agpat4, Agpat9, Cds1, Pla2g2e  
 
Glutathione metabolism 
Anpep, Gsta3, Mgst1, Mgst2, Ggt1  
 
Cytosolic DNA sensing pathway 
Irf7, Ddx58, Casp1, Il18, Zbp1  
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Systemic lupus erythematosus 
Hla-Dmb, Hla-Dqa1, Hla-Dqb1, C2, Hist1h2ae, Hist1h2ai, Hist1h2al 
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Related to Figure 24d: 
Functional categories (mSigDB Hallmark gene sets) overrepresented among mRNAs 
down-regulated in organoids derived from Villin-Cre-ERT2/Ap4fl/fl vs Villin-Cre-ERT2 
mice.  
 
UV response 
Cap2, Tfpi, Mgll, Fzd2, Amph, Kit, Plcb4 
 
KRAS signaling 
Igfbp2, Myh7, Fam46c, Adck3, Atp6v1b1, Capn9, Clps, Tff2 
 
Pancreas beta cells 
Chga, Insm1, Nkx2-2, Syt13  
 
Wnt/β-catenin signaling 
Notch1, Dll1, Axin2, Nkd1 
 
EMT 
Cap2, Igfbp2, Eno2, Jun, Timp3, Gas1, Pthlh 
 
Estrogen response early 
Tiam1, Tpbg, Tff3, Celsr1, Tubb2b, Mreg, Tgif2 
 
IL2/STAT5 signaling 
Tiam1, Ifitm3, Tnfsf10, Cd83, Itih5, Plagl1, Slc39a8 
 
Glycolysis 
Eno2, Tpbg, Tff3, Cacna1h, Efna3, Nanp 
 
Myogenesis 
Myh7, Notch1, Cacna1h, Spdef, Dmpk, Myl7 
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Apoptosis 
Eno2, Jun, Timp3, Ifitm3, Tnfsf10 
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Related to Figure 24d:  
Functional categories (KEGG pathways) overrepresented among mRNAs down-
regulated in organoids derived from Villin-Cre-ERT2/Ap4fl/fl vs Villin-Cre-ERT2 mice.  
 
Axon guidance 
Efna3, Efna4, Sema4c, Dpysl5, Ntn4, Sema5a, Srgap3  
 
Wnt signaling pathway 
Wnt3, Fzd2, Axin2, Jun, Plcb4, Sfrp5, Nkd1 
  
Leukocyte transendothelial migration 
Rassf5, Myl7, Ncf2, Rapgef3, Esam, Nox1 
 
Pathways in cancer 
Wnt3, Fzd2, Axin2, Jun, Rassf5, Kit, Nos2, Pdgfa, Fgfr2 
 
Melanogenesis 
Wnt3, Fzd2, Plcb4, Kit, Creb3l4 
 
Arachidonic acid metabolism 
Pla2g10, Ggt7, Ptgds, Cyp4f2 
  
Calcium signaling pathway 
Plcb4, Nos2, Mylk3, Chrm1, Cacna1h, Itpkb 
 
Regulation of actin cytoskeleton 
Myl7, Pdgfa, Fgfr2, Mylk3, Chrm1, Tiam1 
  
Notch signaling pathway 
Notch1, Dll3, Dll1  
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Related to Figure 24d: 
Functional categories (mSigDB Hallmark gene sets) overrepresented among mRNAs 
up-regulated in organoids derived from Villin-Cre-ERT2/Ap4fl/fl vs Villin-Cre-ERT2 mice.  
 
Xenobiotic metabolism 
Ca2, Cd36, Acox1, Adh1c, Fabp1, Fas, Gcnt2, Papss2, Leap2, Abcc2, Cyp2j2, Enpep, G6pc, 
Slc46a3, Arg2, Xdh  
 
KRAS signaling  
Ca2, Ptgs2, Ereg, Angptl4, Prrx1, Aldh1a3, Mafb, Ace, Spon1, Anxa10, Ptprr, Mall, Hkdc1, Il33   
 
Fatty acid metabolism 
Ca2, Cd36, Acox1, Adh1c, Fabp1, Me1, Aldh1a1, Fabp2, Aqp7, Tp53inp2  
 
Coagulation 
Gp1ba, Mmp15, Apoa1, Ctse, Gsn, Crip2, Apoc3, Proz, Gda  
 
Complement 
Ca2, Cd36, Me1, Gp1ba, Mmp15, Irf7, Lgals3, F5, Apoa4, Lipa   
 
Interferon gamma response  
Fas, Ptgs2, Irf7, Hif1a, Mx1, Oasl, Isg15, Ifit1, Oas3  
 
Bile acid metabolism 
Aldh1a1, Apoa1, Ephx2, Gstk1, Abca8, Sult1b1, Bbox1  
 
Inflamatory response 
Ereg, Gp1ba, Irf7, Hif1a, Il18, Mxd1, Rnf144b, Ptafr  
 
Allograft rejection 
Fas, Ereg, Irf7, Hif1a, Il18, Capg, Gcnt1  
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Heme metabolism 
Ca2, Ctse, Slc7a11, Aqp3, Cdr2, Mpp1, Nfe2  
  
 126 
 
Related to Figure 24d: 
Functional categories (KEGG pathways) overrepresented among mRNAs up-regulated 
in organoids derived from Villin-Cre-ERT2/Ap4fl/fl vs Villin-Cre-ERT2 mice.  
 
PPAR signaling pathway 
Pck1, Acox1, Me1, Cd36, Gk, Fabp1, Fabp2, Slc27a6, Apoa1, Apoc3, Aqp7, Angptl4, Pltp  
 
Drug metabolism cytochrome P450 
Cyp2c8, Adh1c, Ugt2b10, Cyp3a4, Aldh1a3, Gstk1, Gsta1, Gsta2, Maob, Cyp2d6, Fmo5  
  
Metabolism of xenobiotics by cytochrome P450 
Cyp2c8, Adh1c, Ugt2b10, Cyp3a4, Aldh1a3, Gstk1, Gsta1, Gsta2, Cyp1b1 
  
Arachidonic acid metabolism 
Cyp2c8, Ggt1, Cyp2j2, Ephx2, Ptgs2, Alox5  
 
Retinol metabolism 
Cyp2c8, Adh1c, Ugt2b10, Cyp3a4, Dhrs9, Aldh1a1 
 
Renin angiotensin system  
Mme, Ace, Enpep, Ace2 
 
Glycolysis gluconeogenesis 
Pck1, Adh1c, Aldh1a3, G6pc, Aldob 
 
Glutathione metabolism 
Gstk1, Gsta1, Gsta2, Ggt1 
 
Starch and sucrose metabolism 
Ugt2b10, G6pc, Enpp3, Treh 
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Glycosphingolipid biosynthesis 
Gcnt2, St3gal4, B3gnt5  
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11.2 Supplemental Data 2  
Related to Figure 15a,b and 25a,b 
Significantly regulated mRNAs associated with distinct signatures as identified by GSEA.      
Related to Figure 15a,b: 
Combined stem cell signature, ApcMin adenoma 
 Gene ID Mean AP4Wt 
Mean 
AP4∆IEC 
fc - AP4∆IEC 
vs AP4Wt P-value 
Cbx6 2.833 0.280 0.099 0.005 
Cyp11a1 0.789 0.082 0.104 < 0.001 
Tfpi 1.289 0.215 0.167 0.008 
Rdh1 0.204 0.035 0.170 0.001 
Tgif2 2.079 0.390 0.188 0.001 
Nrn1 1.677 0.334 0.199 0.013 
Slc14a1 2.216 0.457 0.206 0.007 
Tmem182 0.182 0.040 0.221 0.040 
Clic6 6.413 1.509 0.235 < 0.001 
Ifitm1 107.524 26.247 0.244 < 0.001 
Adra2a 2.151 0.538 0.250 0.002 
Zbtb16 0.183 0.050 0.272 0.034 
Cgnl1 4.831 1.333 0.276 0.002 
Prelp 4.220 1.167 0.277 0.011 
Slc27a2 1.600 0.453 0.283 0.023 
Limch1 2.531 0.724 0.286 0.004 
Olfm4 48.682 14.460 0.297 0.001 
Fstl1 5.094 1.519 0.298 0.026 
Lgr5 2.396 0.736 0.307 0.002 
Rassf5 0.180 0.056 0.312 0.027 
Fscn1 4.205 1.332 0.317 0.007 
Rasl11b 2.011 0.658 0.327 0.027 
Ptprm 0.561 0.186 0.331 0.046 
Vwa2 0.396 0.133 0.337 0.020 
Fzd2 2.494 0.872 0.350 0.021 
Agr3 1.173 0.417 0.355 0.021 
Wwtr1 2.996 1.071 0.358 0.038 
Kif26b 0.985 0.353 0.358 0.005 
Fam188b 0.369 0.137 0.371 0.012 
Zfp618 1.158 0.436 0.376 0.007 
Smoc2 25.019 9.607 0.384 0.002 
Slc1a2 0.038 0.015 0.384 0.006 
Lfng 12.067 4.709 0.390 0.001 
Mex3a 4.685 1.850 0.395 0.001 
Notch1 1.845 0.731 0.396 0.001 
Cited4 12.147 4.836 0.398 0.017 
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Sorbs2 0.750 0.299 0.399 0.013 
Arid5b 3.783 1.529 0.404 0.007 
St3gal3 4.975 2.011 0.404 0.001 
Mnx1 0.875 0.357 0.408 0.026 
Fam64a 3.867 1.594 0.412 0.005 
Pthlh 4.590 1.907 0.415 0.002 
Dct 0.184 0.077 0.416 0.001 
Dmpk 33.174 14.091 0.425 0.004 
Sorcs2 3.870 1.672 0.432 0.005 
Prkd3 1.615 0.700 0.433 0.005 
Chst11 3.187 1.383 0.434 0.010 
Smo 7.955 3.497 0.440 0.004 
Soat1 6.933 3.051 0.440 0.002 
Esam 3.357 1.485 0.442 0.035 
Klhl8 2.576 1.144 0.444 0.002 
Tcf7 9.897 4.419 0.446 0.009 
Igfbp4 120.004 54.950 0.458 0.002 
Pde3b 3.346 1.548 0.463 0.021 
Pxdn 5.727 2.650 0.463 0.007 
Pls3 20.028 9.301 0.464 0.002 
Nrtn 9.054 4.211 0.465 0.044 
Slco3a1 1.639 0.763 0.465 0.006 
Maged1 21.926 10.215 0.466 0.007 
Cachd1 2.783 1.298 0.467 0.001 
Ppm1f 2.196 1.029 0.469 0.004 
Atp11a 2.796 1.322 0.473 0.004 
Cnn3 41.713 19.768 0.474 0.001 
Ascl2 15.204 7.233 0.476 0.023 
Fads1 17.967 8.565 0.477 0.003 
Arl4c 11.483 5.497 0.479 0.002 
Man2a2 1.211 0.581 0.480 0.011 
Ccdc3 18.479 8.920 0.483 0.018 
Ifitm3 443.447 215.744 0.487 0.001 
Znrf3 4.953 2.414 0.487 0.002 
Ifitm2 349.080 170.144 0.487 0.006 
Fmnl2 3.450 1.687 0.489 0.015 
Gkap1 3.804 1.863 0.490 0.015 
Bcl7a 2.193 1.080 0.492 0.004 
Rhobtb3 1.054 0.519 0.493 0.008 
Kank1 3.380 1.668 0.494 0.013 
Alms1 0.581 0.288 0.497 0.014 
Ttc21b 1.157 0.578 0.500 0.008 
Pole 2.080 1.046 0.503 0.012 
Brca2 0.554 0.279 0.504 0.008 
Zfp12 1.519 0.766 0.504 0.012 
Evl 8.612 4.362 0.506 0.004 
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Sertad4 0.360 0.183 0.509 0.044 
Iffo2 7.661 3.910 0.510 0.034 
Rgs19 2.891 1.479 0.512 0.004 
Kif20a 10.188 5.252 0.516 0.014 
Ung 4.738 2.448 0.517 0.001 
Fam65b 0.417 0.216 0.517 0.031 
Ptprs 7.694 3.979 0.517 0.016 
Tead2 6.553 3.392 0.518 0.006 
Prkacb 5.437 2.822 0.519 0.036 
Aspm 1.700 0.885 0.521 0.006 
Cit 1.095 0.571 0.522 0.011 
Prrc2b 11.454 6.021 0.526 0.007 
Kcnq1 24.450 12.972 0.531 0.004 
Plxnb1 7.280 3.872 0.532 0.009 
Lcp1 3.143 1.678 0.534 0.023 
Ppat 7.629 4.074 0.534 0.018 
Ephb3 13.909 7.498 0.539 0.017 
Nap1l1 42.931 23.236 0.541 0.006 
Slit2 0.541 0.294 0.543 0.010 
Myo1b 5.102 2.786 0.546 0.014 
Trim44 5.776 3.154 0.546 0.008 
Zc3hav1l 0.766 0.419 0.547 0.002 
Rccd1 1.232 0.674 0.548 0.014 
Rassf4 1.268 0.695 0.548 0.027 
Cep192 2.670 1.465 0.549 0.014 
Rprd1a 4.917 2.702 0.550 0.002 
Cd320 5.476 3.013 0.550 0.015 
Il17rd 1.256 0.692 0.551 0.003 
Phlpp1 2.010 1.117 0.556 0.013 
Pds5b 2.190 1.219 0.556 0.010 
Clu 376.724 210.033 0.558 0.042 
Zmym1 1.623 0.909 0.560 0.026 
Gemin8 1.104 0.620 0.562 0.005 
Dtl 1.788 1.006 0.563 0.006 
Clca1 234.069 131.917 0.564 0.033 
Sox4 58.085 32.781 0.564 0.009 
Arhgap39 1.884 1.064 0.564 0.018 
Hirip3 6.611 3.734 0.565 0.017 
Hmga2 1.437 0.812 0.565 0.044 
Nfic 5.047 2.853 0.565 0.010 
Cc2d2a 0.820 0.464 0.565 0.037 
Mpzl1 23.847 13.512 0.567 0.010 
Ilf3 9.584 5.454 0.569 0.016 
Nav1 2.194 1.251 0.570 0.019 
Espl1 3.029 1.727 0.570 0.018 
Cfi 92.039 52.544 0.571 0.050 
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Palb2 0.985 0.564 0.573 0.029 
Spag5 4.246 2.436 0.574 0.024 
Irs1 0.672 0.387 0.576 0.003 
Fbxo21 4.251 2.452 0.577 0.022 
Tnfrsf19 14.029 8.106 0.578 0.008 
Shisa2 9.889 5.719 0.578 0.011 
Cenpf 3.330 1.929 0.579 0.021 
Msi1 2.891 1.675 0.579 0.027 
Zfp503 8.260 4.807 0.582 0.006 
Klhl24 4.655 2.717 0.584 0.029 
Zbtb25 0.939 0.550 0.586 0.034 
Mcm8 1.961 1.150 0.586 0.044 
Ckap2 4.818 2.827 0.587 0.003 
Hebp2 10.149 5.958 0.587 0.009 
Mfge8 18.538 10.944 0.590 0.022 
Myc 25.849 15.303 0.592 0.034 
Apcdd1 3.711 2.198 0.592 0.030 
Dach1 1.242 0.736 0.593 0.018 
Srpk2 1.531 0.909 0.594 0.043 
Nedd4 31.340 18.632 0.595 0.014 
Rnf43 18.439 10.970 0.595 0.023 
Psrc1 1.483 0.882 0.595 0.035 
Slc12a2 41.119 24.558 0.597 0.016 
Phc1 2.284 1.368 0.599 0.002 
Efna4 10.567 6.330 0.599 0.047 
Isyna1 27.972 16.829 0.602 0.049 
Wipi1 3.979 2.411 0.606 0.002 
Cdc42ep1 13.457 8.192 0.609 0.026 
Mdn1 1.188 0.727 0.612 0.032 
Ppp1r9a 1.243 0.763 0.614 0.025 
Tiam1 3.317 2.052 0.619 0.042 
Ccdc18 0.569 0.353 0.619 0.048 
Rnf219 3.001 1.860 0.620 0.038 
Timeless 2.721 1.691 0.621 0.006 
Lrig1 15.265 9.521 0.624 0.025 
Tns3 15.998 9.987 0.624 0.003 
Pogk 2.099 1.316 0.627 0.041 
Cdca7 27.066 17.010 0.628 0.004 
Tbc1d9 1.949 1.231 0.632 0.028 
Notch4 1.812 1.145 0.632 0.034 
Paics 29.262 18.521 0.633 0.023 
Sox9 29.670 18.781 0.633 0.014 
Ttc23 1.019 0.646 0.634 0.001 
Cdca7l 6.817 4.320 0.634 0.046 
Mpp3 0.521 0.331 0.635 0.037 
Slc39a10 4.222 2.689 0.637 0.032 
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Id2 49.195 31.379 0.638 0.008 
Mif 256.148 163.402 0.638 0.047 
Tbc1d4 0.799 0.510 0.638 0.049 
Sesn3 2.992 1.915 0.640 0.002 
Tgif1 15.646 10.084 0.645 0.022 
Napepld 4.053 2.616 0.645 0.025 
Lipt2 15.168 9.840 0.649 0.035 
Tubb2b 22.037 14.342 0.651 0.013 
Ddit4 73.921 48.138 0.651 0.017 
Rasa3 2.869 1.871 0.652 0.049 
Etv6 13.585 8.877 0.653 0.018 
Csnk1e 9.082 5.935 0.654 0.020 
Notch2 2.867 1.883 0.657 0.045 
Dctd 3.878 2.547 0.657 0.044 
Dlgap1 0.168 0.110 0.659 0.028 
Zfhx3 1.432 0.946 0.661 0.015 
Pabpc1 270.241 179.318 0.664 0.007 
Haus4 11.656 7.743 0.664 0.011 
Nfia 3.282 2.200 0.670 0.007 
Trim37 3.634 2.448 0.674 0.041 
Dtx4 3.103 2.095 0.675 0.044 
Cdk6 2.404 1.630 0.678 0.035 
Mcc 1.025 0.698 0.681 0.046 
Mecom 7.895 5.391 0.683 0.042 
Irf2bp2 26.034 17.879 0.687 0.033 
Farp1 6.628 4.585 0.692 0.018 
Lysmd2 11.387 7.897 0.694 0.003 
Zfp341 1.738 1.208 0.695 0.028 
Sfpq 54.134 37.686 0.696 0.015 
Slc30a2 18.234 12.746 0.699 0.037 
Pik3r1 10.178 7.156 0.703 0.010 
Psd3 1.207 0.849 0.703 0.042 
Tmem209 2.748 1.958 0.712 0.047 
Nin 1.616 1.152 0.713 0.017 
Pla2g5 2.213 1.596 0.721 0.012 
Socs2 4.172 3.010 0.721 0.021 
Sestd1 6.436 4.693 0.729 0.045 
Wwp1 2.883 2.107 0.731 0.038 
Sdc4 56.427 41.795 0.741 0.034 
Tspan5 9.061 6.753 0.745 0.001 
Hmbox1 2.401 1.836 0.765 0.011 
Pbx1 4.037 3.092 0.766 0.032 
Yap1 14.531 11.201 0.771 0.040 
Ccnd3 6.943 5.371 0.774 0.031 
Mlxip 6.624 5.238 0.791 0.034 
Utrn 6.492 5.292 0.815 0.044 
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Combined Wnt signature, ApcMin adenoma 
Gene ID Mean AP4Wt 
Mean 
AP4∆IEC 
fc - AP4∆IEC vs 
AP4Wt P-value 
Jag2 4.297 1.038 0.241 0.001 
Gnai1 1.972 0.726 0.368 0.016 
Notch1 1.845 0.731 0.396 0.001 
Hey1 2.135 0.858 0.402 0.006 
Tcf7 9.897 4.419 0.446 0.009 
Skp2 1.609 0.753 0.468 0.007 
Ascl2 15.204 7.233 0.476 0.023 
Ifitm2 349.080 170.144 0.487 0.006 
Fzd1 2.434 1.189 0.489 0.033 
Rhobtb3 1.054 0.519 0.493 0.008 
Ptch1 2.359 1.217 0.516 0.007 
Dvl2 2.119 1.176 0.555 0.015 
Sox4 58.085 32.781 0.564 0.009 
Trp53 20.202 11.806 0.584 0.019 
Ankrd10 5.648 3.306 0.585 0.003 
Myc 25.849 15.303 0.592 0.034 
Nkd1 55.307 33.244 0.601 0.032 
Ncor2 7.104 4.317 0.608 0.029 
Tiam1 3.317 2.052 0.619 0.042 
Jag1 3.298 2.046 0.620 0.005 
Hdac2 19.662 12.201 0.621 0.013 
Notch4 1.812 1.145 0.632 0.034 
Maml1 3.154 2.038 0.646 0.022 
Rasa3 2.869 1.871 0.652 0.049 
Csnk1e 9.082 5.935 0.654 0.020 
Smyd5 4.624 3.027 0.655 0.037 
Notch2 2.867 1.883 0.657 0.045 
Fzd8 1.349 0.892 0.661 0.022 
Rbpj 4.386 2.973 0.678 0.003 
Kat2a 11.300 7.682 0.680 0.031 
Lef1 1.495 1.027 0.687 0.019 
Msi2 3.897 2.699 0.693 0.023 
Smarca5 17.185 11.937 0.695 0.044 
Rnf138 7.062 5.032 0.713 0.027 
Smyd2 13.706 10.088 0.736 0.039 
Adam17 7.137 5.647 0.791 0.045 
Axin1 13.177 11.139 0.845 0.025 
Ccnd2 21.270 29.703 1.396 0.006 
  
 134 
 
Combined Notch signature, ApcMin adenoma 
Gene ID Mean AP4Wt 
Mean 
AP4∆IEC 
fc - AP4∆IEC 
vs AP4Wt P-value 
Jag2 4.297 1.038 0.241 0.001 
Lfng 12.067 4.709 0.390 0.001 
Notch1 1.845 0.731 0.396 0.001 
Fzd1 2.434 1.189 0.489 0.033 
St3gal6 5.465 2.977 0.545 0.003 
Dvl2 2.119 1.176 0.555 0.015 
Sap30 19.381 11.657 0.601 0.008 
Ncor2 7.104 4.317 0.608 0.029 
Jag1 3.298 2.046 0.620 0.005 
Hdac2 19.662 12.201 0.621 0.013 
Notch4 1.812 1.145 0.632 0.034 
Hes1 40.017 25.495 0.637 0.006 
Maml1 3.154 2.038 0.646 0.022 
Notch2 2.867 1.883 0.657 0.045 
Dtx4 3.103 2.095 0.675 0.044 
Rbpj 4.386 2.973 0.678 0.003 
Kat2a 11.300 7.682 0.680 0.031 
Dvl3 6.340 4.384 0.692 0.030 
Ep300 7.420 5.795 0.781 0.008 
Hdac1 36.556 28.566 0.781 0.008 
Rbx1 37.968 29.875 0.787 0.006 
Adam17 7.137 5.647 0.791 0.045 
Snw1 26.577 21.174 0.797 0.039 
Ctbp1 46.874 40.030 0.854 0.024 
Prkca 7.283 8.429 1.157 0.026 
Tcf7l2 6.023 8.102 1.345 0.002 
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c-Myc target genes, ApcMin adenoma 
Gene ID Mean AP4Wt 
Mean 
AP4∆IEC 
fc - AP4∆IEC 
vs AP4Wt P-value 
Ung 4.738 2.448 0.517 0.001 
Tcof1 11.749 6.444 0.548 0.009 
Pprc1 5.890 3.248 0.551 0.019 
Plk4 3.399 1.914 0.563 0.015 
Utp20 4.344 2.534 0.583 0.023 
Mcm5 21.579 12.621 0.585 0.023 
Rcl1 12.163 7.139 0.587 0.016 
Nolc1 20.655 12.198 0.591 0.028 
Myc 25.849 15.303 0.592 0.034 
Mcm4 19.945 11.909 0.597 0.010 
Mybbp1a 25.928 15.493 0.598 0.024 
Gnl3 22.669 13.750 0.607 0.018 
Plk1 29.279 17.793 0.608 0.016 
Slc19a1 4.350 2.671 0.614 0.017 
Cdk4 53.455 33.091 0.619 0.018 
Srm 25.398 16.212 0.638 0.047 
Cbx3 34.089 21.860 0.641 0.014 
Ddx18 22.394 14.787 0.660 0.037 
Ndufaf4 6.584 4.382 0.666 0.024 
Mphosph10 7.746 5.227 0.675 0.018 
Las1l 6.113 4.128 0.675 0.031 
Wdr43 18.349 12.592 0.686 0.042 
Tfb2m 8.685 5.974 0.688 0.025 
Slc29a2 0.843 0.581 0.689 0.019 
Prmt3 3.399 2.363 0.695 0.043 
Mrto4 14.026 9.804 0.699 0.018 
Nip7 10.704 7.597 0.710 0.015 
Hspe1 83.661 62.280 0.744 0.016 
Imp4 7.404 5.681 0.767 0.047 
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Related to Figure 25a,b:                              
Combined stem cell signature, organoids 
Gene ID Mean AP4Wt 
Mean 
AP4∆IEC 
fc - AP4∆IEC 
vs AP4Wt P-value 
Vwa2 0.702 0.142 0.202 0.001 
Slc14a1 0.067 0.015 0.226 0.006 
Ptgds 2.898 0.670 0.231 < 0.001 
Apcdd1 0.860 0.264 0.307 0.030 
Pcdh8 2.049 0.654 0.319 0.006 
Sfrp5 2.008 0.651 0.324 0.001 
Olfm4 401.814 133.163 0.331 < 0.001 
Rassf5 0.247 0.084 0.338 0.008 
Adra2a 6.777 2.294 0.338 < 0.001 
Cap2 0.617 0.214 0.347 0.002 
Dmpk 2.598 0.908 0.350 < 0.001 
St3gal3 5.681 1.997 0.351 < 0.001 
Limch1 0.139 0.051 0.365 0.003 
Ccdc3 2.314 0.850 0.367 0.024 
Tmem182 0.557 0.211 0.378 0.007 
Mylk3 0.614 0.236 0.384 0.002 
Angpt2 0.359 0.138 0.385 0.009 
Nr2e3 5.020 1.937 0.386 < 0.001 
Prelp 2.416 0.980 0.406 0.001 
Chst11 2.465 1.000 0.406 < 0.001 
Kif26b 0.250 0.102 0.407 0.036 
Cbs 5.791 2.382 0.411 0.001 
Slco3a1 0.332 0.146 0.439 0.003 
Cfi 8.813 3.970 0.450 0.002 
H2-Eb1 0.180 0.081 0.451 0.004 
Dct 0.243 0.111 0.455 0.005 
Hemgn 0.823 0.381 0.463 0.004 
Sdr16c5 0.612 0.294 0.481 0.015 
Fzd2 4.407 2.166 0.491 0.002 
Casp12 0.296 0.148 0.500 0.023 
Msi1 4.356 2.209 0.507 0.003 
Cttnbp2 1.387 0.704 0.507 < 0.001 
Tubb2b 28.482 14.493 0.509 < 0.001 
Ifitm3 83.380 42.483 0.510 0.001 
Tead2 2.694 1.388 0.515 0.003 
Kif12 8.281 4.467 0.539 0.001 
Wfdc15b 0.650 0.351 0.540 0.048 
Tgif2 5.037 2.721 0.540 0.004 
Hebp2 1.735 0.942 0.543 0.004 
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Rgmb 9.241 5.061 0.548 0.006 
Pgc 4.296 2.355 0.548 0.003 
Fam65b 0.567 0.316 0.558 0.001 
Nrtn 17.617 9.859 0.560 0.017 
Gkn3 9.091 5.145 0.566 < 0.001 
Klhl23 2.133 1.209 0.567 0.002 
Cyp11a1 0.115 0.066 0.570 0.010 
Smoc2 97.596 55.792 0.572 0.001 
Jun 52.195 29.922 0.573 0.003 
Esam 2.464 1.445 0.586 0.010 
Efna4 19.125 11.221 0.587 0.001 
Cited4 10.291 6.075 0.590 0.005 
Fam20c 4.595 2.714 0.591 0.006 
Tlr2 0.648 0.384 0.593 0.010 
Notch1 4.456 2.651 0.595 < 0.001 
Ptpro 1.473 0.877 0.595 0.015 
Tnfsf10 1.713 1.020 0.596 0.008 
Pthlh 3.205 1.919 0.599 0.001 
Axin2 41.383 24.969 0.603 0.005 
Lgr5 29.496 17.944 0.608 0.002 
Ldhb 0.933 0.571 0.613 0.004 
Pdgfa 49.397 30.625 0.620 0.002 
Tiam1 5.348 3.322 0.621 0.004 
Ascl2 20.796 13.143 0.632 0.002 
Dapk2 9.239 5.876 0.636 0.001 
Lfng 8.832 5.625 0.637 0.008 
Cdc42ep1 22.573 14.399 0.638 0.002 
Cnn3 48.763 31.157 0.639 < 0.001 
4933406C10Rik 1.371 0.876 0.639 0.006 
Tacc1 0.730 0.467 0.639 0.012 
Fgd1 1.382 0.887 0.642 0.016 
Zfp618 1.373 0.882 0.642 0.002 
Slc27a2 11.642 7.520 0.646 0.001 
Cachd1 7.104 4.614 0.649 0.005 
Cyp2e1 2.555 1.666 0.652 0.001 
Sorcs2 7.045 4.607 0.654 0.003 
Rgs12 2.243 1.471 0.656 0.008 
Il17rd 1.943 1.298 0.668 0.009 
Iffo2 9.664 6.463 0.669 0.001 
Mpp3 4.036 2.718 0.673 0.016 
Sox4 64.237 43.346 0.675 0.008 
Nod1 1.966 1.332 0.678 0.008 
1700040L02Rik 3.305 2.243 0.679 0.012 
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Atg16l2 1.296 0.880 0.679 0.011 
Ddit4 88.085 60.079 0.682 0.008 
Ptprm 0.916 0.627 0.684 0.016 
Notch4 0.869 0.594 0.684 0.008 
Cdca7 64.325 44.232 0.688 < 0.001 
Zfp341 2.612 1.799 0.689 < 0.001 
Sesn3 4.417 3.042 0.689 0.006 
Grb7 39.013 26.891 0.689 0.002 
Pold1 17.986 12.419 0.691 0.006 
Arl4c 1.787 1.235 0.691 0.004 
Sema7a 31.048 21.477 0.692 0.003 
Lysmd2 5.601 3.881 0.693 < 0.001 
Zfp503 17.115 11.867 0.693 0.013 
Fgfrl1 14.118 9.796 0.694 0.004 
Smarcd3 0.579 0.402 0.694 0.032 
Evl 4.520 3.144 0.695 0.024 
Cib2 4.401 3.064 0.696 0.008 
Vav3 1.391 0.973 0.699 0.042 
Zfp90 2.470 1.731 0.701 0.010 
Wipi1 7.058 4.959 0.703 0.001 
Aqp4 15.463 10.926 0.707 0.004 
Lrig1 54.543 38.541 0.707 0.001 
Ephb3 15.258 10.790 0.707 0.004 
Ung 12.647 8.946 0.707 0.010 
Sdc4 72.832 51.648 0.709 0.001 
Isyna1 55.774 39.925 0.716 0.006 
Pla2g4a 7.253 5.213 0.719 0.009 
Arhgap39 4.517 3.248 0.719 0.005 
D930015E06Rik 3.648 2.629 0.721 0.003 
Fbxo21 6.634 4.792 0.722 0.013 
Fhdc1 5.190 3.756 0.724 0.002 
Smo 14.499 10.544 0.727 0.003 
Igfbp4 58.600 42.725 0.729 0.007 
Spata24 9.425 6.877 0.730 0.012 
Fam64a 5.239 3.825 0.730 0.005 
Rnf43 34.601 25.325 0.732 0.002 
Irf2bp2 64.700 47.466 0.734 0.032 
Soat1 14.996 11.039 0.736 0.002 
Sertad4 2.360 1.738 0.736 0.002 
Phc1 2.300 1.696 0.737 0.005 
Wwtr1 2.595 1.915 0.738 0.006 
Aqp1 53.646 39.653 0.739 0.017 
Ttc21b 1.899 1.413 0.744 0.006 
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Zfp956 5.813 4.329 0.745 < 0.001 
Kcnq1 57.142 42.575 0.745 0.005 
Timeless 6.475 4.828 0.746 < 0.001 
Acvr2b 3.619 2.699 0.746 < 0.001 
Rassf10 1.270 0.947 0.746 0.004 
Hunk 19.820 14.793 0.746 0.001 
Sox9 44.149 33.015 0.748 0.002 
Arhgef4 0.385 0.288 0.749 0.024 
Mpzl1 20.591 15.463 0.751 < 0.001 
Qsox2 18.237 13.713 0.752 0.008 
Ifitm2 198.896 149.751 0.753 0.003 
Engase 26.287 19.868 0.756 0.006 
Greb1 6.113 4.621 0.756 0.002 
Clic6 35.039 26.492 0.756 < 0.001 
Gpld1 17.060 12.913 0.757 < 0.001 
Farp1 13.258 10.063 0.759 0.001 
Etv6 21.313 16.188 0.760 0.001 
Rccd1 3.521 2.675 0.760 0.011 
Sorbs2 3.397 2.584 0.761 0.006 
Ptprs 22.069 16.822 0.762 0.010 
Gas6 102.714 78.316 0.762 0.003 
Fam49a 1.817 1.387 0.764 0.025 
Pole 6.247 4.796 0.768 < 0.001 
Dtx4 13.068 10.032 0.768 0.003 
Dgkg 1.156 0.888 0.768 0.018 
Rhbdf1 12.681 9.742 0.768 0.008 
Plekhb1 1.451 1.118 0.771 0.022 
Mcc 2.286 1.764 0.771 0.004 
Zkscan17 12.633 9.754 0.772 0.005 
Pde3b 2.329 1.799 0.772 0.005 
Napepld 5.904 4.562 0.773 < 0.001 
Pacsin3 2.024 1.565 0.773 0.012 
Fam43a 0.613 0.474 0.773 0.033 
Gramd1a 1.322 1.024 0.774 0.025 
1110051M20Rik 4.432 3.432 0.774 0.009 
Gins1 6.734 5.225 0.776 0.034 
Zbtb38 5.514 4.279 0.776 0.001 
Fads1 66.039 51.371 0.778 < 0.001 
Bcl7a 4.120 3.209 0.779 0.002 
Espl1 6.491 5.058 0.779 0.007 
Cit 3.219 2.509 0.779 0.003 
Dbp 13.260 10.362 0.781 0.004 
Lcp1 12.024 9.436 0.785 0.002 
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Mnx1 5.302 4.163 0.785 0.048 
Tmem9 10.408 8.181 0.786 0.007 
Phlpp1 5.967 4.703 0.788 0.004 
Zc3hav1l 1.300 1.025 0.789 0.001 
Rasa3 7.163 5.655 0.789 0.001 
Adrbk2 3.678 2.919 0.794 0.007 
Tcf7 4.213 3.348 0.795 0.029 
Fras1 2.047 1.631 0.797 0.036 
Plxnb1 4.983 3.983 0.799 0.010 
Cd320 4.121 3.295 0.800 0.021 
Fam171a1 10.353 8.283 0.800 < 0.001 
Pde8b 0.927 0.746 0.804 0.018 
Mif 974.795 786.847 0.807 0.032 
Dtl 5.768 4.678 0.811 0.022 
Ilf3 20.691 16.805 0.812 < 0.001 
Phlda1 110.713 89.925 0.812 0.012 
Atp11a 3.754 3.051 0.813 0.001 
Zfp783 2.348 1.916 0.816 0.004 
Hirip3 10.231 8.358 0.817 0.006 
Pbx1 4.062 3.325 0.819 0.032 
Gkap1 4.085 3.346 0.819 0.048 
Znrf3 4.325 3.550 0.821 0.020 
Impdh2 76.542 62.866 0.821 0.003 
Nfic 9.383 7.713 0.822 0.050 
Gemin8 1.377 1.136 0.825 0.005 
Afap1 2.165 1.789 0.826 0.003 
Fzd7 13.396 11.071 0.826 0.020 
Csad 8.655 7.156 0.827 0.007 
Ets2 64.227 53.267 0.829 0.011 
Mlxip 13.268 11.020 0.831 < 0.001 
Srl 3.124 2.599 0.832 0.015 
Zfp704 5.650 4.708 0.833 0.004 
Adora1 8.805 7.344 0.834 0.017 
Socs2 4.751 3.968 0.835 < 0.001 
Blnk 6.831 5.731 0.839 0.001 
AU020206 6.421 5.387 0.839 0.050 
Zfp12 2.566 2.153 0.839 0.011 
Maged1 20.344 17.087 0.840 0.038 
Spice1 2.084 1.754 0.842 0.036 
Vdr 31.001 26.098 0.842 0.001 
Psrc1 13.462 11.343 0.843 0.015 
Nin 1.134 0.957 0.844 0.007 
App 193.920 163.702 0.844 0.002 
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BC021891 16.478 13.914 0.844 0.002 
Cdca7l 13.578 11.476 0.845 0.018 
Pla2g5 11.321 9.596 0.848 0.005 
Limk2 46.715 39.660 0.849 0.009 
Zfhx3 3.237 2.754 0.851 0.027 
Slc44a2 12.639 10.755 0.851 0.003 
Lipt2 5.205 4.455 0.856 0.034 
Pck2 49.534 42.484 0.858 0.030 
Cdk6 15.286 13.121 0.858 0.019 
Tgif1 14.378 12.351 0.859 0.010 
Dctd 9.144 7.875 0.861 0.004 
Rprd1a 5.197 4.478 0.862 0.016 
Sept6 2.380 2.053 0.862 0.044 
Kif20a 12.774 11.017 0.862 0.016 
Sfpq 65.732 56.796 0.864 0.004 
Myc 76.280 65.983 0.865 0.013 
Hmbox1 5.374 4.656 0.866 0.017 
Spag5 8.510 7.383 0.868 0.009 
Gabbr1 4.255 3.693 0.868 0.002 
Marveld1 3.917 3.407 0.870 0.028 
Ckap2 13.409 11.673 0.871 0.037 
Zfp462 1.801 1.568 0.871 0.015 
Prkd3 2.252 1.966 0.873 0.034 
Kank1 7.130 6.266 0.879 0.008 
Arid5b 11.172 9.858 0.882 < 0.001 
Nfia 4.597 4.076 0.887 0.025 
Hdac11 17.254 15.330 0.888 0.028 
Ces1d 16.484 14.670 0.890 0.013 
Rpl22 141.929 127.180 0.896 0.016 
Tbc1d9 6.907 6.190 0.896 0.009 
4933431E20Rik 2.049 1.841 0.899 0.027 
Emp2 46.719 42.252 0.904 0.001 
Tns3 13.860 12.536 0.904 0.050 
Aldh7a1 4.823 4.376 0.907 0.025 
Utrn 11.402 10.423 0.914 0.045 
Pabpc1 257.050 235.469 0.916 0.019 
Klhl13 0.979 1.071 1.094 0.048 
Lamb3 35.654 41.027 1.151 0.047 
Mipol1 0.860 0.998 1.160 0.010 
Rpe 16.136 19.183 1.189 0.001 
Atm 3.415 4.282 1.254 0.035 
Id2 12.635 16.023 1.268 0.032 
Vnn1 2.774 3.617 1.304 0.023 
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Phldb2 4.520 5.909 1.307 0.008 
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Combined Wnt signature, organoids 
Gene ID Mean AP4Wt 
Mean 
AP4∆IEC 
fc - AP4∆IEC 
vs AP4Wt P-value 
Notch1 4.456 2.651 0.595 < 0.001 
Axin2 41.383 24.969 0.603 0.005 
Dll1 8.058 4.963 0.616 < 0.001 
Tiam1 5.348 3.322 0.621 0.004 
Ascl2 20.796 13.143 0.632 0.002 
Rgs12 2.243 1.471 0.656 0.008 
Sox4 64.237 43.346 0.675 0.008 
Notch4 0.869 0.594 0.684 0.008 
Bcl7c 3.757 2.810 0.748 0.010 
Trp53 32.987 24.785 0.751 0.005 
Ptch1 4.224 3.176 0.752 0.002 
Ifitm2 198.896 149.751 0.753 0.003 
Frat1 9.286 7.054 0.760 0.008 
Dvl2 5.021 3.848 0.766 0.025 
Jag2 12.974 10.117 0.780 0.036 
Apex1 47.816 37.389 0.782 0.006 
Hdac5 6.714 5.282 0.787 0.041 
Rasa3 7.163 5.655 0.789 0.001 
Tcf7 4.213 3.348 0.795 0.029 
Smyd2 34.225 28.006 0.818 0.003 
Impdh2 76.542 62.866 0.821 0.003 
Kat2a 15.867 13.142 0.828 0.027 
Psen2 3.230 2.723 0.843 0.015 
Smyd5 10.884 9.287 0.853 0.013 
Axin1 18.539 15.889 0.857 0.017 
Tox 4.635 3.992 0.861 0.034 
Skp2 2.170 1.872 0.862 0.022 
Myc 76.280 65.983 0.865 0.013 
Ccnd2 66.420 57.730 0.869 0.011 
Hdac11 17.254 15.330 0.888 0.028 
Numb 14.321 13.698 0.957 0.005 
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Combined Notch signature, organoids 
Gene ID Mean AP4Wt 
Mean 
AP4∆IEC 
fc - AP4∆IEC vs 
AP4Wt P-value 
Dll3 0.700 0.376 0.537 0.006 
Notch1 4.456 2.651 0.595 < 0.001 
Dll1 8.058 4.963 0.616 < 0.001 
Lfng 8.832 5.625 0.637 0.008 
Notch3 2.124 1.353 0.637 0.001 
Mfng 0.298 0.202 0.678 0.007 
Dll4 3.637 2.472 0.680 < 0.001 
Notch4 0.869 0.594 0.684 0.008 
Gm9840 0.286 0.195 0.685 0.012 
Dtx3 2.876 2.037 0.708 0.018 
Hes1 58.314 44.004 0.755 0.009 
Dvl2 5.021 3.848 0.766 0.025 
Dtx4 13.068 10.032 0.768 0.003 
Jag2 12.974 10.117 0.780 0.036 
Ccnd1 42.258 33.371 0.790 < 0.001 
Maml3 3.037 2.481 0.817 0.001 
Ctbp1 54.850 44.844 0.818 0.016 
Dtx2 1.704 1.394 0.818 0.044 
Fzd7 13.396 11.071 0.826 0.020 
Kat2a 15.867 13.142 0.828 0.027 
Psen2 3.230 2.723 0.843 0.015 
Rbx1 34.554 29.270 0.847 0.006 
Sap30 19.486 16.908 0.868 0.045 
Hdac1 27.162 24.273 0.894 0.002 
Numb 14.321 13.698 0.957 0.005 
Psen1 28.568 30.631 1.072 0.002 
Arrb1 11.541 12.788 1.108 0.017 
Dtx3l 3.833 4.799 1.252 0.010 
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c-Myc target genes, organoids 
Gene ID Mean AP4Wt 
Mean 
AP4∆IEC 
fc - AP4∆IEC 
vs AP4Wt P-value 
Ung 12.647 8.946 0.707 0.010 
Mcm5 36.978 27.227 0.736 0.002 
Plk1 35.717 27.060 0.758 < 0.001 
Tcof1 15.961 12.203 0.765 0.004 
Mcm4 29.387 22.827 0.777 0.008 
Dctpp1 51.572 40.219 0.780 0.020 
Cdk4 77.414 60.999 0.788 0.006 
Pus1 29.030 23.018 0.793 0.010 
Rcl1 22.011 17.535 0.797 < 0.001 
Slc19a1 18.863 15.570 0.825 0.002 
Pprc1 12.816 10.754 0.839 0.006 
Plk4 4.608 3.935 0.854 0.007 
Mrto4 16.938 14.524 0.857 0.016 
Myc 76.280 65.983 0.865 0.013 
Noc4l 15.664 13.592 0.868 0.050 
Rrp12 9.255 8.047 0.869 0.042 
Nolc1 39.795 35.251 0.886 0.011 
Hk2 13.263 11.822 0.891 0.021 
Hspe1 105.098 95.664 0.910 0.012 
Mybbp1a 52.743 48.050 0.911 0.014 
Pes1 36.673 33.527 0.914 0.013 
Rabepk 4.127 3.780 0.916 0.030 
Tmem97 85.989 79.351 0.923 0.002 
Tbrg4 27.708 25.648 0.926 0.046 
Nip7 12.845 12.195 0.949 0.009 
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11.3 Supplemental Data 3: related to Figure 17e, 26a, b, d 
 
Supplemental Data 3. Uncropped Western blot membranes                            
Corresponding uncropped membranes of western blots shown in Figure 17e and 26a,b,d. 
Membranes were cut to enable blotting for multiple antibodies. The protein standards are 
depicted to the left. The part of the membranes shown in the stated figures is represented by 
dashed lines. 
